ticlopidine has been researched along with Bleeding in 937 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 9.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 9.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 9.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| "Enhanced clopidogrel responsiveness was associated with an increased risk of bleeding and entry-site complication." | 9.24 | The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. ( Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X, 2017) |
| "In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding." | 9.22 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel." | 9.22 | Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 9.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 9.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 9.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding." | 9.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| "MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel." | 9.20 | MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015) |
| " In this context, we aimed to compare ticagrelor versus high dose clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) who exhibit HPR post fibrinolysis." | 9.20 | Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. ( Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A, 2015) |
| "In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) at the expense of increased nonfatal bleeding." | 9.20 | Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM, 2015) |
| "Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist." | 9.20 | Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015) |
| " In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients." | 9.20 | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015) |
| " Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)." | 9.20 | Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| " clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization." | 9.19 | Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014) |
| "In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the primary ischaemic endpoint as compared with clopidogrel in acute coronary syndrome (ACS) patients planned to undergo percutaneous coronary interventions, but increased the risk of bleeding." | 9.19 | Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014) |
| "The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI)." | 9.19 | Prehospital ticagrelor in ST-segment elevation myocardial infarction. ( Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U, 2014) |
| "This study sought to investigate the relationship of polymorphisms in ABCB1 and the predictive value of thromboelastography (TEG) on bleeding risk in clopidogrel-treated patients with ST-elevation myocardial infarction (STEMI)." | 9.19 | Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. ( Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y, 2014) |
| "We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism." | 9.19 | Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 9.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 9.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| "On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel." | 9.17 | Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013) |
| "Clopidogrel use prior to coronary artery bypass graft surgery in patients presenting with acute coronary syndromes is associated with a greater incidence of procedural related morbidity." | 9.16 | Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. ( Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR, 2012) |
| "The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding." | 9.16 | Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 9.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age." | 9.16 | Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D, 2012) |
| " Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks." | 9.16 | Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012) |
| "In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg)." | 9.15 | Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study). ( Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography." | 9.15 | Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E ( Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Clopidogrel (Plavix®) therapy, although effective for minimizing risk of thrombotic events, is also associated with potential bleeding risk." | 9.15 | Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. ( Carr, ME; Gabriel, D; Khutoryansky, NM; Pusateri, AE; Shenouda, M; Skolnick, BE, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 9.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 9.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 9.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel." | 9.14 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 9.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 9.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding." | 9.14 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 9.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 9.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| "ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events." | 9.14 | Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010) |
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 9.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting." | 9.14 | Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 9.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention." | 9.13 | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| " Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding." | 9.13 | Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding." | 9.13 | Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 9.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel." | 9.13 | Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J, 2008) |
| "The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction." | 9.12 | Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. ( Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS, 2007) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 9.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 9.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications." | 9.11 | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005) |
| "To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy." | 9.11 | A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)." | 9.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "The results of the meta-analysis suggest that ABCB1 C3435T polymorphism may increase the risk of bleeding in Asian patients treated with clopidogrel." | 8.95 | Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. ( Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 8.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 8.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| "The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding." | 8.91 | Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. ( Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY, 2015) |
| "Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin." | 8.91 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 8.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 8.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 8.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| "In ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, administration of a 600-mg LD of clopidogrel is associated with a lower risk of MACE than is administration of a 300-mg LD, without increasing the risk of major bleeding." | 8.90 | Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. ( Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A, 2014) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 8.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "To perform a meta-analysis of the association between CYP2C19 loss- and gain-of-function variants and cardiovascular outcomes and bleeding in patients with coronary artery disease treated with clopidogrel, and to explore the causes of heterogeneity between studies." | 8.88 | Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. ( Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M, 2012) |
| "Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well." | 8.88 | The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012) |
| "Ticagrelor, an oral P2Y(12) receptor antagonist used as part of dual antiplatelet therapy in the treatment of acute coronary syndromes (ACS), has many favorable characteristics when compared with the more frequently used P2Y(12) receptor antagonist clopidogrel." | 8.88 | Review of ticagrelor in the management of acute coronary syndromes. ( Burgess, S; Juergens, CP; Mallard, TA, 2012) |
| "Although some patients suffer from dyspnea when administered with ticagrelor, there is no evidence of any untoward effects on the cardiovascular or pulmonary systems." | 8.88 | Safety profile and bleeding risk of ticagrelor compared with clopidogrel. ( Lincoff, AM; May, CH, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 8.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| " In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk." | 8.84 | Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008) |
| "Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS)." | 8.31 | miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. ( Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL, 2023) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "Enhanced platelet inhibition delivered by clopidogrel is associated with an increased risk for major bleeding and death in patients on OAC who undergo PCI." | 7.91 | Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. ( Bernlochner, I; Fiedler, KA; Goedel, A; Hoppmann, P; Kastrati, A; Laugwitz, KL; Maeng, M; Massberg, S; Mayer, K; Mehilli, J; Sarafoff, N; Schunkert, H; Schüpke, S; Sibbing, D; von Olshausen, G, 2019) |
| "Our study shows that the recommended dose of prasugrel had significantly higher in-hospital bleeding complications without reducing ischemic events compared with clopidogrel." | 7.88 | Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. ( Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2018) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 7.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| "Bleeding is one of the possible adverse events during clopidogrel therapy." | 7.88 | Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018) |
| " Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk." | 7.88 | Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM, 2018) |
| "To report incidence of bleeding after image-guided percutaneous core needle biopsy performed in patients taking clopidogrel within 5 days." | 7.85 | Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel-A Retrospective Review. ( Atwell, T; Knudsen, J; McBane, R; McMenomy, B; Pieper, M; Schmitz, J; Wennberg, P, 2017) |
| "The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear." | 7.85 | Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after ( Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME, 2017) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 7.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel." | 7.83 | Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 7.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)." | 7.83 | Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016) |
| "Results of a study of bleeding events and other inhospital outcomes with the use of clopidogrel versus prasugrel in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) are reported." | 7.83 | Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2016) |
| "To evaluate the effect of bleedings for up to 12months on clinical events and therapeutic compliance in unselected STEMI patients treated with prasugrel or clopidogrel." | 7.83 | One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. ( Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L, 2016) |
| "To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease." | 7.83 | [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016) |
| " However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2." | 7.83 | Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. ( Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 7.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 7.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "We hypothesized that perioperative measurement of platelet function with a point-of-care P2Y12 inhibitor assay could predict bleeding during CABG in patients exposed to clopidogrel." | 7.81 | Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. ( Agnihotri, A; Aranki, S; Cannon, CP; Guo, J; Kumar, A; Maree, AO; McLean, DS; Reed, GW; Rosenfield, K; Shekar, P, 2015) |
| "There is a known bleeding risk with administration of the antiplatelet drug clopidogrel, but in certain patients the likelihood of thrombosis is too high to cease its administration perioperatively." | 7.81 | Uninterrupted perioperative clopidogrel and bleeding-related events after total joint arthroplasty: a case series. ( Bono, J; Nandi, S; Shubert, D, 2015) |
| "This study is the first to analyze differences in bleeding times between clopidogrel and prasugrel treatments during dental extraction." | 7.81 | Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy. ( Braunitzer, G; Dézsi, BB; Dézsi, CA; Hangyási, DB; Koritsánszky, L, 2015) |
| "Greater antithrombotic potency new antiplatelet agents have been added such as prasugrel (PR) and ticagrelor to the traditional use of clopidogrel (CL) in the treatment of acute coronary syndrome (ACS)." | 7.81 | [Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty]. ( Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 7.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months." | 7.80 | Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014) |
| "The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats." | 7.80 | Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014) |
| "To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel." | 7.80 | Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 7.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " Patients displaying low on-treatment platelet reactivity (LPR) and/or at high risk of bleeding were switched to clopidogrel 75 mg and tested again 15 days later." | 7.79 | Switching acute coronary syndrome patients from prasugrel to clopidogrel. ( Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB, 2013) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 7.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| " This study sought to determine if trauma patients on preinjury clopidogrel with a higher degree of platelet inhibition (PI), as determined by the VerifyNow P2Y12 Test, experienced bleeding complications more frequently than did patients with a lower degree of PI." | 7.79 | Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. ( Ali, K; Cheng, J; Kram, B; Short, S; Taylor, S; Vasquez, D, 2013) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 7.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "The PLATO (Platelet Inhibition and Patient Outcomes) randomized trial (NCT00391872) in patients with acute coronary syndromes (ACS) reported that ticagrelor (in addition to aspirin) reduced the rate of the composite end point of myocardial infarction (MI), stroke, or cardiovascular death compared with clopidogrel (in addition to aspirin) by 16% over 12 months (P < 0." | 7.79 | Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. ( Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D, 2013) |
| "Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD." | 7.79 | Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013) |
| "The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications." | 7.79 | Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013) |
| " the pharmacokinetics of clopidogrel do not allow for bleeding time to return to normal until the drug has been discontinued for five days." | 7.78 | Operative treatment of hip fractures in patients on clopidogrel: a case-control study. ( Chaput, CD; Patel, KV; Probe, RA; Wallace, HC, 2012) |
| "Guidelines stipulate that clopidogrel should be interrupted ≥ 5 days prior to elective coronary artery bypass graft (CABG) surgery to reduce the risk of bleeding unless the need for revascularization and/or the net benefit of the clopidogrel outweighs the potential risks of bleeding." | 7.78 | Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption. ( Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS, 2012) |
| " This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery." | 7.78 | Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012) |
| "To assess the impact of cytochrome P450 (CYP) 2C19*17 allelic variant on platelet aggregation and bleeding risk in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI) and treated with clopidogrel." | 7.78 | Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. ( Chen, H; Dai, ZL; Wu, XY, 2012) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 7.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma." | 7.78 | Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. ( Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| " Clopidogrel (a compound that inhibits adenosine diphosphate-induced platelet aggregation) is often prescribed for primary or secondary prevention of cardiovascular disease and has been associated with bleeding complications in patients undergoing surgical procedures." | 7.78 | Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis. ( Bechara, RI; Berkowitz, DM; Parks, C; Zalt, MB, 2012) |
| "Coronary artery bypass grafting (CABG) performed within 5 days of clopidogrel administration is associated with increased bleeding." | 7.77 | Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. ( Cruden, NL; Hilton, JD; Klinke, WP; Morch, K; Ofiesh, J; Wong, DR, 2011) |
| "The objective of this study was to examine the clinical efficacy of clopidogrel treatment on death and recurrent myocardial infarction (MI) among MI patients revascularized by coronary artery bypass graft surgery (CABG)." | 7.77 | Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. ( Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2011) |
| "We do not routinely discontinue clopidogrel before colonoscopy because we have judged the cardiovascular risks of that practice to exceed the risks of post-polypectomy bleeding (PPB)." | 7.77 | The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. ( Davila, RE; Feagins, LA; Harford, WV; Spechler, SJ; Uddin, FS, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 7.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 7.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "Data are lacking on the efficacy and safety of a loading dose (LD) of clopidogrel in elderly patients with acute myocardial infarction (AMI)." | 7.77 | Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry). ( Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T, 2011) |
| " We sought to determine if carbon monoxide-releasing molecule-2 [tricarbonyldichlororuthenium (II) dimer, CORM-2] would improve coagulation in rabbit plasma in vitro via thrombelastography and in an in vivo preclinical rabbit model of ear bleeding time following administration of clopidogrel (20 mg/kg) with aspirin (10 mg/kg) via gavage." | 7.77 | Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits. ( Arkebauer, MR; Chawla, N; Gomes, SB; Mangla, D; Nielsen, VG; Sadacharam, K; Vosseller, K; Wasko, KA, 2011) |
| "To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel." | 7.76 | Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010) |
| "The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI." | 7.76 | Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding." | 7.76 | Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010) |
| "CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding." | 7.76 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 7.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 7.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 7.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 7.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern." | 7.76 | National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. ( Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010) |
| "Current guidelines recommend dual antiplatelet therapy using aspirin and clopidogrel for non-ST elevation acute coronary syndromes (ACS)." | 7.75 | Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. ( De Servi, S; Mariani, G; Mariani, M, 2009) |
| "The new P2Y(12) antagonist prasugrel produces greater inhibition of ADP-induced platelet aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of clopidogrel, but increases major bleeding." | 7.75 | Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. ( Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC, 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 7.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 7.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage." | 7.74 | Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007) |
| "Clopidogrel, with or without aspirin, does not increase bleeding complications after TBLB in healthy pigs." | 7.73 | Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. ( Becker, HD; Ernst, A; Feller-Kopman, D; Garland, R; Herth, F; Wahidi, MM, 2005) |
| "We report a rare case in which life-threatening subcutaneous hemorrhage following minor blunt trauma developed in an elderly patient taking ticlopidine and aspirin." | 7.73 | Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report. ( Hagiwara, A; Matsuda, T; Shimazaki, S, 2005) |
| " Patients who are on chronic warfarin therapy and receive a coronary stent need to be treated with the triple therapy of aspirin, clopidogrel and warfarin; however, the bleeding risk in these patients is unknown." | 7.73 | Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. ( Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 7.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)." | 7.73 | Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006) |
| "Pulmonary hemorrhage following percutaneous coronary intervention is a very rare complication that has been previously reported in association with abciximab and tirofiban, but not with clopidogrel." | 7.71 | Diffuse alveolar hemorrhage after clopidogrel use. ( Kilaru, PK; Kozman, HA; Schweiger, MJ; Weil, TR, 2001) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 6.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| " The prevalence of adverse events was assessed at each visit through a direct interview." | 6.78 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013) |
| "Fatal bleeding was low and did not differ between groups." | 6.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| " Whether this is worth both the risk of non-compliance with twice-a-day dosing in real-life patients lacking the same motivation as their trial-volunteer counterparts, and the 2000-fold difference in incremental cost, is the remaining matter for debate." | 6.48 | Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. ( Davies, JE; Francis, DP; Nijjer, SS, 2012) |
| " Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1." | 6.47 | Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011) |
| "In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS." | 5.51 | Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. ( Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH, 2022) |
| "to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials." | 5.51 | Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 5.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 5.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Vorapaxar is a novel protease-activated receptor-1 (PAR-1) antagonist recently approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease." | 5.42 | Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. ( Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA, 2015) |
| " However, it is unclear whether antiplatelet monotherapy with ticagrelor alone versus ticagrelor plus aspirin reduces the incidence of clinically relevant bleeding without increasing the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in ACS patients undergoing percutaneous coronary intervention (PCI) with DES implantation guided by either intravascular ultrasound (IVUS) or angiography who have completed a 1-month course of DAPT with aspirin plus ticagrelor." | 5.41 | Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice ( Chen, F; Chen, SL; Gao, DS; Gao, XF; Ge, Z; Han, YL; He, YQ; Kan, J; Kong, XQ; Li, F; Lin, S; Liu, ZZ; Qian, XS; Qu, H; Shao, YB; Tao, L; Tian, NL; Wang, Y; Wang, ZZ; Wen, SY; Xia, Y; Xiao, PX; Yang, Q; Yang, S; Ye, F; Zeng, HS; Zhang, JJ; Zuo, GF, 2021) |
| "In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective." | 5.40 | Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014) |
| "Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial." | 5.38 | Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? ( DiNicolantonio, JJ; Serebruany, VL, 2012) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 5.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 5.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 5.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 5.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS)." | 5.24 | Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. ( Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V, 2017) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| " Ticagrelor was more effective than clopidogrel in TAPT; however, when using the combination of aspirin, ticagrelor, and tirofiban, close monitoring is required for possible bleeding complications." | 5.24 | Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. ( Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y, 2017) |
| "The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents." | 5.24 | 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017) |
| " However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment." | 5.24 | Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. ( Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D, 2017) |
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 5.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| "Enhanced clopidogrel responsiveness was associated with an increased risk of bleeding and entry-site complication." | 5.24 | The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. ( Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X, 2017) |
| "In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly patients increased the risk of bleeding, without affording a significant prevention of ischaemic events." | 5.24 | Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. ( Ariotti, S; Franzone, A; Gargiulo, G; Heg, D; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Tebaldi, M; Valgimigli, M; Windecker, S, 2017) |
| "Accordingly, 50 mg clopidogrel plus aspirin, and 75 mg clopidogrel plus aspirin were all superior to aspirin alone as stroke prevention in patients with cerebral infarction or transient ischemic attack combined with intracranial and extracranial arteriostenosis." | 5.24 | The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( Dong, AQ; Liu, H; Liu, JQ; Su, N; Wu, HJ; Zuo, FT, 2017) |
| "Long-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for secondary stroke prevention in patients with noncardioembolic ischemic stroke." | 5.22 | Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. ( Moustafa, B; Testai, FD, 2022) |
| "In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding." | 5.22 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "We examined the effects of cytochrome P450 2C19 (CYP2C19) polymorphisms on the efficacy and safety of prasugrel and clopidogrel in a post hoc analysis of the PRASugrel compared with clopidogrel For Japanese patIenTs with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (PRASFIT-ACS) study." | 5.22 | Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H, 2016) |
| "The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel." | 5.22 | Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel." | 5.22 | Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 5.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| " In contrast to overall PLATO results, but similar to PLATO-US cohort, PHILO revealed numerical inferiority of ticagrelor with regard to death, myocardial infarction, stroke, and bleeding over clopidogrel." | 5.22 | Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA? ( Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A, 2016) |
| "Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation." | 5.22 | 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Despite broad differences in clinical profiles and indications for percutaneous coronary intervention by region in a large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic end points compared with clopidogrel without an excess in severe bleeding in both the US and non-US subgroups." | 5.22 | Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD, 2016) |
| "Eighty-three acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with planned GPI use were randomized to receive high-dose bolus tirofiban, double-bolus eptifibatide, or abciximab followed by a 12-hour infusion." | 5.22 | A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. ( French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S, 2016) |
| "Policosanol reduced platelet reactivity to a similar extent as high maintenance dose of clopidogrel without increasing bleeding rate." | 5.22 | Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. ( Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 5.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 5.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding." | 5.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| "We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled." | 5.20 | High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015) |
| "MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel." | 5.20 | MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015) |
| "Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders." | 5.20 | 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015) |
| "This prospective, randomized, multicenter study is going to assess the hypothesis that in persistent or permanent AF patients (score of CHA₂DS₂VASc≥2) after PCI-eS, the combination therapy of oral anticoagulation (warfarin) and ticagrelor (90 mg/bid) could reduce the risk of bleeding events." | 5.20 | Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. ( Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P, 2015) |
| " In this context, we aimed to compare ticagrelor versus high dose clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) who exhibit HPR post fibrinolysis." | 5.20 | Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. ( Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A, 2015) |
| "The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin." | 5.20 | Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). ( Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M, 2015) |
| "Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding Cohort, among whom 2148 patients received either prasugrel or clopidogrel according to current guidelines." | 5.20 | Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. ( Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S, 2015) |
| "In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) at the expense of increased nonfatal bleeding." | 5.20 | Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM, 2015) |
| "Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist." | 5.20 | Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015) |
| " In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients." | 5.20 | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015) |
| " Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)." | 5.20 | Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015) |
| "1% of the patients received polypharmacy and clopidogrel, respectively, which can increase the risk of drug-drug interactions and bleeding." | 5.19 | Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital. ( Guidoni, CM; Obreli-Neto, PR; Pereira, LR, 2014) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| " clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization." | 5.19 | Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014) |
| "In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), prasugrel reduced the primary ischaemic endpoint as compared with clopidogrel in acute coronary syndrome (ACS) patients planned to undergo percutaneous coronary interventions, but increased the risk of bleeding." | 5.19 | Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. ( De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P, 2014) |
| "In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14." | 5.19 | An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014) |
| "The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI)." | 5.19 | Prehospital ticagrelor in ST-segment elevation myocardial infarction. ( Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U, 2014) |
| "This study sought to investigate the relationship of polymorphisms in ABCB1 and the predictive value of thromboelastography (TEG) on bleeding risk in clopidogrel-treated patients with ST-elevation myocardial infarction (STEMI)." | 5.19 | Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. ( Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y, 2014) |
| "Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding." | 5.19 | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW, 2014) |
| "Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models." | 5.19 | Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014) |
| "We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism." | 5.19 | Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014) |
| "If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding." | 5.17 | Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. ( Adriaenssens, T; De Smet, BJ; Dewilde, WJ; Heestermans, AA; Herrman, JP; Kelder, JC; Oirbans, T; ten Berg, JM; Tijsen, JG; van 't Hof, AW; Verheugt, FW; Vis, MM; Vrolix, M, 2013) |
| " Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only." | 5.17 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013) |
| "Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding." | 5.17 | Effect of platelet inhibition with cangrelor during PCI on ischemic events. ( Angiolillo, DJ; Bhatt, DL; Bramucci, E; Gallup, D; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; McLaurin, BT; Prats, J; Price, MJ; Radke, PW; Skerjanec, S; Spriggs, D; Steg, PG; Stone, GW; Tauth, J; Todd, M; Tousek, F; White, HD; Widimský, P, 2013) |
| "High residual platelet reactivity (RPR) on clopidogrel treatment has been associated with increased risk for ischemic events during follow-up in patients with acute coronary syndromes." | 5.17 | Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). ( Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E, 2013) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 5.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 5.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel." | 5.17 | Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013) |
| "Clopidogrel use prior to coronary artery bypass graft surgery in patients presenting with acute coronary syndromes is associated with a greater incidence of procedural related morbidity." | 5.16 | Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. ( Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR, 2012) |
| "The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding." | 5.16 | Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012) |
| "A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)." | 5.16 | Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012) |
| "In patients undergoing nonurgent percutaneous coronary intervention and in comparison with clopidogrel, intravenous and oral elinogrel therapy did not significantly increase thrombolysis in myocardial infarction major or minor bleeding, although bleeding requiring medical attention was more common." | 5.16 | A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC ( Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 5.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age." | 5.16 | Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D, 2012) |
| " Patients with an episode of noncardioembolic ischemic stroke at least 8 days prior to randomization, who were aged <75 years or had a body weight >50 kg were randomized to 50 or 75 mg clopidogrel once daily for 52 weeks." | 5.16 | Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. ( Minematsu, K; Tanahashi, N; Uchiyama, S, 2012) |
| "Presentation with an acute coronary syndrome (ACS) on chronic aspirin therapy is an independent predictor of adverse short-term outcomes." | 5.15 | Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. ( Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C, 2011) |
| "In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg)." | 5.15 | Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study). ( Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography." | 5.15 | Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E ( Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U, 2011) |
| " We explored the relationship between GFR and angiographic and clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients receiving pharamacologic reperfusion, with or without clopidogrel." | 5.15 | Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. ( Ahmed, S; Cannon, CP; Michael Gibson, C; Murphy, SA; Sabatine, MS, 2011) |
| "Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard-dose clopidogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis." | 5.15 | Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. ( Angiolillo, DJ; Aragon, JR; Berger, PB; Bertrand, OF; Cannon, CP; Garratt, KN; Kandzari, DE; Lee, MS; Manoukian, SV; Price, MJ; Puri, S; Robbins, M; Schork, NJ; Spriggs, D; Stillablower, ME; Stillabower, ME; Stinis, CT; Tanguay, JF; Teirstein, PS; Topol, EJ, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| " As the indications for clopidogrel expand, an increasing number of patients undergoing off-pump coronary artery bypass surgery (OPCAB) are also undergoing dual antiplatelet therapy (DAPT), with its higher risk of bleeding complications." | 5.15 | Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. ( Ahn, SW; Kwak, YL; Lee, JS; Shim, JK; Song, JW; Yoo, KJ, 2011) |
| "Clopidogrel (Plavix®) therapy, although effective for minimizing risk of thrombotic events, is also associated with potential bleeding risk." | 5.15 | Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. ( Carr, ME; Gabriel, D; Khutoryansky, NM; Pusateri, AE; Shenouda, M; Skolnick, BE, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 5.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 5.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 5.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "This was a prospective observational study of 15 532 patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial who were randomly assigned to clopidogrel or placebo, and followed-up for a median of 28 months for the occurrence of the primary endpoint (cardiovascular death, myocardial infarction, or stroke), all-cause mortality, and bleeding complications." | 5.14 | The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. ( Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009) |
| "Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel." | 5.14 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 5.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 5.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding." | 5.14 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009) |
| "Cangrelor, when administered intravenously 30 minutes before PCI and continued for 2 hours after PCI, was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours." | 5.14 | Platelet inhibition with cangrelor in patients undergoing PCI. ( Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD, 2009) |
| "Clopidogrel therapy may be more effective in current smokers, but it may also confer a greater bleeding risk than in nonsmokers." | 5.14 | Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. ( Berger, JS; Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Lincoff, AM; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 5.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| " The baseline corrected bleeding times were not significantly different between the ticlopidine-alone and ticlopidine/ Ginkgo biloba groups, and changes in platelet aggregation were not significantly different between the groups." | 5.14 | Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. ( Cho, JY; Jang, IJ; Kim, BH; Kim, JR; Kim, KP; Lee, KH; Lee, YO; Lim, KS; Shin, SG; Yoon, SH; Yu, KS, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 5.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| "In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)." | 5.14 | Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010) |
| " In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5." | 5.14 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010) |
| "ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events." | 5.14 | Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010) |
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 5.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation." | 5.14 | Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. ( Anand, SS; Bhatt, DL; Connolly, SJ; Eikelboom, JW; Fox, KA; Hirsh, J; Mehta, SR; Paré, G; Simonsen, K; Yusuf, S, 2010) |
| "Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting." | 5.14 | Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 5.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention." | 5.13 | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| " Among a high-risk NSTEMI population not undergoing PCI within 24 hours of arrival, the nonrandomized short-term use of clopidogrel is associated with a lower risk of inhospital mortality without an increased risk of major bleeding." | 5.13 | Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su ( Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding." | 5.13 | Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 5.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "The present study suggested benefit of tailored antiplatelet therapy during elective PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding risk." | 5.13 | Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J, 2008) |
| "We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel." | 5.13 | Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J, 2008) |
| "Clopidogrel in mild or moderate CKD patients may not have the same beneficial effect as it does in patients with normal renal function, but was not associated with a greater relative risk of bleeding based on renal function." | 5.13 | The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ, 2008) |
| "Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "Addition of clopidogrel to medical reperfusion of STEMI with fibrinolysis, heparin, and aspirin before reaching the hospital is feasible in medically equipped ambulances without an apparent increase in bleeding." | 5.12 | Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. ( Adgey, J; Cannon, CP; Lambert, Y; Lapostolle, F; Montalescot, G; Sabatine, MS; Soulat, L; Verheugt, FW, 2007) |
| "The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction." | 5.12 | Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. ( Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS, 2007) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 5.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 5.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke." | 5.11 | Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004) |
| "In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications." | 5.11 | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005) |
| "In this phase 2 study, which was designed to assess safety when administered at the time of percutaneous coronary intervention, prasugrel and clopidogrel both resulted in low rates of bleeding." | 5.11 | Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. ( Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD, 2005) |
| "To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy." | 5.11 | A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| " Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)." | 5.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "These results suggest that poststenting treatment by ticlopidine/aspirin is an effective alternative to coumadin anticoagulation, achieving low rates of subacute closure and bleeding complications." | 5.08 | Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. ( Aubry, P; Benveniste, E; Bunouf, P; Cattan, S; Chevalier, B; Commeau, P; Cribier, A; Eiferman, C; Grollier, G; Guerin, Y; Henry, M; Karrillon, GJ; Lefevre, T; Livarek, B; Louvard, Y; Makowski, S; Marco, J; Monassier, JP; Morice, MC; Pernes, JM; Rioux, P; Spaulding, C; Zemour, G, 1996) |
| "As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone." | 5.08 | A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. ( Baim, DS; Cutlip, DE; Diver, DJ; Giambartolomei, A; Gordon, PC; Ho, KK; Kuntz, RE; Lasorda, DM; Leon, MB; Pocock, SJ; Popma, JJ; Williams, DO, 1998) |
| "For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding." | 4.98 | Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018) |
| "The results of the meta-analysis suggest that ABCB1 C3435T polymorphism may increase the risk of bleeding in Asian patients treated with clopidogrel." | 4.95 | Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. ( Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y, 2017) |
| " With respect to intracranial hemorrhage, aspirin + clopidogrel yielded worse outcomes than 7 treatments, including placebo, apixaban, aspirin, aspirin + dipyridamole, cilostazol, clopidogrel, and dabigatran (OR, 2." | 4.95 | The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. ( Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y, 2017) |
| "Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding." | 4.95 | Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. ( Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W, 2017) |
| " The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events." | 4.95 | The role of prasugrel in the management of acute coronary syndromes: a systematic review. ( Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E, 2017) |
| "The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infarction and ischaemic stroke, and an increased risk of major and minor bleeding compared with aspirin alone." | 4.95 | Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. ( Bellesini, M; Donadini, MP; Middeldorp, S; Squizzato, A; Takeda, A, 2017) |
| "Despite the demonstrated benefits of Prasugrel, a new generation thienopyridine, in the prevention of thrombotic complications after percutaneous coronary interventions (PCI) for Acute Coronary Syndromes (ACS), its use is still precluded to those many patients arriving to the cath lab pre-treated with Clopidogrel." | 4.93 | Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. ( Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M, 2016) |
| " We sought to determine the effect of switching from clopidogrel to a novel P2Y12 receptor inhibitor on the occurrence of major adverse cardiovascular events (MACE) and bleeding." | 4.93 | The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review. ( Chandrasekhar, J; Froeschl, M; Hibbert, B; May, ML; Mehran, R; So, D, 2016) |
| "High on-clopidogrel platelet reactivity (HcPR) during dual-antiplatelet therapy is a marker of vascular risk, in particular stent thrombosis, in patients with acute coronary syndromes (ACS)." | 4.93 | On-treatment platelet reactivity: State of the art and perspectives. ( Giusti, B; Grifoni, E; Marcucci, R, 2016) |
| "Switching from clopidogrel to prasugrel does not increase bleeding complications during follow-up of patients undergoing percutaneous coronary intervention; however, the strength of the data is not sufficient to make definitive clinical recommendations." | 4.93 | Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies. ( Cavallari, I; De Luca, L; Patti, G; Ricottini, E, 2016) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Dual antithrombotic regimen of warfarin and clopidogrel is comparable to the recommended triple therapy in respect to the prevention of thromboembolic outcomes of MI/ death and ischemic stroke, while the risk of bleeding is similar in those patients with indications for chronic oral anticoagulation undergoing percutaneous coronary intervention with stent implantation." | 4.93 | [Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation]. ( Du, M; Ma, G; Shi, Y; Zhang, D, 2016) |
| " The secondary outcome was bleeding events and resistance to the effects of clopidogrel." | 4.93 | Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis. ( Wang, CH; Wang, YQ; Zhang, JH, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 4.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 4.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| "The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding." | 4.91 | Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. ( Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY, 2015) |
| "Ticagrelor is recommended in local and international guidelines as first-line therapy in combination with aspirin in patients presenting with acute coronary syndromes (ACS)." | 4.91 | Practical experience with ticagrelor: an Australian and New Zealand perspective. ( Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ, 2015) |
| "Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin." | 4.91 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 4.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| " However, prasugrel and ticagrelor have a more consistent, faster-acting and more potent antiplatelet effect than clopidogrel, which translates into improved clinical outcomes, although at the expense of an increased bleeding risk." | 4.91 | Antiplatelet therapy in acute coronary syndromes. ( Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "New P2Y12 inhibitors decreased death in patients undergoing PCI compared with clopidogrel with a considerable safety and tolerability profile; however, the risk/benefit ratio of ischemic and bleeding events should be further investigated." | 4.91 | Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. ( Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 4.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| "The two new drugs prasugrel and ticagrelor were included in the current guidelines for the treatment of patients with acute coronary syndrome." | 4.90 | [Dual platelet inhibitors in intensive care units]. ( Delle Karth, G; Siller-Matula, JM, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 4.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| " In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis." | 4.90 | Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014) |
| "In ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, administration of a 600-mg LD of clopidogrel is associated with a lower risk of MACE than is administration of a 300-mg LD, without increasing the risk of major bleeding." | 4.90 | Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. ( Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A, 2014) |
| "Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel." | 4.90 | Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014) |
| " In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 4.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| " The combination of acetylsalicylic acid (ASA) plus dipyridamole (DP) was more protective against recurrent stroke than ASA alone (RR = 0." | 4.89 | Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. ( Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA, 2013) |
| " The thienopyridines are an integral part of antithrombotic therapy and are prescribed for various indications including acute coronary syndrome, peripheral vascular disease and cerebrovascular disease." | 4.89 | Metabolic differences of current thienopyridine antiplatelet agents. ( Fareed, J; Jeske, W; Thethi, I, 2013) |
| "To perform a meta-analysis of the association between CYP2C19 loss- and gain-of-function variants and cardiovascular outcomes and bleeding in patients with coronary artery disease treated with clopidogrel, and to explore the causes of heterogeneity between studies." | 4.88 | Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. ( Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M, 2012) |
| "Contrary to the findings of post hoc analyses of randomized trials, observational studies showed that recent exposure to clopidogrel before coronary artery bypass grafting is associated with increased risk of postoperative death, reoperations for bleeding, blood loss, and need of blood transfusions." | 4.88 | Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. ( Airaksinen, KE; Biancari, F; Lip, GY, 2012) |
| "Carriers of the CYP2C19*17 variant have greater therapeutic responsiveness to clopidogrel than non-carriers, but they have an increased risk of developing bleeding as well." | 4.88 | The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. ( Hu, YF; Li, Y; Tang, HL; Xie, HG, 2012) |
| "Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events." | 4.88 | Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012) |
| " New platelet inhibitors prasugrel and ticagrelor are more effective than the traditional clopidogrel, but their use is also accompanied by more frequent bleeding complications." | 4.88 | [New antithrombotic drugs]. ( Mustonen, P; Puurunen, M, 2012) |
| "P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization." | 4.88 | Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012) |
| " Addition of clopidogrel was associated with an increase in fatal hemorrhage (OR, 1." | 4.88 | Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. ( Benavente, OR; Hart, RG; Palacio, S; Pearce, LA, 2012) |
| "Ticagrelor, an oral P2Y(12) receptor antagonist used as part of dual antiplatelet therapy in the treatment of acute coronary syndromes (ACS), has many favorable characteristics when compared with the more frequently used P2Y(12) receptor antagonist clopidogrel." | 4.88 | Review of ticagrelor in the management of acute coronary syndromes. ( Burgess, S; Juergens, CP; Mallard, TA, 2012) |
| "Although some patients suffer from dyspnea when administered with ticagrelor, there is no evidence of any untoward effects on the cardiovascular or pulmonary systems." | 4.88 | Safety profile and bleeding risk of ticagrelor compared with clopidogrel. ( Lincoff, AM; May, CH, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 4.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| "Enhanced platelet inhibition by clopidogrel decreases the risk of ischemic events but carries a risk for a concomitant increase in bleeding." | 4.87 | Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM, 2011) |
| "Clinicians will be able to understand the safety profile of using different doses of clopidogrel and the incidence of bleeding when used alone or in combination with other antiplatelet agents." | 4.87 | The safety of clopidogrel. ( Kleiman, NS; Mangalpally, KK, 2011) |
| " The withdrawal of clopidogrel earlier than 4-6 weeks after bare metal stent implantation or less than 12 months after drug-eluting stent implantation is very risky and poses a high risk of stent thrombosis and high perioperative mortality." | 4.87 | Antiplatelet therapy in the perioperative period. ( Táborský, M; Václavík, J, 2011) |
| "Literature was accessed through MEDLINE (1966-October 2010 week 1), EMBASE (1980-2010 week 40), and a bibliographic review of published articles using the search terms acute coronary syndrome, clopidogrel, and prasugrel." | 4.87 | Thienopyridines in Acute Coronary Syndrome. ( Desilets, AR; Goodwin, MM; Willett, KC, 2011) |
| " The benefits in mortality and reinfarction were driven by the treatment with prasugrel or ticagrelor, without a significant difference in terms of major bleeding complications as compared to standard-dose clopidogrel (5% vs." | 4.87 | Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. ( Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M, 2011) |
| "Prasugrel's clinical benefits were counterbalanced by an increase in bleeding risk compared with conventional thienopyridine treatment with clopidogrel." | 4.87 | Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. ( Martin, MT; Nutescu, EA; Spinler, SA, 2011) |
| "Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y(12) inhibitor, for 6?12 months after percutaneous coronary intervention with drug-eluting stent implantation in all patients and for 1 year in all patients after an acute coronary syndrome (ACS), irrespective of revascularization strategy." | 4.87 | Antiplatelet options for secondary prevention in acute coronary syndromes. ( Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J, 2011) |
| "Studies that reported clopidogrel metabolism, platelet reactivity or clinically relevant outcomes (cardiovascular disease [CVD] events and bleeding), and information on CYP2C19 genotype were included." | 4.87 | CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. ( Casas, JP; Hingorani, AD; Holmes, MV; Perel, P; Shah, T, 2011) |
| " Aspirin and, more recently, clopidogrel are among the most important treatments of cardiovascular diseases." | 4.86 | [Long-term use of oral antiplatelet therapy: from studies to practice]. ( Helft, G, 2010) |
| "Both clopidogrel and aspirin have been shown to decrease the rate of cardiovascular events and especially stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)." | 4.86 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. ( Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A, 2010) |
| " Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy." | 4.86 | Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010) |
| " Recent phase III data demonstrate that prasugrel is superior to clopidogrel in preventing cardiovascular morbidity and mortality in patients with acute coronary syndrome undergoing percutaneous coronary intervention, although with a greater risk of bleeding." | 4.86 | Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. ( Armani, AM, 2010) |
| "Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine." | 4.85 | Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009) |
| " Administration of antiplatelet therapy--a glycoprotein IIb-IIIa inhibitor with or without clopidogrel--before catheterization in patients with high-risk features confers substantially reduced risk of ischemic events while potentially increasing bleeding risk." | 4.85 | Does timing matter? Upstream or downstream administration of antiplatelet therapy. ( Pollack, CV; Slattery, D, 2009) |
| " The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial demonstrated a similar ischemic event rate to 30 days with a significantly lower bleeding event rate (enhanced net clinical benefit) in favor of bivalirudin monotherapy (with provisional platelet glycoprotein [GP] IIb/IIIa receptor blockade) in comparison with unfractionated heparin plus GP IIb/IIIa blockade in patients undergoing primary PCI for STEMI." | 4.85 | Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. ( Kereiakes, DJ, 2009) |
| "Earlier studies may have overestimated the risk of bleeding in patient undergoing CABG with prior clopidogrel exposure (5-10-fold increase)." | 4.85 | Coronary bypass surgery in patients treated with clopidogrel. Is it safe? ( Carrel, T; Englberger, L, 2009) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention." | 4.85 | Prasugrel: Clinical development and therapeutic application. ( Guerra, DR; Tcheng, JE, 2009) |
| " In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk." | 4.84 | Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008) |
| "To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease." | 4.84 | Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007) |
| "Clopidogrel has demonstrated improved outcomes for patients with acute coronary syndromes in several large randomized controlled trials." | 4.84 | Clopidogrel: who, when, and how? ( Cannon, CP, 2007) |
| " We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks." | 4.84 | Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is currently the standard therapy after coronary stent implantation to prevent a life-threatening stent thrombosis." | 4.84 | Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. ( Gawaz, M; Geisler, T; May, AE, 2008) |
| "To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin." | 4.84 | Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008) |
| "Prasugrel has demonstrated a greater platelet inhibition and a decreased incidence of ischemic events compared with clopidogrel, but with an increased incidence of bleeding events." | 4.84 | Prasugrel: a novel antiplatelet agent. ( Haber, SL; Riley, AB; Tafreshi, MJ, 2008) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| " Addition of aspirin and clopidogrel to patients already on warfarin increases the risk of bleeding, while withholding antiplatelet therapy increases the risk of stent thrombosis." | 4.82 | Antiplatelet therapy in anticoagulated patients requiring coronary intervention. ( Arab, D; Cho, L; Joyal, D; Lewis, B; Leya, F; Steen, L, 2005) |
| " The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events." | 4.80 | Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. ( Boysen, G, 1999) |
| "Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS)." | 4.31 | miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. ( Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL, 2023) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "To investigate the associations of perioperative P2Y12 reaction units (PRU) measured using VerifyNow with ischemic and bleeding events, and to determine the PRU threshold in the setting of elective neuro-endovascular treatment (EVT) for intracranial/extracranial vascular disease in patients taking aspirin and clopidogrel." | 4.12 | P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment. ( Fujii, S; Fujita, K; Hirai, S; Ishikawa, M; Karakama, J; Miki, K; Nemoto, S; Sumita, K; Yamaoka, H; Yoshimura, M, 2022) |
| "Enhanced platelet inhibition delivered by clopidogrel is associated with an increased risk for major bleeding and death in patients on OAC who undergo PCI." | 3.91 | Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. ( Bernlochner, I; Fiedler, KA; Goedel, A; Hoppmann, P; Kastrati, A; Laugwitz, KL; Maeng, M; Massberg, S; Mayer, K; Mehilli, J; Sarafoff, N; Schunkert, H; Schüpke, S; Sibbing, D; von Olshausen, G, 2019) |
| "Our study shows that the recommended dose of prasugrel had significantly higher in-hospital bleeding complications without reducing ischemic events compared with clopidogrel." | 3.88 | Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. ( Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2018) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 3.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| "Bleeding is one of the possible adverse events during clopidogrel therapy." | 3.88 | Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. ( Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L, 2018) |
| "Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent." | 3.88 | Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018) |
| " Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk." | 3.88 | Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM, 2018) |
| " Prasugrel was associated with fewer MACE, whereas clopidogrel had fewer major bleeding events." | 3.85 | Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. ( Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K, 2017) |
| "We studied 671 myocardial infarction (MI) patients treated with percutaneous coronary intervention in the TRANSLATE-ACS Registry who had VerifyNow platelet function testing performed while on clopidogrel treatment during their index hospitalization (April 2010-October 2012)." | 3.85 | Association of measured platelet reactivity with changes in P2Y ( Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Peterson, ED; Schulte, PJ; Stone, GW; Wang, TY; Zettler, ME, 2017) |
| "Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited." | 3.85 | Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry. ( Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I, 2017) |
| "Results of the current study showed that CYP4F2 rs3093135 TT variant carriers had a higher antiplatelet effect of ticagrelor, and more frequently had nonprocedural bleeding during ticagrelor therapy, as compared with AA and AT variant carriers." | 3.85 | The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. ( Giedraitiene, A; Kupstyte, N; Lesauskaite, V; Tatarunas, V; Zaliunas, R, 2017) |
| " Parameters associated with a presumably higher risk of bleeding and side-effects against the more effective P2Y12 inhibitors were the most prominent factors for the prescription of clopidogrel." | 3.85 | Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. ( Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R, 2017) |
| "Base-case scenario results at 30 days indicated that the incremental cost per major cardiovascular or bleeding event avoided for genotype-guided treatment was US$8525 and US$42,198 compared with universal clopidogrel and prasugrel, respectively." | 3.85 | CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. ( Borse, MS; Dong, OM; Farley, JF; Lee, CR; Polasek, MJ; Stouffer, GA, 2017) |
| "The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES." | 3.85 | Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017) |
| " However, the risk of rebleeding remains high, especially in patients with chronic ICH and those pretreated with clopidogrel." | 3.85 | Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage. ( Baschin, M; Greinacher, A; Kohlmann, T; Schroeder, HW; Selleng, S; Thiele, T; Westphal, A; Zeden, JP, 2017) |
| "The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR." | 3.85 | Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. ( Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017) |
| " Commonly used medications such as warfarin, heparin, aspirin, clopidogrel, and Opalmon (limaprost alfadex) were included as medications associated with bleeding tendency." | 3.85 | Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection. ( Lee, JH; Park, TK; Shin, SJ, 2017) |
| "CYP2C19 genetic polymorphisms had significant influence on the antiplatelet effect of clopidogrel, and could be considered as risk factors of ischemic or bleeding events and even clinical outcomes of patients with intracranial aneurysms treated with stent-assisted coiling." | 3.85 | Influence of CYP2C19 genetic polymorphisms on clinical outcomes of intracranial aneurysms treated with stent-assisted coiling. ( Ge, H; He, H; Jiang, Y; Jin, H; Li, Y; Liu, P; Lv, X; Ren, H, 2017) |
| "In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding." | 3.85 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "To report incidence of bleeding after image-guided percutaneous core needle biopsy performed in patients taking clopidogrel within 5 days." | 3.85 | Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel-A Retrospective Review. ( Atwell, T; Knudsen, J; McBane, R; McMenomy, B; Pieper, M; Schmitz, J; Wennberg, P, 2017) |
| "The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear." | 3.85 | Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after ( Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME, 2017) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 3.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| "Aspirin and clopidogrel are both acceptable antiplatelet options for the secondary prevention of noncardioembolic ischemic stroke." | 3.85 | Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. ( Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H, 2017) |
| " DPP-4 inhibitor-related bleeding was assessed with metformin as negative control, and aspirin, clopidogrel, and prasugrel illustrated positive comparators." | 3.85 | Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events. ( Hansen, RA; Rahman, MM; Scalese, MJ, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| " Compared to patients treated with aspirin+clopidogrel, patients treated with aspirin+prasugrel had fewer BARC 3 or 5 bleedings (two [0." | 3.83 | Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). ( Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J, 2016) |
| "The risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel." | 3.83 | Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. ( Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 3.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)." | 3.83 | Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016) |
| "Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period." | 3.83 | Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016) |
| "Results of a study of bleeding events and other inhospital outcomes with the use of clopidogrel versus prasugrel in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) are reported." | 3.83 | Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2016) |
| "Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)." | 3.83 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016) |
| "To evaluate the effect of bleedings for up to 12months on clinical events and therapeutic compliance in unselected STEMI patients treated with prasugrel or clopidogrel." | 3.83 | One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. ( Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L, 2016) |
| "To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease." | 3.83 | [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016) |
| " However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2." | 3.83 | Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. ( Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 3.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism." | 3.83 | Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu ( Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M, 2016) |
| " The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding." | 3.83 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. ( Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A, 2016) |
| "This study explores bleeding risk of warfarin patients undergoing radial catheterization." | 3.81 | Warfarin: Impact on hemostasis after radial catheterization. ( Gilchrist, IC; Kunselman, AR; Lippe, CM; Reineck, EA, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 3.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "We hypothesized that perioperative measurement of platelet function with a point-of-care P2Y12 inhibitor assay could predict bleeding during CABG in patients exposed to clopidogrel." | 3.81 | Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. ( Agnihotri, A; Aranki, S; Cannon, CP; Guo, J; Kumar, A; Maree, AO; McLean, DS; Reed, GW; Rosenfield, K; Shekar, P, 2015) |
| "There is a known bleeding risk with administration of the antiplatelet drug clopidogrel, but in certain patients the likelihood of thrombosis is too high to cease its administration perioperatively." | 3.81 | Uninterrupted perioperative clopidogrel and bleeding-related events after total joint arthroplasty: a case series. ( Bono, J; Nandi, S; Shubert, D, 2015) |
| "This study is the first to analyze differences in bleeding times between clopidogrel and prasugrel treatments during dental extraction." | 3.81 | Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy. ( Braunitzer, G; Dézsi, BB; Dézsi, CA; Hangyási, DB; Koritsánszky, L, 2015) |
| "This observational, nonrandomized study of ST-segment elevation myocardial infarction patients suggests that the administration of a loading dose of prasugrel in patients pre-treated with a loading dose of clopidogrel is not associated with an excess of major bleeding events." | 3.81 | Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. ( Auer, R; Baumbach, A; Carballo, D; Engstrøm, T; Gencer, B; Heg, D; Jüni, P; Kelbæk, H; Klingenberg, R; Lüscher, TF; Mach, F; Matter, CM; Meier, B; Moschovitis, A; Ostojic, M; Räber, L; Rodondi, N; Roffi, M; Stefanini, GG; Tüller, D; von Birgelen, C; Windecker, S; Zanchin, T, 2015) |
| "Patients on prasugrel had fewer cardiovascular events as compared to patients on clopidogrel twice daily with no difference in bleeding events." | 3.81 | Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population. ( Khatri, S; Pierce, T, 2015) |
| "Greater antithrombotic potency new antiplatelet agents have been added such as prasugrel (PR) and ticagrelor to the traditional use of clopidogrel (CL) in the treatment of acute coronary syndrome (ACS)." | 3.81 | [Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty]. ( Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M, 2015) |
| "Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding." | 3.81 | Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015) |
| "This ecological comparison of bleeding reports and dispensed prescriptions showed a signal towards a higher prevalence of bleeding reports in women on clopidogrel treatment while the opposite was found for low-dose aspirin." | 3.80 | Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. ( Holm, L; Loikas, D; Malmström, RE; Mejyr, S; Rydberg, DM; Schenck-Gustafsson, K; von Euler, M; Wettermark, B, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| " However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding." | 3.80 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 3.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "In a novel application, we prospectively monitored ischemic, bleeding, and mortality outcomes among patients initiating prasugrel versus clopidogrel in routine care during the first 2 years following the approval of prasugrel." | 3.80 | Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. ( Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G, 2014) |
| "We prospectively enrolled patients older than 20 years who had a history of noncardioembolic strokes, including transient ischemic attacks, were treated with ticlopidine for at least 6 months." | 3.80 | Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. ( Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014) |
| " We applied this method in examining the effect of an antiplatelet agent, clopidogrel, on events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted in coronary artery." | 3.80 | Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment. ( Ho, PM; Magid, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S, 2014) |
| "The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available." | 3.80 | Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. ( Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU, 2014) |
| " Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk." | 3.80 | Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. ( Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO, 2014) |
| "The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats." | 3.80 | Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014) |
| "To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel." | 3.80 | Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 3.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " Patients displaying low on-treatment platelet reactivity (LPR) and/or at high risk of bleeding were switched to clopidogrel 75 mg and tested again 15 days later." | 3.79 | Switching acute coronary syndrome patients from prasugrel to clopidogrel. ( Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB, 2013) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 3.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| " The aim of this study was to ascertain whether it is necessary to stop clopidogrel preoperatively to avoid postoperative complications following hip hemiarthroplasty surgery in patients with intracapsular hip fracture." | 3.79 | Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties. ( Hossain, FS; Koch, L; Rambani, R; Ribee, H, 2013) |
| " Whether the bolus dose alone is sufficient for ST-elevation myocardial infarction patients receiving a high loading dose of clopidogrel is unknown." | 3.79 | Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. ( Berglund, U; Janzon, M; Nilsson, L, 2013) |
| " This study sought to determine if trauma patients on preinjury clopidogrel with a higher degree of platelet inhibition (PI), as determined by the VerifyNow P2Y12 Test, experienced bleeding complications more frequently than did patients with a lower degree of PI." | 3.79 | Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. ( Ali, K; Cheng, J; Kram, B; Short, S; Taylor, S; Vasquez, D, 2013) |
| " We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES)." | 3.79 | Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. ( Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation." | 3.79 | The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013) |
| "The PLATO (Platelet Inhibition and Patient Outcomes) randomized trial (NCT00391872) in patients with acute coronary syndromes (ACS) reported that ticagrelor (in addition to aspirin) reduced the rate of the composite end point of myocardial infarction (MI), stroke, or cardiovascular death compared with clopidogrel (in addition to aspirin) by 16% over 12 months (P < 0." | 3.79 | Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. ( Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D, 2013) |
| "Clopidogrel is safer than ticagrelor in regard to bleeding." | 3.79 | Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. ( Biondi-Zoccai, G; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Niazi, AK; Tomek, A, 2013) |
| "Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD." | 3.79 | Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013) |
| "The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel." | 3.79 | Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. ( Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G, 2013) |
| "Patients with atrial fibrillation (AF) often receive, in addition to warfarin, antithrombotic drugs to manage other comorbid conditions." | 3.79 | The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. ( Azoulay, L; Dell'Aniello, S; Renoux, C; Simon, T; Suissa, S, 2013) |
| "The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications." | 3.79 | Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013) |
| " the pharmacokinetics of clopidogrel do not allow for bleeding time to return to normal until the drug has been discontinued for five days." | 3.78 | Operative treatment of hip fractures in patients on clopidogrel: a case-control study. ( Chaput, CD; Patel, KV; Probe, RA; Wallace, HC, 2012) |
| " Phenotyping of platelet response to clopidogrel was a better predictor of stent thrombosis than genotyping." | 3.78 | Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. ( Delle-Karth, G; Grzybowski, T; Huber, K; Jilma, B; Kozinski, M; Kubica, J; Lang, IM; Linkowska, K; Maurer, G; Neunteufl, T; Siller-Matula, JM, 2012) |
| " We applied these new methods in examining the effect of an anti-platelet agent, clopidogrel, on subsequent events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted into a coronary artery." | 3.78 | Extension of Kaplan-Meier methods in observational studies with time-varying treatment. ( Ho, PM; Magid, D; Powers, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S, 2012) |
| "For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel." | 3.78 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012) |
| "Guidelines stipulate that clopidogrel should be interrupted ≥ 5 days prior to elective coronary artery bypass graft (CABG) surgery to reduce the risk of bleeding unless the need for revascularization and/or the net benefit of the clopidogrel outweighs the potential risks of bleeding." | 3.78 | Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption. ( Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS, 2012) |
| " This study aimed to assess the risk of bleeding complications in patients receiving clopidogrel at the time of cardiac device surgery." | 3.78 | Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. ( Acheré, C; Boulé, S; Brigadeau, F; Goéminne-Boulé, C; Guédon-Moreau, L; Kacet, S; Klug, D; Kouakam, C; Lacroix, D; Marquié, C; Vanesson-Bricout, C, 2012) |
| "Simulated cohort of patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention (PCI), consisting of three arms: those receiving genotype-guided antiplatelet therapy with clopidogrel or prasugrel, those receiving clopidogrel regardless of genotype, and those receiving prasugrel regardless of genotype." | 3.78 | Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. ( Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES, 2012) |
| " The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine." | 3.78 | Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012) |
| "Patients receiving clopidogrel beyond 12 months had a lower risk of death or myocardial infarction compared patients receiving clopidogrel ≤12 months." | 3.78 | Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. ( Faxon, DP; Gaziano, M; Kinlay, S; Lawler, E; Young, M, 2012) |
| "To assess the impact of cytochrome P450 (CYP) 2C19*17 allelic variant on platelet aggregation and bleeding risk in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI) and treated with clopidogrel." | 3.78 | Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. ( Chen, H; Dai, ZL; Wu, XY, 2012) |
| "Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge." | 3.78 | Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 3.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| "On July 20, 2011, the Food and Drug Administration (FDA) approved ticagrelor (Brilinta™) for use during acute coronary syndromes." | 3.78 | Ticagrelor FDA approval issues revisited. ( Serebruany, VL, 2012) |
| "We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years." | 3.78 | [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma." | 3.78 | Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. ( Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| "The aim of this study was to evaluate the prevalence of triple antithrombotic therapy (TT) (warfarin, aspirin and clopidogrel) in patients following an acute coronary syndrome (ACS), the bleeding risk compared to double antiplatelet therapy (DAPT) (aspirin and clopidogrel) and evaluate the accuracy of the HAS-BLED risk score in predicting serious bleeding events in TT patients." | 3.78 | Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. ( Braun, OÖ; Koul, S; Lumsden, J; Ohman, J; Rydell, E; Scherstén, F; Smith, JG; Svensson, PJ; van der Pals, J; Wieloch, M, 2012) |
| " Clopidogrel (a compound that inhibits adenosine diphosphate-induced platelet aggregation) is often prescribed for primary or secondary prevention of cardiovascular disease and has been associated with bleeding complications in patients undergoing surgical procedures." | 3.78 | Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis. ( Bechara, RI; Berkowitz, DM; Parks, C; Zalt, MB, 2012) |
| "We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age." | 3.78 | [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012) |
| "Our results show that renal failure history and clopidogrel and GPIIb/IIIa receptor antagonist use are independent risk factors for in-hospital bleeding in patients with acute coronary syndrome." | 3.78 | [Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization]. ( Chen, YD; Jin, ZN; Liu, H; Liu, X; Lü, SZ; Song, XT, 2012) |
| "Coronary artery bypass grafting (CABG) performed within 5 days of clopidogrel administration is associated with increased bleeding." | 3.77 | Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. ( Cruden, NL; Hilton, JD; Klinke, WP; Morch, K; Ofiesh, J; Wong, DR, 2011) |
| "The objective of this study was to examine the clinical efficacy of clopidogrel treatment on death and recurrent myocardial infarction (MI) among MI patients revascularized by coronary artery bypass graft surgery (CABG)." | 3.77 | Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. ( Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2011) |
| "We do not routinely discontinue clopidogrel before colonoscopy because we have judged the cardiovascular risks of that practice to exceed the risks of post-polypectomy bleeding (PPB)." | 3.77 | The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. ( Davila, RE; Feagins, LA; Harford, WV; Spechler, SJ; Uddin, FS, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 3.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "Although clopidogrel pretreatment benefits patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes, these benefits are less well established among patients undergoing elective PCI--in particular, when they are treated with the direct thrombin inhibitor, bivalirudin." | 3.77 | Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). ( Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN, 2011) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 3.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "Data are lacking on the efficacy and safety of a loading dose (LD) of clopidogrel in elderly patients with acute myocardial infarction (AMI)." | 3.77 | Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry). ( Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T, 2011) |
| " We sought to determine if carbon monoxide-releasing molecule-2 [tricarbonyldichlororuthenium (II) dimer, CORM-2] would improve coagulation in rabbit plasma in vitro via thrombelastography and in an in vivo preclinical rabbit model of ear bleeding time following administration of clopidogrel (20 mg/kg) with aspirin (10 mg/kg) via gavage." | 3.77 | Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits. ( Arkebauer, MR; Chawla, N; Gomes, SB; Mangla, D; Nielsen, VG; Sadacharam, K; Vosseller, K; Wasko, KA, 2011) |
| "Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis." | 3.77 | Clopidogrel (plavix). ( Comin, J; Kallmes, D, 2011) |
| "To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel." | 3.76 | Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010) |
| "The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI." | 3.76 | Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding." | 3.76 | Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010) |
| "CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding." | 3.76 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| " This study sought to evaluate procedural major bleeding and myocardial infarction in patients undergoing stent implantation with adjunctive clopidogrel compared with ticlopidine." | 3.76 | Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation. ( Hayashi, F; Iijima, R; Nakamura, M; Sugi, K, 2010) |
| "Higher clopidogrel use 12 months after drug-eluting stent implantation was associated with a greater risk of subsequent bleeding events." | 3.76 | Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. ( Anstrom, KJ; Barron, JJ; Califf, RM; Curtis, LH; Cziraky, MJ; Eisenstein, EL; Hammill, BG; Krucoff, MW; Petersen, JL; Schulman, KA; Wahl, PM, 2010) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 3.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "Previous DAPT studies consistently demonstrated greater efficacy but an increased risk of bleeding compared with aspirin alone in patients with acute coronary syndromes or undergoing percutaneous coronary intervention." | 3.76 | Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. ( Bhatt, DL; Boden, WE; Flather, MD, 2010) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 3.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 3.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 3.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern." | 3.76 | National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. ( Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010) |
| " Our algorithm, which is in the process of being implemented, is consistent with published and generally accepted standards of care and is based on data from the pivotal Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, which compared clopidogrel with prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention." | 3.76 | An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. ( Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F, 2010) |
| "Current guidelines recommend dual antiplatelet therapy using aspirin and clopidogrel for non-ST elevation acute coronary syndromes (ACS)." | 3.75 | Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. ( De Servi, S; Mariani, G; Mariani, M, 2009) |
| "The new P2Y(12) antagonist prasugrel produces greater inhibition of ADP-induced platelet aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of clopidogrel, but increases major bleeding." | 3.75 | Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. ( Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC, 2009) |
| " Clopidogrel (Plavix), a selective P(2)Y(12) antagonist, prevents platelets from clotting but thereby increases the risk of severe or fatal bleeding." | 3.75 | Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. ( Andrésson, T; Bjarnadottir, M; Bjornsson, JM; Fabre, JE; Gurney, ME; Hategen, G; Kiselyov, A; Magnusson, O; Mishra, R; Onua, E; Polozov, A; Ramírez, JL; Sigthorsson, G; Singh, J; Stefansson, K; Thorsteinsdottir, M; Yu, P; Zeller, W; Zembower, D; Zhang, J; Zhou, N, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "Acute coronary syndrome (ACS) guidelines recommend that most patients receive dual antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) at the time of presentation to prevent recurrent ischemic events." | 3.75 | Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. ( Bittira, B; Brister, S; Eikelboom, J; Fitchett, D; Fremes, S; Graham, J; Gupta, M; Karkouti, K; Lee, A; Love, M; Mazer, D; McArthur, R; Peterson, M; Singh, S; Verma, S; Yau, T, 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 3.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| " 2 patients who were treated with concomitant warfarin had bleeding complications (severe epistaxis and gastrointestinal bleeding)." | 3.74 | Safety and efficacy of clopidogrel in children with heart disease. ( Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008) |
| "The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period." | 3.74 | Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 3.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding." | 3.74 | Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. ( Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V, 2008) |
| "To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage." | 3.74 | Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007) |
| " Bleeding caused by some combination of nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase-2-selective NSAIDS, aspirin, and clopidogrel was the most common reason for ADR-related MICU admissions." | 3.74 | Admissions to a medical intensive care unit related to adverse drug reactions. ( Rivkin, A, 2007) |
| " Fibrin(ogen) deposition, light transmittance aggregometry (LTA; collagen, U46619, and ADP), and bleeding time (BT) were also evaluated." | 3.74 | A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. ( Badimon, L; Casaní, L; Vilahur, G, 2007) |
| "To determine the risk of major and minor bleeding associated with the CTT compared with two other regimens using the combination of either ASA and clopidogrel or ASA and warfarin in patients with cardiovascular disease." | 3.74 | Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute. ( Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M, 2007) |
| "We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)." | 3.74 | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008) |
| "The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors." | 3.74 | What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008) |
| "In patients with RI undergoing PCI, adding abciximab to clopidogrel plus aspirin increases the risk of bleeding without benefit in reducing the risk of ischemic complications within the first 30 days." | 3.74 | Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. ( Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S, 2008) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Clopidogrel, with or without aspirin, does not increase bleeding complications after TBLB in healthy pigs." | 3.73 | Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. ( Becker, HD; Ernst, A; Feller-Kopman, D; Garland, R; Herth, F; Wahidi, MM, 2005) |
| "We report a rare case in which life-threatening subcutaneous hemorrhage following minor blunt trauma developed in an elderly patient taking ticlopidine and aspirin." | 3.73 | Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report. ( Hagiwara, A; Matsuda, T; Shimazaki, S, 2005) |
| " Patients who are on chronic warfarin therapy and receive a coronary stent need to be treated with the triple therapy of aspirin, clopidogrel and warfarin; however, the bleeding risk in these patients is unknown." | 3.73 | Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. ( Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006) |
| " Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy." | 3.73 | Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 3.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)." | 3.73 | Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006) |
| "We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period." | 3.72 | Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004) |
| "Pulmonary hemorrhage following percutaneous coronary intervention is a very rare complication that has been previously reported in association with abciximab and tirofiban, but not with clopidogrel." | 3.71 | Diffuse alveolar hemorrhage after clopidogrel use. ( Kilaru, PK; Kozman, HA; Schweiger, MJ; Weil, TR, 2001) |
| " A significant increase in postoperative hemorrhage and a higher percentage of reoperations for this reason was observed in the patients treated with ticlopidine." | 3.67 | Ticlopidine as a hemorrhagic risk factor in coronary surgery. ( Avello, F; Carmona, J; Criado, A; Juffé, A; Otero, C, 1985) |
| " Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months." | 2.84 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017) |
| "Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events." | 2.84 | Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2017) |
| "Major bleeding is associated with high subsequent mortality in ACS." | 2.80 | Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. ( Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2015) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 2.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| " The PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI (PRASFIT-Elective) study investigated the efficacy and safety of different prasugrel dosing regimens in Japanese patients undergoing elective PCI." | 2.79 | Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| " The prevalence of adverse events was assessed at each visit through a direct interview." | 2.78 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013) |
| "Major bleeding was strongly associated with 30-day mortality (OR 50." | 2.76 | Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. ( Aout, M; Barthelemy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Connor, S'; Montalescot, G; Payot, L; Silvain, J; Vicaut, E, 2011) |
| "Serious bleeding was associated with a significantly increased adjusted hazard ratio of 5." | 2.76 | Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- ( Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD, 2011) |
| "Fatal bleeding was low and did not differ between groups." | 2.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| " Some recent studies have suggested that a higher clopidogrel maintenance dosage could enhance ex vivo platelet inhibition and thereby overcome resistance to clopidogrel." | 2.75 | High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. ( Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010) |
| " Monafram was introduced intravenously to 284 patients just before angioplasty at standard dosage - 0." | 2.75 | [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010) |
| " A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis." | 2.69 | A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| "Aspirin was established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients with coronary artery disease based on limited data by contemporary standards." | 2.53 | A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. ( Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC, 2016) |
| "Major bleeding was the primary end point, whereas all-cause death, myocardial infarction (MI), stent thrombosis, and stroke were secondary ones." | 2.52 | Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. ( Ballocca, F; Bangalore, S; Barbero, U; Capodanno, D; Cerrato, E; Conrotto, F; D'Ascenzo, F; Dewilde, W; DiNicolantonio, J; Fernández, S; Gaita, F; Giordana, F; Grossomarra, W; Lamberts, M; Meier, P; Meynet, I; Moretti, C; Omedè, P; Persson, J; Quadri, G; Reed, M; Rubboli, A; Taha, S; Zoccai, G, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| " The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events." | 2.50 | Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014) |
| " Other adverse events observed in patients treated with this platelet inhibitor are discussed, including hematological complications, and cutaneous and hepatic idiosyncratic reactions." | 2.50 | Efficacy and safety of prasugrel in acute coronary syndrome patients. ( Delzor, F; Nanau, RM; Neuman, MG, 2014) |
| " Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie." | 2.49 | [Thrombocyte aggregation inhibitors: what are the risks?]. ( Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013) |
| " A "one size fits all" approach to clopidogrel dosing is probably flawed." | 2.49 | Clopidogrel "resistance": where are we now? ( Hobson, AR; Qureshi, Z, 2013) |
| " The comparator was standard dosage of clopidogrel." | 2.49 | Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. ( Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A, 2013) |
| " Whether this is worth both the risk of non-compliance with twice-a-day dosing in real-life patients lacking the same motivation as their trial-volunteer counterparts, and the 2000-fold difference in incremental cost, is the remaining matter for debate." | 2.48 | Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. ( Davies, JE; Francis, DP; Nijjer, SS, 2012) |
| " The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option." | 2.48 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012) |
| " Therefore the optimal dosage and duration of clopidogrel therapy is of utmost importance." | 2.48 | Clinical use of clopidogrel. ( Byrne, RA; Sarafoff, N; Sibbing, D, 2012) |
| " The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications)." | 2.47 | Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. ( Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP, 2011) |
| "Cangrelor is an intravenous direct and reversible inhibitor of the P2Y(12) receptor providing the highest level of inhibition and elinogrel is an intravenous and oral P2Y(12) antagonist with a direct and reversible action." | 2.47 | [Myocardial infarction: Role of new antiplatelet agents]. ( Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J, 2011) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| " Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1." | 2.47 | Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011) |
| "Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile." | 2.46 | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. ( Banning, AP; Bedogni, F; Bhindi, R; Biondi Zoccai, GG; Brambilla, N; Lanotte, S; Latini, RA; Laudisa, ML; Pizzocri, S; Testa, L; Valgimigli, M; Van Gaal, WJ, 2010) |
| "Tirofiban is safe and effective in patients with ACS." | 2.46 | Safety evaluation of tirofiban. ( Tebaldi, M; Valgimigli, M, 2010) |
| " We conclude that the benefits of prasugrel are overestimated, and the risks, especially during chronic use are underestimated." | 2.45 | Prasugrel development - claims and achievements. ( Kopyleva, O; Serebruany, V; Shalito, I, 2009) |
| "Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone." | 2.45 | Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? ( Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009) |
| " For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important." | 2.45 | Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. ( Spinler, SA, 2009) |
| "Despite many recent advancements in the treatment of coronary heart disease, it continues to be an important source of patient morbidity and mortality as well as a significant source of healthcare-related expenditures." | 2.44 | The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes. ( Collins, JS; Gurm, HS, 2007) |
| "Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience." | 2.42 | Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. ( Kerr, JL; Oppelt, TF; Rowen, RC, 2004) |
| "Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy." | 2.40 | Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. ( Schafer, AI, 1997) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "To describe and evaluate the bleeding-related adverse events associated with use of P2Y12 inhibitors utilizing data from the FDA Adverse Event Reporting System (FAERS) database." | 1.51 | Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system. ( Abou-Ali, A; Fahmy, AI; Mekkawy, MA, 2019) |
| "to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials." | 1.51 | Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019) |
| "Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit." | 1.46 | Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2017) |
| "Bleeding was the primary outcome." | 1.46 | Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017) |
| "The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear." | 1.46 | Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). ( Cabrera-Fuentes, HA; Cho, YR; Kim, MH; Kim, YD; Lee, K; Park, K; Park, TH; Serebruany, VL; Yoon, SC, 2017) |
| "All hematomas were without clinical consequences." | 1.43 | Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy. ( Bernat, I; Dragounová, E; Hromádka, M; Jirouš, Š; Pechman, V; Rokyta, R; Seidlerová, J; Tůmová, P, 2016) |
| "Immunological TRALI was tested in mice exhibiting severe thrombocytopenia or platelet dysfunction." | 1.43 | Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse. ( de la Salle, H; El Mdawar, MB; Gachet, C; Hechler, B; Heim, V; Magnenat, S; Maître, B, 2016) |
| "There was no major adverse cardiac event (MACE) and pouch infection were observed among 3 groups in perioperation." | 1.43 | [Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy]. ( Cong, H; Li, X; Li, Z; Wang, Z; Zhang, F; Zhang, L, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 1.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 1.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Major bleeding was a significant correlate of DAPT ANA within 6 months." | 1.42 | Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015) |
| "Vorapaxar is a novel protease-activated receptor-1 (PAR-1) antagonist recently approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease." | 1.42 | Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. ( Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA, 2015) |
| "Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA." | 1.40 | Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. ( Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014) |
| "Furthermore, using a carotid artery thrombosis model, these agents prolonged the time for thrombotic occlusion in mice in vivo." | 1.40 | The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. ( Espinosa, EV; Karim, ZA; Khasawneh, FT; Lin, OA; Vemana, HP, 2014) |
| "Bleeding was assessed using the Bleeding Academic Research Consortium criteria." | 1.40 | Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. ( Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S, 2014) |
| "In a murine model of myocardial reperfusion injury caused by transient coronary artery occlusion, APT102 also decreased infarct size by 51%, whereas clopidogrel was not effective." | 1.40 | Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. ( Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X, 2014) |
| " The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI." | 1.40 | A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. ( Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG, 2014) |
| "Intrahepatic hemorrhage is a very rare complication of warfarin, and our patient experienced intrahepatic and subgaleal hemorrhage although she did not have any risk factors for bleeding or instability of the international normalized ratio control." | 1.39 | Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. ( Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC, 2013) |
| "Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions." | 1.38 | Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012) |
| "We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0." | 1.38 | Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012) |
| "Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial." | 1.38 | Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? ( DiNicolantonio, JJ; Serebruany, VL, 2012) |
| "An increasing proportion of trauma patients are on anticoagulation or antiplatelet therapy." | 1.37 | A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients. ( Bansal, V; Coimbra, R; Doucet, J; Fortlage, D; Lee, J; Potenza, B, 2011) |
| "Coronary artery disease was associated with increased risk (OR=11." | 1.36 | Femoral artery complications after cardiac catheterization: a study of patient profile. ( Almaroof, B; Castillo-Sang, M; Cireddu, J; Engoren, M; Kasper, G; Sferra, J; Tsang, AW; Zelenock, GB, 2010) |
| "Thrombosis is still the first cause of microsurgery failure." | 1.36 | [Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers]. ( Dumont, LA; Gangloff, D; Garrido-Stowhas, I; Rongières, M; Tchénio, P, 2010) |
| "Nuisance bleeding is common in patients on prolonged DAPT post-DES implantation and can impact compliance." | 1.36 | Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. ( Ben-Dor, I; Collins, SD; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kaneshige, K; Kent, KM; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Scheinowitz, M; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2010) |
| "Approaches to the treatment of acute coronary syndrome in patients with thrombocytopenia might be better directed toward the evaluation of platelet function rather than toward absolute platelet count, and the risk-benefit equation of invasive procedures and antithrombotic therapies may need to incorporate this information." | 1.36 | Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. ( Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW, 2010) |
| "We report on a severely injured trauma patient who suffered a high velocity motorcycle accident." | 1.36 | High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. ( Hanke, A; Posch, A; Schöchl, H; Solomon, C; Voelckel, W, 2010) |
| "Ticagrelor has shown a significant ischemic benefit and an increase in non-surgical bleeding over clopidogrel in the large phase 3 Platelet Inhibition and Patient Outcomes trial." | 1.36 | Emerging oral antiplatelet therapies for acute coronary syndromes. ( Pollack, CV, 2010) |
| " The long-term use of antiplatelet agents is a key component of secondary prevention measures following acute coronary syndromes, including ST-segment elevation myocardial infarction." | 1.36 | Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. ( Minarelli, M; Valgimigli, M, 2010) |
| "Despite a lack of clear recommendations to guide decision-making, reductions in enoxaparin sodium dosage in the elderly and in patients with mild and moderate renal dysfunction are common in patients with acute coronary syndrome." | 1.35 | Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study. ( Beckerman, P; Ben-Artzi, M; Ben-Yehuda, A; Haber, G; Levin, A; Muszkat, M; Varon, D, 2009) |
| "Non-ST-elevation acute coronary syndrome is associated with significant morbidity and mortality." | 1.35 | Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. ( Bonaca, M; Giugliano, R; Hoekstra, JW; Lefebvre, CW, 2009) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 1.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 1.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| "Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1." | 1.32 | [Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| "Hemorrhage was present in 9 cases of group B (21." | 1.30 | [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997) |
| "In 8 patients with liver cirrhosis who underwent hepatectomy, one patient with a prolonged T2 (260 secs) and a normal skin BT bled postoperatively, however, 3 patients with a prolonged skin BT (greater than 15 min) and a normal T2 had no hemorrhagic complications." | 1.27 | Clinical application of a new in vitro bleeding time device on surgical patients. ( Itoh, T; Kambayashi, J; Mori, T; Sakon, M; Tsujinaka, T; Uemura, Y, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (0.53) | 18.7374 |
| 1990's | 20 (2.13) | 18.2507 |
| 2000's | 260 (27.75) | 29.6817 |
| 2010's | 636 (67.88) | 24.3611 |
| 2020's | 16 (1.71) | 2.80 |
| Authors | Studies |
|---|---|
| Lyu, SQ | 1 |
| Zhu, J | 2 |
| Wang, J | 2 |
| Wu, S | 1 |
| Zhang, H | 3 |
| Shao, XH | 1 |
| Yang, YM | 1 |
| Schultz-Lebahn, A | 1 |
| Nissen, PH | 1 |
| Pedersen, TF | 1 |
| Tang, M | 1 |
| Hvas, AM | 1 |
| Piccin Padilla, M | 1 |
| Macedo, LSDN | 1 |
| França, ACW | 1 |
| Meirelles, I | 1 |
| Magliano, CADS | 1 |
| Santos, MDS | 1 |
| Lee, YJ | 1 |
| Cho, JY | 3 |
| Yun, KH | 2 |
| Lee, SJ | 1 |
| Hong, SJ | 4 |
| Ahn, CM | 3 |
| Kim, BK | 4 |
| Ko, YG | 3 |
| Choi, D | 3 |
| Hong, MK | 6 |
| Jang, Y | 5 |
| Kim, JS | 4 |
| Wang, X | 7 |
| Zhu, Q | 1 |
| Wu, Y | 4 |
| Li, H | 5 |
| Deng, X | 1 |
| Cheng, J | 2 |
| Zhang, Z | 2 |
| Ma, Y | 1 |
| Shi, T | 1 |
| Fujita, K | 1 |
| Fujii, S | 1 |
| Hirai, S | 1 |
| Yamaoka, H | 1 |
| Ishikawa, M | 1 |
| Karakama, J | 1 |
| Miki, K | 1 |
| Yoshimura, M | 1 |
| Nemoto, S | 1 |
| Sumita, K | 1 |
| Moustafa, B | 1 |
| Testai, FD | 1 |
| Liu, H | 4 |
| Shao, T | 1 |
| Yang, T | 1 |
| Li, D | 1 |
| Wang, H | 3 |
| Cheng, Y | 1 |
| Zhang, T | 1 |
| Zhang, J | 3 |
| Serebruany, VL | 15 |
| Tanguay, JF | 5 |
| Gurvich, ML | 1 |
| Marciniak, TA | 1 |
| Atar, D | 2 |
| Mo, ZZ | 1 |
| Yuan, Z | 1 |
| Peng, YY | 1 |
| Zhou, WL | 1 |
| Dai, W | 1 |
| Wang, G | 2 |
| Tang, J | 1 |
| Zhang, W | 1 |
| Chen, BL | 1 |
| Girotra, S | 1 |
| Stebbins, A | 1 |
| Wruck, L | 1 |
| Marquis-Gravel, G | 1 |
| Gupta, K | 1 |
| Farrehi, P | 1 |
| Benziger, CP | 1 |
| Effron, MB | 7 |
| Whittle, J | 1 |
| Muñoz, D | 1 |
| Kripalani, S | 1 |
| Anderson, RD | 1 |
| Jain, SK | 1 |
| Polonsky, TS | 1 |
| Ahmad, FS | 1 |
| Roe, MT | 14 |
| Rothman, RL | 1 |
| Harrington, RA | 24 |
| Hernandez, AF | 1 |
| Jones, WS | 2 |
| Lim, GB | 1 |
| Tan, WK | 1 |
| Watanabe, H | 1 |
| Kimura, T | 8 |
| Jimeno-Sánchez, J | 1 |
| Fuertes-Ferre, G | 1 |
| Ruiz-Aranjuelo, A | 1 |
| Caballero-Jambrina, I | 1 |
| Diarte-de Miguel, JA | 1 |
| Ortas-Nadal, MR | 1 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Cao, D | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Godino, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 1 |
| De Caterina, R | 3 |
| Condorelli, G | 1 |
| Ferrante, G | 2 |
| Stefanini, GG | 3 |
| Cho, YH | 1 |
| Kim, YH | 5 |
| Suh, Y | 1 |
| Her, AY | 2 |
| Cho, S | 2 |
| Jeon, DW | 3 |
| Yoo, SY | 2 |
| Cho, DK | 2 |
| Hong, BK | 1 |
| Kwon, H | 1 |
| Shin, DH | 2 |
| Nam, CM | 1 |
| Ferraris, VA | 2 |
| Kim, GU | 1 |
| Lee, S | 3 |
| Choe, J | 1 |
| Hwang, SW | 1 |
| Park, SH | 2 |
| Ye, BD | 1 |
| Byeon, JS | 1 |
| Myung, SJ | 1 |
| Yang, SK | 1 |
| Yang, DH | 1 |
| Ge, Z | 1 |
| Gao, XF | 1 |
| Kan, J | 1 |
| Kong, XQ | 1 |
| Zuo, GF | 1 |
| Ye, F | 1 |
| Tian, NL | 1 |
| Lin, S | 1 |
| Liu, ZZ | 1 |
| Shao, YB | 1 |
| He, YQ | 1 |
| Wen, SY | 1 |
| Yang, Q | 1 |
| Xia, Y | 1 |
| Wang, ZZ | 1 |
| Xiao, PX | 1 |
| Li, F | 1 |
| Zeng, HS | 1 |
| Yang, S | 2 |
| Wang, Y | 12 |
| Tao, L | 1 |
| Gao, DS | 1 |
| Qu, H | 1 |
| Qian, XS | 1 |
| Han, YL | 4 |
| Chen, F | 1 |
| Zhang, JJ | 1 |
| Chen, SL | 1 |
| Ohman, EM | 12 |
| Steg, PG | 34 |
| James, SK | 13 |
| Povsic, TJ | 2 |
| White, J | 2 |
| Rockhold, F | 1 |
| Plotnikov, A | 1 |
| Mundl, H | 1 |
| Strony, J | 2 |
| Sun, X | 2 |
| Husted, S | 17 |
| Tendera, M | 1 |
| Montalescot, G | 33 |
| Bahit, MC | 1 |
| Ardissino, D | 6 |
| Bueno, H | 2 |
| Claeys, MJ | 3 |
| Nicolau, JC | 3 |
| Cornel, JH | 10 |
| Goto, S | 3 |
| Kiss, RG | 6 |
| Güray, Ü | 1 |
| Park, DW | 4 |
| Bode, C | 3 |
| Welsh, RC | 6 |
| Gibson, CM | 16 |
| Rubboli, A | 5 |
| Saia, F | 5 |
| Sciahbasi, A | 3 |
| Leone, AM | 1 |
| Palmieri, C | 2 |
| Bacchi-Reggiani, ML | 2 |
| Calabrò, P | 4 |
| Bordoni, B | 1 |
| Piccalò, G | 1 |
| Franco, N | 1 |
| Nicolino, A | 1 |
| Magnavacchi, P | 2 |
| Vignali, L | 1 |
| Mameli, S | 1 |
| Dallago, M | 1 |
| Maggiolini, S | 1 |
| Steffanon, L | 2 |
| Piovaccari, G | 1 |
| Di Pasquale, G | 2 |
| De Luca, L | 3 |
| D'Ascenzo, F | 5 |
| Musumeci, G | 6 |
| Parodi, G | 3 |
| Varbella, F | 1 |
| Marchese, A | 1 |
| De Servi, S | 7 |
| Berti, S | 1 |
| Bolognese, L | 3 |
| Zhai, Y | 1 |
| He, H | 2 |
| Ma, X | 1 |
| Xie, J | 1 |
| Meng, T | 1 |
| Dong, Y | 1 |
| Lu, J | 2 |
| Alfredsson, J | 1 |
| Neely, B | 4 |
| Neely, ML | 4 |
| Bhatt, DL | 39 |
| Goodman, SG | 8 |
| Tricoci, P | 4 |
| Mahaffey, KW | 15 |
| White, HD | 16 |
| Fox, KA | 26 |
| Prabhakaran, D | 7 |
| Winters, KJ | 7 |
| Armstrong, PW | 10 |
| Melkonian, M | 1 |
| Jarzebowski, W | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| Belmin, J | 1 |
| Lafuente-Lafuente, C | 1 |
| Lindholm, D | 2 |
| Hagström, E | 2 |
| Becker, RC | 16 |
| Cannon, CP | 23 |
| Himmelmann, A | 9 |
| Katus, HA | 7 |
| Maurer, G | 3 |
| López-Sendón, JL | 2 |
| Storey, RF | 23 |
| Siegbahn, A | 3 |
| Wallentin, L | 20 |
| Sukul, D | 1 |
| Seth, M | 1 |
| Dixon, SR | 1 |
| Khandelwal, A | 1 |
| LaLonde, TA | 1 |
| Gurm, HS | 3 |
| Rao, SV | 5 |
| Qiao, M | 1 |
| Bi, Q | 1 |
| Fu, P | 1 |
| Song, Z | 1 |
| Guo, F | 1 |
| Coons, JC | 1 |
| Iasella, CJ | 1 |
| Chanas, T | 1 |
| Wang, N | 1 |
| Williams, K | 1 |
| Boyd, A | 1 |
| Lyons, J | 1 |
| Eckardt, J | 1 |
| Rihtarchik, L | 1 |
| Merkel, A | 1 |
| Chambers, A | 1 |
| Lemon, LS | 1 |
| Smith, R | 1 |
| Ensor, CR | 1 |
| Oimatsu, Y | 1 |
| Kaikita, K | 1 |
| Ishii, M | 1 |
| Mitsuse, T | 1 |
| Ito, M | 1 |
| Arima, Y | 1 |
| Sueta, D | 1 |
| Takahashi, A | 1 |
| Iwashita, S | 1 |
| Yamamoto, E | 1 |
| Kojima, S | 1 |
| Hokimoto, S | 1 |
| Tsujita, K | 1 |
| Bagai, A | 2 |
| Peterson, ED | 10 |
| McCoy, LA | 3 |
| Zettler, ME | 2 |
| Stone, GW | 23 |
| Henry, TD | 9 |
| Cohen, DJ | 11 |
| Schulte, PJ | 4 |
| Anstrom, KJ | 3 |
| Wang, TY | 9 |
| Ducrocq, G | 2 |
| Budaj, A | 10 |
| Held, C | 8 |
| Lopes, RD | 8 |
| Sorbets, E | 2 |
| Jang, HJ | 1 |
| Park, SD | 1 |
| Park, HW | 1 |
| Suh, J | 1 |
| Oh, PC | 2 |
| Moon, J | 1 |
| Lee, K | 4 |
| Kang, WC | 2 |
| Kwon, SW | 1 |
| Kim, TH | 2 |
| Xanthopoulou, I | 7 |
| Davlouros, P | 1 |
| Deftereos, S | 3 |
| Hamilos, M | 4 |
| Sitafidis, G | 4 |
| Kanakakis, I | 3 |
| Vavouranakis, M | 3 |
| Goudevenos, J | 4 |
| Lekakis, J | 4 |
| Alexopoulos, D | 8 |
| Secemsky, EA | 1 |
| Yeh, RW | 4 |
| Kereiakes, DJ | 7 |
| Cutlip, DE | 4 |
| Massaro, JM | 2 |
| Apruzzese, PK | 1 |
| Mauri, L | 5 |
| Pareek, M | 1 |
| Ten Berg, JM | 10 |
| Kristensen, SD | 4 |
| Grove, EL | 3 |
| Cuisset, T | 9 |
| Deharo, P | 1 |
| Quilici, J | 7 |
| Johnson, TW | 1 |
| Deffarges, S | 1 |
| Bassez, C | 1 |
| Bonnet, G | 1 |
| Fourcade, L | 2 |
| Mouret, JP | 2 |
| Lambert, M | 4 |
| Verdier, V | 1 |
| Morange, PE | 6 |
| Alessi, MC | 7 |
| Bonnet, JL | 7 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 1 |
| Huber, K | 17 |
| Halvorsen, S | 1 |
| Van de Werf, F | 5 |
| Rodés-Cabau, J | 4 |
| Masson, JB | 1 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 2 |
| Al-Qoofi, F | 1 |
| Généreux, P | 8 |
| Maluenda, G | 3 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Choi, HI | 1 |
| Ahn, JM | 3 |
| Kang, SH | 3 |
| Lee, PH | 1 |
| Kang, SJ | 3 |
| Lee, SW | 6 |
| Lee, CW | 3 |
| Park, SW | 3 |
| Park, SJ | 4 |
| Martin, AC | 2 |
| Houssany-Pissot, S | 1 |
| Zlotnik, D | 1 |
| Taylor, G | 2 |
| Godier, A | 3 |
| Hansson, EC | 1 |
| Jeppsson, A | 1 |
| Tatarunas, V | 1 |
| Kupstyte, N | 1 |
| Zaliunas, R | 1 |
| Giedraitiene, A | 1 |
| Lesauskaite, V | 1 |
| Piccolo, R | 3 |
| Gargiulo, G | 3 |
| Franzone, A | 3 |
| Santucci, A | 3 |
| Ariotti, S | 4 |
| Baldo, A | 2 |
| Tumscitz, C | 1 |
| Moschovitis, A | 2 |
| Windecker, S | 6 |
| Valgimigli, M | 16 |
| Sun, Q | 1 |
| Chang, S | 1 |
| Lu, S | 1 |
| Zhang, Y | 5 |
| Chang, Y | 1 |
| Liu, Y | 4 |
| Hao, Y | 1 |
| Hao, Z | 1 |
| Geng, G | 1 |
| Han, W | 1 |
| Chen, Q | 1 |
| Wang, D | 4 |
| Liu, L | 5 |
| Jia, K | 1 |
| Zhou, Y | 4 |
| Huang, C | 1 |
| Yan, H | 2 |
| Zhu, W | 1 |
| Xu, W | 1 |
| Zhang, L | 6 |
| Buhatem Medeiros, F | 1 |
| Pepe Medeiros de Rezende, N | 1 |
| Bertoldi Franco, J | 1 |
| Porrio de Andrade, AC | 1 |
| Timerman, L | 1 |
| Gallottini, M | 1 |
| Itagiba Neves, IL | 1 |
| Ortega, KL | 1 |
| Tscharre, M | 1 |
| Egger, F | 2 |
| Machata, M | 1 |
| Rohla, M | 2 |
| Michael, N | 1 |
| Neumayr, M | 1 |
| Zweiker, R | 1 |
| Hajos, J | 1 |
| Adlbrecht, C | 1 |
| Suppan, M | 1 |
| Helmreich, W | 1 |
| Eber, B | 1 |
| Weiss, TW | 2 |
| Nakamura, M | 7 |
| Iijima, R | 5 |
| Ako, J | 1 |
| Shinke, T | 1 |
| Okada, H | 1 |
| Ito, Y | 1 |
| Ando, K | 1 |
| Anzai, H | 1 |
| Tanaka, H | 1 |
| Ueda, Y | 1 |
| Takiuchi, S | 1 |
| Nishida, Y | 1 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 1 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Morita, T | 1 |
| Zen, K | 1 |
| Yasaka, Y | 1 |
| Inoue, K | 1 |
| Ishiwata, S | 1 |
| Ochiai, M | 1 |
| Hamasaki, T | 1 |
| Yokoi, H | 5 |
| Didier, R | 1 |
| Morice, MC | 4 |
| Barragan, P | 4 |
| Noryani, AAL | 2 |
| Noor, HA | 2 |
| Majwal, T | 2 |
| Hovasse, T | 2 |
| Castellant, P | 3 |
| Schneeberger, M | 2 |
| Maillard, L | 2 |
| Bressolette, E | 2 |
| Wojcik, J | 2 |
| Delarche, N | 3 |
| Blanchard, D | 4 |
| Jouve, B | 2 |
| Ormezzano, O | 2 |
| Paganelli, F | 5 |
| Levy, G | 2 |
| Sainsous, J | 2 |
| Carrie, D | 5 |
| Furber, A | 3 |
| Berlan, J | 1 |
| Darremont, O | 2 |
| Le Breton, H | 3 |
| Lyuycx-Bore, A | 2 |
| Gommeaux, A | 2 |
| Cassat, C | 2 |
| Kermarrec, A | 2 |
| Cazaux, P | 3 |
| Druelles, P | 3 |
| Dauphin, R | 2 |
| Armengaud, J | 2 |
| Dupouy, P | 3 |
| Champagnac, D | 2 |
| Ohlmann, P | 2 |
| Ben Amer, H | 1 |
| Ungi, I | 3 |
| Gilard, M | 4 |
| Gaussem, P | 2 |
| Belleville-Rolland, T | 1 |
| Helley, D | 1 |
| Bachelot-Loza, C | 2 |
| Yuan, C | 1 |
| Zhong, L | 1 |
| Huang, RC | 1 |
| Park, KH | 2 |
| Jeong, MH | 5 |
| Kim, HK | 1 |
| Ahn, TH | 2 |
| Seung, KB | 4 |
| Oh, DJ | 2 |
| Choi, DJ | 4 |
| Kim, HS | 11 |
| Gwon, HC | 4 |
| Seong, IW | 3 |
| Hwang, KK | 3 |
| Chae, SC | 2 |
| Kim, KB | 2 |
| Kim, YJ | 2 |
| Cha, KS | 3 |
| Oh, SK | 3 |
| Chae, JK | 3 |
| Jiang, M | 1 |
| You, JHS | 1 |
| Pailleret, C | 1 |
| Ait Hamou, Z | 1 |
| Rosencher, N | 1 |
| Samama, CM | 2 |
| Eyraud, V | 1 |
| Chilot, F | 1 |
| Baillard, C | 1 |
| Borse, MS | 1 |
| Dong, OM | 1 |
| Polasek, MJ | 1 |
| Farley, JF | 1 |
| Stouffer, GA | 1 |
| Lee, CR | 1 |
| Baber, U | 6 |
| Chandrasekhar, J | 4 |
| Sartori, S | 4 |
| Aquino, M | 3 |
| Kini, AS | 2 |
| Kapadia, S | 1 |
| Weintraub, W | 1 |
| Muhlestein, JB | 1 |
| Vogel, B | 2 |
| Faggioni, M | 2 |
| Farhan, S | 2 |
| Weiss, S | 1 |
| Strauss, C | 1 |
| Toma, C | 1 |
| DeFranco, A | 1 |
| Baker, BA | 4 |
| Keller, S | 1 |
| Rao, S | 1 |
| Pocock, S | 3 |
| Dangas, G | 4 |
| Mehran, R | 15 |
| Stuckey, TD | 6 |
| Kirtane, AJ | 7 |
| Brodie, BR | 7 |
| Witzenbichler, B | 9 |
| Litherland, C | 2 |
| Weisz, G | 6 |
| Rinaldi, MJ | 7 |
| Neumann, FJ | 15 |
| Metzger, DC | 5 |
| Cox, DA | 7 |
| Duffy, PL | 5 |
| Mazzaferri, EL | 5 |
| Gurbel, PA | 10 |
| Ben-Yehuda, O | 3 |
| Simonton, CA | 1 |
| Harada, Y | 1 |
| Michel, J | 2 |
| Lohaus, R | 2 |
| Mayer, K | 5 |
| Emmer, R | 1 |
| Lahmann, AL | 2 |
| Colleran, R | 1 |
| Giacoppo, D | 1 |
| Wolk, A | 2 |
| Han, Y | 4 |
| Adriaenssens, T | 4 |
| Tölg, R | 3 |
| Seyfarth, M | 4 |
| Maeng, M | 5 |
| Zrenner, B | 3 |
| Jacobshagen, C | 5 |
| Wöhrle, J | 3 |
| Kufner, S | 3 |
| Morath, T | 7 |
| Ibrahim, T | 3 |
| Bernlochner, I | 6 |
| Fischer, M | 3 |
| Schunkert, H | 6 |
| Laugwitz, KL | 7 |
| Mehilli, J | 11 |
| Byrne, RA | 7 |
| Kastrati, A | 16 |
| Schulz-Schüpke, S | 3 |
| Baschin, M | 1 |
| Selleng, S | 1 |
| Zeden, JP | 1 |
| Westphal, A | 1 |
| Kohlmann, T | 1 |
| Schroeder, HW | 1 |
| Greinacher, A | 1 |
| Thiele, T | 1 |
| Petousis, S | 2 |
| Kanakakis, J | 1 |
| Skalidis, E | 1 |
| Kochiadakis, G | 1 |
| Vardas, PE | 1 |
| Rosenberg, K | 1 |
| Oldgren, J | 2 |
| Lip, GYH | 4 |
| Ellis, SG | 2 |
| Merkely, B | 4 |
| Zeymer, U | 8 |
| Gropper, S | 1 |
| Nordaby, M | 1 |
| Kleine, E | 1 |
| Harper, R | 1 |
| Manassie, J | 1 |
| Januzzi, JL | 1 |
| Hohnloser, SH | 2 |
| Sibbing, D | 13 |
| Aradi, D | 5 |
| Gross, L | 3 |
| Trenk, D | 4 |
| Geisler, T | 4 |
| Orban, M | 4 |
| Hadamitzky, M | 3 |
| Komócsi, A | 4 |
| Dézsi, CA | 3 |
| Holdt, L | 2 |
| Felix, SB | 2 |
| Parma, R | 3 |
| Klopotowski, M | 3 |
| Schwinger, RHG | 1 |
| Rieber, J | 2 |
| Koltowski, L | 2 |
| Huczek, Z | 4 |
| Massberg, S | 6 |
| Harding, SA | 2 |
| Holley, A | 1 |
| Wilkins, B | 1 |
| Fairley, S | 1 |
| Simmonds, M | 1 |
| Larsen, PD | 1 |
| Benedetto, U | 2 |
| Bianco, M | 1 |
| Conrotto, F | 2 |
| Moretti, C | 3 |
| D'Onofrio, A | 1 |
| Agrifoglio, M | 1 |
| Colombo, A | 9 |
| Ribichini, F | 1 |
| Tarantini, G | 2 |
| D'Amico, M | 1 |
| Salizzoni, S | 1 |
| Rinaldi, M | 1 |
| Ponzetto, A | 1 |
| Figura, N | 1 |
| Feagins, LA | 2 |
| He, RX | 1 |
| Zhou, TN | 1 |
| Yuan, WJ | 1 |
| Liu, YJ | 1 |
| Fu, WX | 1 |
| Jing, QM | 2 |
| Liu, HW | 1 |
| Wang, XZ | 2 |
| Ahn, S | 1 |
| Lee, J | 4 |
| Min, SK | 1 |
| Ha, J | 1 |
| Min, SI | 1 |
| Kim, SY | 1 |
| Cho, MJ | 1 |
| Prader, R | 1 |
| De Broca, B | 1 |
| Chevallier, D | 1 |
| Amiel, J | 1 |
| Durand, M | 1 |
| Bossard, M | 1 |
| Granger, CB | 5 |
| Faxon, DP | 4 |
| Jolly, SS | 2 |
| Widimsky, P | 7 |
| Niemela, K | 1 |
| Natarajan, MK | 2 |
| Gao, P | 3 |
| Fox, KAA | 1 |
| Yusuf, S | 16 |
| Mehta, SR | 16 |
| Spartalis, M | 1 |
| Tzatzaki, E | 1 |
| Spartalis, E | 1 |
| Damaskos, C | 1 |
| Athanasiou, A | 1 |
| Moris, D | 1 |
| Politou, M | 1 |
| Castini, D | 1 |
| Persampieri, S | 1 |
| Cazzaniga, S | 1 |
| Centola, M | 1 |
| Lucreziotti, S | 1 |
| Salerno-Uriarte, D | 1 |
| Sponzilli, C | 1 |
| Carugo, S | 1 |
| Zocca, P | 1 |
| van der Heijden, LC | 1 |
| Kok, MM | 1 |
| Löwik, MM | 1 |
| Hartmann, M | 1 |
| Stoel, MG | 1 |
| Louwerenburg, JW | 1 |
| de Man, FHAF | 1 |
| Linssen, GCM | 1 |
| Knottnerus, IL | 1 |
| Doggen, CJM | 1 |
| van Houwelingen, KG | 1 |
| von Birgelen, C | 2 |
| Pappas, C | 1 |
| Sfantou, D | 1 |
| Squizzato, A | 2 |
| Bellesini, M | 2 |
| Takeda, A | 1 |
| Middeldorp, S | 1 |
| Donadini, MP | 2 |
| Zhong, Z | 1 |
| Hou, J | 1 |
| Zhang, Q | 2 |
| Li, B | 1 |
| Li, C | 2 |
| Liu, Z | 1 |
| Yang, M | 1 |
| Zhong, W | 1 |
| He, X | 1 |
| Wu, H | 1 |
| Zhong, M | 1 |
| Zhao, P | 1 |
| Novkovic, M | 1 |
| Matic, D | 1 |
| Kusic-Tisma, J | 1 |
| Antonijevic, N | 1 |
| Radojkovic, D | 1 |
| Rakicevic, L | 1 |
| Kounis, NG | 1 |
| Koniari, I | 2 |
| Tsigkas, G | 1 |
| Chourdakis, E | 1 |
| Roumeliotis, A | 1 |
| Patsouras, N | 1 |
| Soufras, G | 1 |
| Hahalis, G | 3 |
| Bath, PM | 2 |
| Woodhouse, LJ | 1 |
| Appleton, JP | 1 |
| Beridze, M | 1 |
| Christensen, H | 1 |
| Dineen, RA | 1 |
| Duley, L | 1 |
| England, TJ | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 2 |
| James, M | 1 |
| Krishnan, K | 1 |
| Markus, HS | 1 |
| Montgomery, AA | 1 |
| Pocock, SJ | 2 |
| Randall, M | 1 |
| Ranta, A | 1 |
| Robinson, TG | 1 |
| Scutt, P | 1 |
| Venables, GS | 1 |
| Sprigg, N | 1 |
| Godschalk, TC | 1 |
| Gimbel, ME | 1 |
| Nolet, WW | 1 |
| van Kessel, DJ | 1 |
| Amoroso, G | 1 |
| Dewilde, WJ | 2 |
| Wykrzykowska, JJ | 1 |
| Janssen, PW | 2 |
| Bergmeijer, TO | 1 |
| Kelder, JC | 3 |
| Heestermans, T | 1 |
| Baschera, D | 1 |
| Oberle, J | 1 |
| Grubhofer, F | 1 |
| Schmid, SL | 1 |
| Peterson, BE | 1 |
| May, J | 1 |
| Duerschmied, D | 1 |
| Brachmann, J | 1 |
| Darius, H | 2 |
| Frey, N | 2 |
| Rottbauer, W | 2 |
| Schäfer, A | 3 |
| Thiele, H | 1 |
| Johnston, SC | 6 |
| Easton, JD | 4 |
| Farrant, M | 1 |
| Barsan, W | 1 |
| Conwit, RA | 1 |
| Elm, JJ | 1 |
| Kim, AS | 1 |
| Lindblad, AS | 1 |
| Palesch, YY | 1 |
| Ding, L | 2 |
| Peng, B | 1 |
| Lewis, SR | 1 |
| Pritchard, MW | 1 |
| Schofield-Robinson, OJ | 1 |
| Alderson, P | 1 |
| Smith, AF | 1 |
| Hoorntje, JCA | 1 |
| Kitazono, T | 1 |
| Ikeda, Y | 3 |
| Nishikawa, M | 4 |
| Yoshiba, S | 1 |
| Abe, K | 1 |
| Ogawa, A | 1 |
| Wu, Z | 1 |
| Liu, AF | 1 |
| Zhou, J | 1 |
| Wang, K | 3 |
| Qiu, H | 1 |
| Jiang, WJ | 1 |
| Wang, HY | 1 |
| Li, Y | 13 |
| Xu, XM | 1 |
| Li, J | 3 |
| Wernly, B | 1 |
| Lichtenauer, M | 1 |
| Hoppe, UC | 1 |
| Lauten, A | 1 |
| Navarese, EP | 3 |
| Jung, C | 1 |
| Fahmy, AI | 1 |
| Mekkawy, MA | 1 |
| Abou-Ali, A | 1 |
| Goedel, A | 1 |
| Fiedler, KA | 1 |
| von Olshausen, G | 1 |
| Schüpke, S | 1 |
| Hoppmann, P | 2 |
| Sarafoff, N | 2 |
| Sonneveld, MJ | 1 |
| Honkoop, P | 1 |
| Ter Borg, PCJ | 1 |
| Radaelli, F | 1 |
| Mogavero, G | 1 |
| Paggi, S | 1 |
| Jeong, HG | 1 |
| Yoon, JS | 1 |
| Bae, HJ | 1 |
| Oirbans, T | 1 |
| Verheugt, FW | 8 |
| De Smet, BJ | 1 |
| Herrman, JP | 1 |
| Vrolix, M | 3 |
| Heestermans, AA | 2 |
| Vis, MM | 1 |
| Tijsen, JG | 1 |
| van 't Hof, AW | 4 |
| Kerneis, M | 1 |
| Silvain, J | 7 |
| Abtan, J | 2 |
| Cayla, G | 6 |
| O'Connor, SA | 3 |
| Barthélémy, O | 4 |
| Vignalou, JB | 1 |
| Beygui, F | 7 |
| Brugier, D | 1 |
| Martin, R | 1 |
| Collet, JP | 14 |
| Helft, G | 2 |
| Le Feuvre, C | 1 |
| Georges, JL | 1 |
| Leclercq, F | 2 |
| Eltchaninoff, H | 2 |
| Prunier, F | 1 |
| Sebagh, L | 1 |
| Cattan, S | 2 |
| Vicaut, E | 3 |
| Metzger, JP | 1 |
| Mischnik, M | 1 |
| Boyanova, D | 1 |
| Hubertus, K | 1 |
| Geiger, J | 1 |
| Philippi, N | 1 |
| Dittrich, M | 1 |
| Wangorsch, G | 1 |
| Timmer, J | 1 |
| Dandekar, T | 1 |
| Hamm, CW | 9 |
| Price, MJ | 10 |
| Leonardi, S | 5 |
| Gallup, D | 1 |
| Bramucci, E | 2 |
| Radke, PW | 1 |
| Tousek, F | 1 |
| Tauth, J | 1 |
| Spriggs, D | 2 |
| McLaurin, BT | 1 |
| Angiolillo, DJ | 12 |
| Liu, T | 2 |
| Prats, J | 6 |
| Todd, M | 1 |
| Skerjanec, S | 2 |
| Turkmen, S | 1 |
| Fettser, DV | 3 |
| Kagliian, KÉ | 1 |
| Serchelik, A | 1 |
| Arystanova, AZh | 1 |
| Tekin, K | 1 |
| Balli, M | 1 |
| Batyraliev, TA | 3 |
| Samko, AN | 2 |
| Sidorenko, BA | 3 |
| Hossain, FS | 1 |
| Rambani, R | 1 |
| Ribee, H | 1 |
| Koch, L | 1 |
| Wallace, HC | 1 |
| Probe, RA | 1 |
| Chaput, CD | 1 |
| Patel, KV | 1 |
| Novitskaya, E | 2 |
| Rene, C | 2 |
| Dean, A | 1 |
| Wang, WE | 1 |
| Zeng, C | 1 |
| Osinski, D | 1 |
| Thevenin, A | 1 |
| Devys, JM | 1 |
| Fiorelli, EM | 1 |
| Bonzi, M | 1 |
| Oprea, AD | 1 |
| Popescu, WM | 1 |
| Netsch, C | 1 |
| Stoehrer, M | 1 |
| Brüning, M | 1 |
| Gabuev, A | 1 |
| Bach, T | 1 |
| Herrmann, TR | 1 |
| Gross, AJ | 1 |
| Berglund, U | 1 |
| Nilsson, L | 1 |
| Janzon, M | 2 |
| Short, S | 1 |
| Kram, B | 1 |
| Taylor, S | 1 |
| Ali, K | 1 |
| Vasquez, D | 1 |
| Diercks, DB | 1 |
| Kontos, MC | 1 |
| Hollander, JE | 2 |
| Mumma, BE | 1 |
| Holmes, DN | 1 |
| Wiviott, S | 2 |
| Saucedo, JF | 1 |
| de Lemos, JA | 2 |
| Marino, M | 3 |
| Campo, G | 2 |
| Guastaroba, P | 2 |
| Taglieri, N | 1 |
| Tondi, S | 3 |
| Manari, A | 1 |
| Guiducci, V | 1 |
| Sangiorgio, P | 1 |
| Varani, E | 1 |
| De Palma, R | 2 |
| Marzocchi, A | 1 |
| Wheatcroft, S | 1 |
| Rodriguez, L | 2 |
| Conde, D | 2 |
| Lalor, N | 2 |
| Elissamburu, P | 2 |
| Trivi, M | 2 |
| Seivani, Y | 1 |
| Abdel-Wahab, M | 2 |
| Geist, V | 1 |
| Richardt, G | 3 |
| Sulimov, DS | 1 |
| El-Mawardy, M | 1 |
| Toelg, R | 1 |
| Akin, I | 1 |
| Wessel, DL | 1 |
| Berger, F | 1 |
| Li, JS | 2 |
| Dähnert, I | 1 |
| Rakhit, A | 1 |
| Fontecave, S | 1 |
| Newburger, JW | 1 |
| Zhao, X | 3 |
| Wang, C | 6 |
| Meng, X | 3 |
| Cui, L | 1 |
| Jia, J | 1 |
| Dong, Q | 1 |
| Xu, A | 1 |
| Zeng, J | 1 |
| Wang, Z | 3 |
| Xia, H | 1 |
| Callender, RA | 1 |
| Mukalel, J | 1 |
| Altamirano, AV | 1 |
| Pivalizza, EG | 2 |
| Cattano, D | 2 |
| Huang, Y | 1 |
| Li, M | 3 |
| Li, JY | 1 |
| Xia, YP | 1 |
| Mao, L | 1 |
| Hu, B | 1 |
| Stevens, SR | 3 |
| Hochman, JS | 3 |
| Gottlieb, S | 3 |
| Martinez, F | 2 |
| Dalby, AJ | 3 |
| Boden, WE | 5 |
| Aylward, PE | 3 |
| Bassand, JP | 4 |
| McGuire, DK | 1 |
| Steinberg, BA | 1 |
| Kim, S | 2 |
| Piccini, JP | 3 |
| Fonarow, GC | 1 |
| Thomas, L | 2 |
| Ezekowitz, MD | 2 |
| Ansell, J | 1 |
| Kowey, P | 1 |
| Singer, DE | 2 |
| Gersh, B | 1 |
| Hylek, E | 1 |
| Go, AS | 2 |
| Chang, P | 1 |
| Liang, ZY | 1 |
| Zhang, XL | 2 |
| Yan, CH | 1 |
| Kang, J | 1 |
| García Rodríguez, LA | 1 |
| Johansson, S | 2 |
| Cea Soriano, L | 1 |
| Liew, D | 1 |
| De Abreu Lourenço, R | 1 |
| Adena, M | 1 |
| Chim, L | 1 |
| Aylward, P | 2 |
| DiNicolantonio, JJ | 2 |
| Tomek, A | 3 |
| Chatterjee, S | 3 |
| Niazi, AK | 1 |
| Biondi-Zoccai, G | 2 |
| Lee, HY | 1 |
| Park, KW | 5 |
| Kang, HJ | 4 |
| Koo, BK | 4 |
| Kim, MA | 1 |
| Oh, BH | 1 |
| Park, MW | 1 |
| Her, SH | 1 |
| Choi, YS | 2 |
| Park, CS | 1 |
| Koh, YS | 1 |
| Park, HJ | 1 |
| Kim, PJ | 1 |
| Kim, CJ | 1 |
| Jeon, DS | 2 |
| Shin, DI | 1 |
| Seo, SM | 1 |
| Yoo, KD | 1 |
| Kim, DB | 1 |
| Kim, HY | 1 |
| Lee, JM | 2 |
| Chung, WS | 1 |
| Shin, JG | 1 |
| Chang, K | 1 |
| Darvish-Kazem, S | 1 |
| Gandhi, M | 1 |
| Marcucci, M | 1 |
| Douketis, JD | 1 |
| Tehrani, S | 1 |
| Rozelle, C | 1 |
| Solomon, A | 1 |
| Steele, EA | 1 |
| Wilhelm, TJ | 1 |
| Post, S | 1 |
| Grosdidier, C | 3 |
| Loundou, AD | 1 |
| Loosveld, M | 2 |
| Camoin, L | 2 |
| Pankert, M | 3 |
| Beguin, S | 2 |
| Suh, SY | 1 |
| Choi, H | 1 |
| Moon, CI | 1 |
| Han, SH | 1 |
| Ahn, T | 2 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Goudevenos, JA | 3 |
| Parissis, H | 1 |
| Ntalas, IV | 3 |
| Angelidis, C | 1 |
| Vavuranakis, M | 1 |
| Stefanadis, C | 2 |
| Bell, AD | 1 |
| Ackman, ML | 2 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Verma, S | 3 |
| Wong, G | 2 |
| Callender, R | 1 |
| Altamirano, A | 1 |
| Tezino, T | 1 |
| Al Khudairy, A | 1 |
| Al-Hadeedi, O | 1 |
| Sayana, MK | 1 |
| Galvin, R | 1 |
| Quinlan, JF | 1 |
| Lin, TH | 1 |
| Lai, WT | 1 |
| Hsin, HT | 1 |
| Li, AH | 1 |
| Wang, CL | 2 |
| Kuo, CT | 1 |
| Hwang, JJ | 1 |
| Chiang, FT | 1 |
| Chang, SC | 1 |
| Park, JJ | 2 |
| Yang, HM | 1 |
| Park, BE | 1 |
| Rhew, JY | 1 |
| Jeon, HK | 2 |
| Shin, ES | 2 |
| Oh, JH | 2 |
| Yoon, JH | 3 |
| Lee, SY | 1 |
| Park, TH | 3 |
| Moon, KW | 1 |
| Kwon, HM | 2 |
| Chae, IH | 3 |
| Gulba, D | 1 |
| Bonello, L | 7 |
| Chen, Y | 2 |
| Tang, Y | 2 |
| Huang, X | 2 |
| Xie, Y | 1 |
| Curkovic, I | 1 |
| Egbring, M | 1 |
| Kullak-Ublick, GA | 1 |
| Harris, NS | 1 |
| Kristensen, SR | 1 |
| Karon, BS | 1 |
| Rydberg, DM | 1 |
| Holm, L | 1 |
| Mejyr, S | 1 |
| Loikas, D | 1 |
| Schenck-Gustafsson, K | 1 |
| von Euler, M | 1 |
| Wettermark, B | 1 |
| Malmström, RE | 1 |
| Han, S | 1 |
| Lee, SG | 1 |
| Rha, SW | 2 |
| Lim, DS | 3 |
| Hur, SH | 3 |
| Yang, JY | 1 |
| Lee, NH | 3 |
| Lee, BK | 1 |
| Kim, KS | 1 |
| Lee, SU | 1 |
| Cheong, SS | 1 |
| Suh, IW | 1 |
| Park, HS | 3 |
| Nah, DY | 1 |
| Jang, JS | 1 |
| Limbruno, U | 2 |
| Varenhorst, C | 4 |
| Jensevik, K | 2 |
| Jernberg, T | 2 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Lagerqvist, B | 5 |
| James, S | 10 |
| Bosch, X | 3 |
| Marrugat, J | 4 |
| Sanchis, J | 3 |
| Malloy, RJ | 1 |
| Kanaan, AO | 1 |
| Silva, MA | 2 |
| Donovan, JL | 2 |
| Park, IC | 1 |
| Baek, YH | 1 |
| Han, SY | 1 |
| Chung, WT | 1 |
| Cho, DS | 1 |
| Damman, P | 1 |
| Koul, S | 6 |
| Eriksson, P | 1 |
| Erlinge, D | 6 |
| Feres, F | 4 |
| Costa, RA | 1 |
| Abizaid, A | 3 |
| Leon, MB | 4 |
| Marin-Neto, JA | 2 |
| Botelho, RV | 1 |
| King, SB | 1 |
| Negoita, M | 1 |
| Liu, M | 2 |
| de Paula, JE | 1 |
| Mangione, JA | 2 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 2 |
| Costa, JR | 2 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Nakagawa, I | 2 |
| Wada, T | 2 |
| Nishimura, F | 1 |
| Yamada, S | 2 |
| Nakagawa, H | 1 |
| Kichikawa, K | 2 |
| Nakase, H | 2 |
| Guidoni, CM | 1 |
| Obreli-Neto, PR | 1 |
| Pereira, LR | 1 |
| Enomoto, Y | 1 |
| Tokue, M | 1 |
| Ito, N | 1 |
| Nagashima, Y | 1 |
| Araki, T | 1 |
| Yamazaki, K | 1 |
| Utsunomiya, M | 1 |
| Hori, M | 1 |
| Itaya, H | 1 |
| Shiba, M | 1 |
| Hara, H | 1 |
| Sugi, K | 2 |
| Ariyaratnam, P | 1 |
| McLean, LA | 1 |
| Kotidis, K | 1 |
| Loubani, M | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Arntz, HR | 3 |
| Boudriot, E | 2 |
| Garlichs, C | 2 |
| Hoffmann, S | 2 |
| Ince, H | 4 |
| Klingenheben, T | 2 |
| Weil, J | 2 |
| Zugck, C | 2 |
| Helms, TM | 2 |
| Silber, S | 2 |
| Gasparovic, H | 2 |
| Petricevic, M | 4 |
| Lin, OA | 1 |
| Karim, ZA | 1 |
| Vemana, HP | 1 |
| Espinosa, EV | 1 |
| Khasawneh, FT | 1 |
| Lamberts, M | 3 |
| Gislason, GH | 7 |
| Lip, GY | 5 |
| Lassen, JF | 2 |
| Olesen, JB | 3 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 5 |
| Køber, L | 6 |
| Torp-Pedersen, C | 8 |
| Hansen, ML | 5 |
| Lippe, CM | 1 |
| Reineck, EA | 1 |
| Kunselman, AR | 1 |
| Gilchrist, IC | 3 |
| Tornyos, A | 1 |
| Pintér, T | 1 |
| Vorobcsuk, A | 1 |
| Kónyi, A | 1 |
| Faluközy, J | 1 |
| Veress, G | 1 |
| Magyari, B | 1 |
| Horváth, IG | 1 |
| Alcocer, F | 1 |
| Novak, Z | 1 |
| Combs, BR | 1 |
| Lowman, B | 1 |
| Passman, MA | 1 |
| Mujib, M | 1 |
| Jordan, WD | 1 |
| Gagne, JJ | 1 |
| Rassen, JA | 1 |
| Choudhry, NK | 1 |
| Bohn, RL | 1 |
| Patrick, AR | 1 |
| Sridhar, G | 1 |
| Daniel, GW | 1 |
| Liu, J | 1 |
| Schneeweiss, S | 1 |
| Tang, XF | 2 |
| Fan, JY | 2 |
| Meng, J | 1 |
| Jin, C | 1 |
| Yuan, JQ | 2 |
| Yang, YJ | 1 |
| Kohriyama, T | 1 |
| Mihara, C | 1 |
| Yokoyama, T | 1 |
| Torii, T | 1 |
| Yamada, A | 1 |
| Takamatsu, K | 1 |
| Ota, T | 1 |
| Noda, K | 1 |
| Kataoka, S | 1 |
| Ito, H | 1 |
| Nomura, E | 1 |
| Ohtsuki, T | 1 |
| Aoki, S | 1 |
| Nezu, T | 1 |
| Takeda, I | 1 |
| Mukai, T | 1 |
| Hosomi, N | 1 |
| Matsumoto, M | 1 |
| Xu, S | 2 |
| Shetterly, S | 2 |
| Raebel, MA | 2 |
| Ho, PM | 2 |
| Tsai, TT | 2 |
| Magid, D | 2 |
| Ma, YY | 1 |
| Xu, B | 2 |
| Gao, RL | 2 |
| Kleiman, NS | 4 |
| Sabouret, P | 1 |
| Taiel-Sartral, M | 1 |
| Nanau, RM | 1 |
| Delzor, F | 1 |
| Neuman, MG | 1 |
| De Luca, G | 5 |
| Bellandi, B | 1 |
| Comito, V | 1 |
| Valenti, R | 2 |
| Marcucci, R | 3 |
| Carrabba, N | 1 |
| Migliorini, A | 2 |
| Ramazzotti, RN | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Antoniucci, D | 2 |
| Bach, RG | 2 |
| Heras, M | 3 |
| Horrow, J | 6 |
| Lassila, R | 3 |
| Morais, J | 3 |
| Wojdyla, D | 3 |
| Ndrepepa, G | 3 |
| Schulz, S | 8 |
| Pöhler, A | 1 |
| Pache, J | 2 |
| Braun, S | 4 |
| Hausleiter, J | 3 |
| Kazi, DS | 2 |
| Garber, AM | 1 |
| Shah, RU | 1 |
| Dudley, RA | 1 |
| Mell, MW | 1 |
| Rhee, C | 1 |
| Moshkevich, S | 1 |
| Boothroyd, DB | 1 |
| Owens, DK | 1 |
| Hlatky, MA | 1 |
| Maya, J | 2 |
| Sherwood, MW | 1 |
| Wiviott, SD | 10 |
| Peng, SA | 1 |
| Delemos, J | 1 |
| Vranckx, P | 4 |
| Tebaldi, M | 4 |
| Biscaglia, S | 1 |
| Parrinello, G | 1 |
| Saito, S | 3 |
| Isshiki, T | 4 |
| Ogawa, H | 3 |
| Nanto, S | 3 |
| Takayama, M | 3 |
| Kitagawa, K | 3 |
| Miyazaki, S | 3 |
| Rangé, G | 1 |
| Yayehd, K | 1 |
| Belle, L | 1 |
| Thuaire, C | 1 |
| Richard, P | 1 |
| Barbou, F | 1 |
| Köning, R | 1 |
| Chassaing, S | 1 |
| Teiger, E | 1 |
| Berthier, R | 1 |
| Decomis, MP | 1 |
| Claudel, JP | 1 |
| Brunel, P | 1 |
| De Poli, F | 2 |
| Albert, F | 1 |
| Goedicke, J | 2 |
| Schirmer, A | 1 |
| Patel, MR | 2 |
| Wojdyla, DM | 2 |
| Emanuelsson, H | 6 |
| Hiatt, WR | 3 |
| Rossini, R | 4 |
| Visconti, LO | 1 |
| Castiglioni, B | 1 |
| Lettieri, C | 4 |
| Lettino, M | 1 |
| Piccaluga, E | 1 |
| Savonitto, S | 2 |
| Trabattoni, D | 1 |
| Capodanno, D | 4 |
| Buffoli, F | 1 |
| Parolari, A | 1 |
| Dionigi, G | 1 |
| Boni, L | 1 |
| Biglioli, F | 1 |
| Valdatta, L | 1 |
| Droghetti, A | 1 |
| Bozzani, A | 1 |
| Setacci, C | 1 |
| Ravelli, P | 1 |
| Crescini, C | 1 |
| Staurenghi, G | 1 |
| Scarone, P | 1 |
| Francetti, L | 1 |
| D'Angelo, F | 1 |
| Gadda, F | 1 |
| Comel, A | 1 |
| Salvi, L | 1 |
| Lorini, L | 1 |
| Antonelli, M | 1 |
| Bovenzi, F | 1 |
| Cremonesi, A | 1 |
| Guagliumi, G | 4 |
| Liang, J | 1 |
| Shi, D | 1 |
| Zhao, Y | 2 |
| Han, H | 1 |
| Liu, W | 1 |
| Yang, L | 1 |
| Legrand, V | 3 |
| Chenu, P | 1 |
| Martinez, C | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 2 |
| Magne, J | 2 |
| Barbato, E | 1 |
| Wijns, W | 1 |
| Takeuchi, K | 1 |
| Takayama, S | 1 |
| Izuhara, C | 1 |
| Siller-Matula, JM | 5 |
| Delle Karth, G | 1 |
| Wilcox, R | 1 |
| Iqbal, K | 1 |
| Costigan, T | 1 |
| Lopez-Sendon, J | 4 |
| Ramos, Y | 2 |
| Bae, JP | 2 |
| Faries, DE | 3 |
| Ernst, FR | 2 |
| Lipkin, C | 2 |
| Zhao, Z | 2 |
| Moretz, C | 2 |
| Lieu, HD | 2 |
| Moeckel, D | 1 |
| Jeong, SS | 1 |
| Broekman, MJ | 1 |
| Nguyen, A | 1 |
| Drosopoulos, JH | 1 |
| Marcus, AJ | 1 |
| Robson, SC | 1 |
| Chen, R | 1 |
| Abendschein, D | 1 |
| Chen, S | 1 |
| Shen, Q | 1 |
| He, L | 1 |
| Peng, Y | 1 |
| Blicher, TM | 1 |
| Hommel, K | 1 |
| Kristensen, SL | 2 |
| Madsen, M | 1 |
| Kamper, AL | 1 |
| Sood, A | 1 |
| Trinh, QD | 1 |
| Sharma, M | 1 |
| Pearce, LA | 3 |
| Benavente, OR | 3 |
| Anderson, DC | 1 |
| Connolly, SJ | 5 |
| Palacio, S | 2 |
| Coffey, CS | 2 |
| Hart, RG | 5 |
| Lapostolle, F | 2 |
| Cantor, WJ | 1 |
| Cequier, A | 1 |
| Chettibi, M | 1 |
| Hammett, CJ | 1 |
| Stibbe, O | 1 |
| Ecollan, P | 2 |
| Heutz, WM | 1 |
| Swahn, E | 1 |
| Willems, FF | 1 |
| Baradat, C | 1 |
| Licour, M | 1 |
| Tsatsaris, A | 1 |
| Clemmensen, P | 2 |
| Grieco, N | 1 |
| Danchin, N | 3 |
| Schmitt, J | 1 |
| Goldstein, P | 1 |
| Tiroch, K | 2 |
| Zhang, JH | 2 |
| Yao, Y | 2 |
| Ma, YL | 1 |
| Gao, Z | 1 |
| Chen, J | 2 |
| Song, L | 1 |
| Meng, XM | 1 |
| Kristensen, KE | 1 |
| Zhu, HJ | 1 |
| Rasmussen, HB | 1 |
| Markowitz, JS | 1 |
| Hansen, PR | 4 |
| Schrör, K | 3 |
| Gawaz, M | 4 |
| Thompson, PL | 1 |
| Aryal, MR | 1 |
| Karmacharya, P | 1 |
| Pandit, A | 1 |
| Hakim, F | 1 |
| Pathak, R | 1 |
| Mainali, NR | 1 |
| Ukaigwe, A | 1 |
| Mahmood, M | 1 |
| Badal, M | 1 |
| Fortuin, FD | 1 |
| Almendro-Delia, M | 1 |
| Blanco Ponce, E | 1 |
| Gomez-Domínguez, R | 1 |
| Gonzalez-Matos, C | 1 |
| Lobo-Gonzalez, M | 1 |
| Caballero-Garcia, A | 1 |
| Hidalgo-Urbano, R | 1 |
| Cruz-Fernandez, MJ | 1 |
| Garcia-Rubira, JC | 1 |
| Russo, N | 1 |
| Calabria, P | 1 |
| Romano, M | 2 |
| Inashvili, A | 1 |
| Sirbu, V | 2 |
| Valsecchi, O | 2 |
| Senni, M | 1 |
| Gavazzi, A | 3 |
| Vyas, A | 1 |
| El Accaoui, R | 1 |
| Blevins, A | 1 |
| Karrowni, W | 1 |
| Tantry, US | 6 |
| Gesheff, M | 1 |
| Liu, F | 2 |
| Bliden, KP | 1 |
| Briguori, C | 2 |
| Rizzi, A | 1 |
| Imperadore, F | 1 |
| Sangiorgi, GM | 1 |
| Carosio, G | 1 |
| Steffenino, G | 1 |
| Galvani, M | 1 |
| La Vecchia, L | 1 |
| Maggioni, AP | 1 |
| Driscoll-Shempp, P | 1 |
| Normand, SL | 1 |
| Braunwald, E | 12 |
| Holmes, DR | 2 |
| Krucoff, MW | 3 |
| Hermiller, J | 1 |
| Dauerman, HL | 3 |
| Simon, DI | 1 |
| Kandzari, DE | 3 |
| Garratt, KN | 2 |
| Lee, DP | 1 |
| Pow, TK | 1 |
| Ver Lee, P | 1 |
| Jeger, RV | 1 |
| Pfisterer, ME | 1 |
| von Felten, S | 1 |
| Alber, H | 1 |
| Bonetti, PO | 1 |
| Eberli, F | 1 |
| Erne, P | 1 |
| Pedrazzini, G | 1 |
| Rickli, H | 1 |
| Galatius, S | 1 |
| Kaiser, CA | 1 |
| Lokhnygina, Y | 1 |
| Huang, Z | 1 |
| Chen, E | 1 |
| Moliterno, DJ | 7 |
| Jennings, LK | 3 |
| Berland, J | 1 |
| Endresen, K | 1 |
| Benamer, H | 1 |
| Boschat, J | 1 |
| Geersing, GJ | 1 |
| Kappelle, LJ | 1 |
| Braun, OÖ | 2 |
| Bico, B | 1 |
| Chaudhry, U | 1 |
| Wagner, H | 1 |
| Tydén, P | 1 |
| Scherstén, F | 4 |
| Jovinge, S | 1 |
| Svensson, PJ | 2 |
| Gustav Smith, J | 1 |
| van der Pals, J | 2 |
| Sáez, ME | 1 |
| González-Pérez, A | 1 |
| Nagy, P | 1 |
| Rodríguez, LA | 1 |
| Lu, W | 1 |
| Chen, L | 2 |
| Fu, C | 1 |
| Zuo, P | 1 |
| Ma, G | 2 |
| Andell, P | 2 |
| Martinsson, A | 1 |
| Smith, JG | 3 |
| Harnek, J | 1 |
| Götberg, M | 1 |
| Norström, E | 1 |
| Björnsson, S | 1 |
| Mack, M | 1 |
| Yadav, M | 1 |
| Xu, K | 4 |
| Parvataneni, R | 3 |
| Hahn, R | 1 |
| Kodali, SK | 1 |
| Bolanos, MD | 1 |
| Dzeshka, MS | 1 |
| Brown, RA | 1 |
| Zheng, M | 1 |
| Shang, X | 1 |
| Yan, C | 1 |
| Mudra, H | 2 |
| von Hodenberg, E | 1 |
| von Merzljak, B | 1 |
| Rifatov, N | 1 |
| Feuchtenberger, A | 1 |
| Valina, C | 1 |
| Desmet, W | 3 |
| Hengstenberg, C | 1 |
| Schömig, A | 8 |
| Garg, P | 1 |
| Galper, BZ | 1 |
| Reed, GW | 2 |
| Kumar, A | 3 |
| Guo, J | 3 |
| Aranki, S | 2 |
| Shekar, P | 2 |
| Agnihotri, A | 2 |
| Maree, AO | 3 |
| McLean, DS | 3 |
| Rosenfield, K | 2 |
| Perperis, A | 2 |
| Karvounis, H | 1 |
| Patsilinakos, S | 1 |
| Ziakas, A | 1 |
| Barampoutis, N | 2 |
| Panagiotidis, T | 1 |
| Akinosoglou, K | 1 |
| Bultas, J | 1 |
| Stoler, R | 1 |
| Cortese, B | 1 |
| Wilensky, M | 1 |
| Deliargyris, EN | 5 |
| Costa, F | 4 |
| Moscarella, E | 2 |
| Ando, G | 2 |
| Oreto, G | 2 |
| Zijlstra, F | 2 |
| Patialiakas, A | 1 |
| Thury, A | 1 |
| McFadden, E | 1 |
| Colangelo, S | 1 |
| Roffi, M | 3 |
| Menozzi, A | 1 |
| de Cesare, N | 1 |
| Garbo, R | 1 |
| Meliga, E | 1 |
| Testa, L | 2 |
| Gabriel, HM | 1 |
| Airoldi, F | 1 |
| Ferlini, M | 1 |
| Liistro, F | 1 |
| Dellavalle, A | 1 |
| Kalantzi, KI | 2 |
| Tsoumani, ME | 2 |
| Vakalis, JN | 1 |
| Vasilakopoulos, V | 2 |
| Vardakis, K | 2 |
| Vemmos, KN | 1 |
| Voukelatou, M | 2 |
| Giannakoulas, G | 2 |
| Giatrakos, I | 2 |
| Giogiakas, V | 2 |
| Goumas, G | 2 |
| Dimoulis, N | 2 |
| Draganigos, A | 2 |
| Efthimiadis, I | 2 |
| Thoma, M | 2 |
| Kazakos, E | 2 |
| Kipouridis, N | 2 |
| Konstantinou, S | 2 |
| Bourdakis, A | 2 |
| Nikolopoulos, D | 2 |
| Peltekis, L | 2 |
| Prokopakis, N | 2 |
| Sinteles, I | 2 |
| Stroumbis, CS | 1 |
| Terzoudi, K | 2 |
| Tsilias, K | 2 |
| Xaraktsis, I | 2 |
| Charmpas, C | 2 |
| Hatziathanasiou, G | 2 |
| Christogiannis, Z | 2 |
| Panagiotakos, DB | 2 |
| Tselepis, AD | 2 |
| Klingenberg, R | 2 |
| Heg, D | 4 |
| Räber, L | 3 |
| Carballo, D | 2 |
| Nanchen, D | 1 |
| Gencer, B | 2 |
| Auer, R | 2 |
| Jaguszewski, M | 1 |
| Stähli, BE | 1 |
| Jakob, P | 1 |
| Templin, C | 1 |
| Meier, B | 2 |
| Vogt, P | 1 |
| Maier, W | 1 |
| Landmesser, U | 1 |
| Rodondi, N | 2 |
| Mach, F | 2 |
| Jüni, P | 2 |
| Lüscher, TF | 3 |
| Matter, CM | 2 |
| Taha, S | 1 |
| Omedè, P | 1 |
| Grossomarra, W | 1 |
| Persson, J | 2 |
| Dewilde, W | 1 |
| Fernández, S | 1 |
| Cerrato, E | 1 |
| Meynet, I | 1 |
| Ballocca, F | 1 |
| Barbero, U | 1 |
| Quadri, G | 1 |
| Giordana, F | 2 |
| DiNicolantonio, J | 1 |
| Bangalore, S | 1 |
| Reed, M | 1 |
| Meier, P | 1 |
| Zoccai, G | 1 |
| Gaita, F | 2 |
| Tangelder, MJ | 1 |
| Nwachuku, CE | 1 |
| Jaff, M | 1 |
| Baumgartner, I | 3 |
| Duggal, A | 1 |
| Adams, G | 1 |
| Ansel, G | 1 |
| Grosso, M | 1 |
| Mercuri, M | 1 |
| Shi, M | 1 |
| Minar, E | 3 |
| Moll, FL | 2 |
| Angoulvant, D | 1 |
| Villejoubert, O | 1 |
| Bejan-Angoulvant, T | 1 |
| Ivanes, F | 1 |
| Saint Etienne, C | 1 |
| Fauchier, L | 1 |
| Cai, TQ | 1 |
| Wickham, LA | 1 |
| Sitko, G | 1 |
| Michener, MS | 1 |
| Raubertas, R | 1 |
| Handt, L | 1 |
| Chintala, M | 1 |
| Seiffert, D | 2 |
| Forrest, M | 1 |
| Lin, L | 1 |
| Chen, YF | 1 |
| Lin, WW | 1 |
| Lin, CH | 1 |
| Lee, SA | 1 |
| Suh, JW | 1 |
| Yoon, CH | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Kim, SH | 2 |
| Jia, M | 1 |
| Li, Z | 3 |
| Chu, H | 1 |
| Li, L | 2 |
| Chen, K | 1 |
| Kirtane, A | 1 |
| Freynhofer, MK | 2 |
| ten Berg, J | 2 |
| Janssen, P | 1 |
| Patti, G | 7 |
| Mangiacapra, F | 1 |
| Morel, O | 1 |
| Palmerini, T | 3 |
| Adamo, M | 1 |
| Garcia-Garcia, HM | 1 |
| Binder, A | 1 |
| Aledort, L | 1 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 1 |
| Kikkert, WJ | 2 |
| Wiegerinck, EM | 1 |
| Stabile, E | 1 |
| Ussia, GP | 1 |
| Sharma, S | 2 |
| Baan, J | 1 |
| Rubino, P | 1 |
| Barbanti, M | 1 |
| Tamburino, C | 1 |
| Poliacikova, P | 1 |
| Piek, JJ | 1 |
| Delewi, R | 1 |
| Verdoia, M | 4 |
| Barbieri, L | 3 |
| Suryapranata, H | 3 |
| Shubert, D | 1 |
| Bono, J | 1 |
| Nandi, S | 1 |
| Biocina, B | 3 |
| Milicic, D | 1 |
| Rotim, C | 1 |
| Boban, M | 1 |
| Gao, F | 2 |
| Shen, H | 2 |
| Wang, ZJ | 2 |
| Yang, SW | 2 |
| Liu, XL | 2 |
| Zhou, YJ | 2 |
| Kochman, J | 2 |
| Grygier, M | 1 |
| Scislo, P | 1 |
| Wilimski, R | 1 |
| Ochala, A | 1 |
| Lesiak, M | 1 |
| Olasinska-Wisniewska, A | 1 |
| Grabowski, M | 1 |
| Mazurek, T | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Yudi, MB | 2 |
| Eccleston, D | 2 |
| Andrianopoulos, N | 3 |
| Farouque, O | 2 |
| Duffy, SJ | 3 |
| Brennan, A | 2 |
| Reid, C | 1 |
| Clark, DJ | 3 |
| Ajani, AE | 3 |
| Clare, RM | 1 |
| Gao, R | 1 |
| Lim, ST | 1 |
| Santoso, A | 2 |
| Yu, CM | 1 |
| Chen, HB | 1 |
| Liang, HB | 1 |
| Liu, XW | 1 |
| Zhang, XY | 1 |
| Huang, BY | 1 |
| Xiu, J | 1 |
| Van Gaal, WJ | 2 |
| Schrale, R | 1 |
| Gunasekara, A | 1 |
| Amerena, J | 1 |
| Mussap, CJ | 1 |
| Ong, WL | 1 |
| Koh, TL | 1 |
| Fletcher, J | 1 |
| Gruen, R | 1 |
| Royce, P | 1 |
| Oh, S | 1 |
| Peters, JI | 1 |
| Folch, E | 1 |
| Dézsi, BB | 1 |
| Koritsánszky, L | 1 |
| Braunitzer, G | 1 |
| Hangyási, DB | 1 |
| Kelbæk, H | 1 |
| Tüller, D | 1 |
| Baumbach, A | 1 |
| Zanchin, T | 2 |
| Ostojic, M | 1 |
| Engstrøm, T | 1 |
| Guimarães, PO | 1 |
| Melloni, C | 1 |
| Hafley, G | 1 |
| Zamoryakhin, D | 2 |
| Polzin, A | 2 |
| Afzal, S | 1 |
| Balzer, J | 1 |
| Rassaf, T | 1 |
| Kelm, M | 2 |
| Zeus, T | 2 |
| Tan, S | 1 |
| Xiao, X | 1 |
| Ma, H | 1 |
| Yu, S | 1 |
| Xu, R | 1 |
| Hong, H | 1 |
| Khatri, S | 1 |
| Pierce, T | 1 |
| Würtz, M | 1 |
| Thomas, MR | 1 |
| Nishi, H | 1 |
| Nakahara, I | 1 |
| Matsumoto, S | 1 |
| Hashimoto, T | 1 |
| Ohta, T | 1 |
| Sadamasa, N | 1 |
| Ishibashi, R | 1 |
| Gomi, M | 1 |
| Saka, M | 1 |
| Miyata, H | 1 |
| Watanabe, S | 1 |
| Okata, T | 1 |
| Sonoda, K | 1 |
| Kouge, J | 1 |
| Ishii, A | 1 |
| Nagata, I | 1 |
| Kira, J | 1 |
| Filipini, E | 1 |
| Nau, G | 1 |
| Cura, F | 1 |
| Huang, CH | 1 |
| Arif, SA | 1 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Gutierrez, JA | 1 |
| Blankenship, JC | 3 |
| Gan, XD | 1 |
| Wei, BZ | 1 |
| Fang, D | 1 |
| Fang, Q | 1 |
| Li, KY | 1 |
| Ding, SL | 1 |
| Peng, S | 1 |
| Wan, J | 1 |
| Bhal, V | 1 |
| Herr, MJ | 1 |
| Dixon, M | 1 |
| Akins, S | 1 |
| Hord, E | 1 |
| White, MM | 1 |
| Kotha, J | 1 |
| Bertilsson, M | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Cyr, DD | 3 |
| Keltai, M | 6 |
| Hibbert, B | 3 |
| Froeschl, M | 4 |
| So, D | 1 |
| May, ML | 1 |
| Pokov, AN | 1 |
| Kim, MH | 4 |
| Bacquelin, R | 1 |
| Oger, E | 1 |
| Filippi, E | 1 |
| Hacot, JP | 1 |
| Auffret, V | 1 |
| Le Guellec, M | 1 |
| Coudert, I | 1 |
| Moquet, B | 1 |
| Rialan, A | 1 |
| Rouault, G | 1 |
| Boulanger, B | 1 |
| Treuil, J | 1 |
| Leurent, G | 1 |
| Bedossa, M | 1 |
| Boulmier, D | 1 |
| Avez, B | 1 |
| Grifoni, E | 1 |
| Giusti, B | 1 |
| Tanaka, Y | 1 |
| Karnyski, J | 1 |
| Dhillon, SS | 1 |
| Harris, K | 1 |
| Dannenberg, L | 1 |
| Sophia Popp, V | 1 |
| Lee, JH | 3 |
| Ahn, SG | 1 |
| Lee, JW | 1 |
| Youn, YJ | 1 |
| Ahn, MS | 1 |
| Kim, JY | 1 |
| Yoo, BS | 1 |
| Lee, SH | 2 |
| Yoon, J | 1 |
| Kim, J | 1 |
| Choi, E | 1 |
| Hung, OY | 1 |
| Samady, H | 1 |
| Oliphant, CS | 1 |
| Trevarrow, BJ | 1 |
| Dobesh, PP | 1 |
| Eckart, D | 1 |
| Morse, MA | 1 |
| Blackwell, KL | 1 |
| Ready, NE | 1 |
| Zafar, SY | 1 |
| Beaven, AW | 1 |
| Strickler, JH | 1 |
| Onken, JE | 1 |
| Houterloot, L | 1 |
| Tijssen, JG | 2 |
| Giatti, S | 1 |
| Hunter, JB | 1 |
| Carlson, ML | 1 |
| Sweeney, AD | 1 |
| Tombers, NM | 1 |
| Wanna, GB | 1 |
| Driscoll, CL | 1 |
| Haynes, DS | 1 |
| Huang, F | 1 |
| Yang, J | 1 |
| Wu, Q | 1 |
| Zou, Y | 1 |
| Zhu, E | 1 |
| Jackson, LR | 3 |
| Ju, C | 2 |
| Zettler, M | 2 |
| Messenger, JC | 3 |
| Effron, M | 1 |
| Shen, DL | 1 |
| Wang, B | 1 |
| Bai, J | 1 |
| Han, Q | 1 |
| Liu, C | 1 |
| Huang, XH | 1 |
| Zhang, JY | 1 |
| Parikh, PB | 1 |
| Maehara, A | 3 |
| Fu, A | 1 |
| Singh, K | 1 |
| Abunassar, J | 1 |
| Malhotra, N | 1 |
| Le May, M | 1 |
| Labinaz, M | 3 |
| Glover, C | 2 |
| Marquis, JF | 3 |
| Dick, A | 2 |
| Chong, AY | 2 |
| So, DY | 3 |
| Ricottini, E | 2 |
| Cavallari, I | 1 |
| Kwon, TJ | 1 |
| Park, Y | 2 |
| Choi, YM | 1 |
| Ahn, JH | 1 |
| Kim, KH | 1 |
| Koh, JS | 1 |
| Park, JR | 1 |
| Hwang, SJ | 2 |
| Kwak, CH | 2 |
| Hwang, JY | 2 |
| Smith, SC | 2 |
| Jeong, YH | 2 |
| Lemesle, G | 4 |
| Schurtz, G | 1 |
| Meurice, T | 1 |
| Tricot, O | 1 |
| Lemaire, N | 1 |
| Caudmont, S | 1 |
| Philias, A | 1 |
| Ketelers, R | 1 |
| Lamblin, N | 1 |
| Bauters, C | 2 |
| Hromádka, M | 1 |
| Bernat, I | 1 |
| Seidlerová, J | 1 |
| Jirouš, Š | 1 |
| Dragounová, E | 1 |
| Pechman, V | 1 |
| Tůmová, P | 1 |
| Rokyta, R | 1 |
| Yang, C | 2 |
| Qian, J | 1 |
| Tang, X | 3 |
| Hu, Y | 1 |
| Parker, WA | 1 |
| Lefkovits, J | 1 |
| Ramchand, J | 1 |
| Yip, T | 1 |
| Oqueli, E | 1 |
| Reid, CM | 2 |
| Guo, LZ | 1 |
| Park, JS | 1 |
| Jin, E | 1 |
| Shim, CH | 1 |
| Choi, SY | 1 |
| Noh, Y | 1 |
| Shin, S | 1 |
| Lim, HS | 1 |
| Bae, SK | 1 |
| Oh, E | 1 |
| Kim, GJ | 1 |
| Kim, JH | 1 |
| Jones, DW | 1 |
| Goodney, PP | 1 |
| Conrad, MF | 1 |
| Nolan, BW | 1 |
| Rzucidlo, EM | 1 |
| Powell, RJ | 1 |
| Cronenwett, JL | 1 |
| Stone, DH | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 2 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Pan, Y | 2 |
| Yang, X | 1 |
| Zhang, C | 1 |
| Jing, J | 1 |
| Xian, Y | 1 |
| Li, R | 1 |
| Jing, Q | 1 |
| Wang, Q | 1 |
| Liu, P | 2 |
| Zhang, P | 1 |
| Chin, CT | 1 |
| Leiva-Pons, JL | 2 |
| Corbalán, R | 2 |
| Schiele, F | 1 |
| Otoshi, T | 1 |
| Kataoka, Y | 1 |
| Nakagawa, A | 1 |
| Otsuka, K | 1 |
| Tomii, K | 1 |
| Hechler, B | 1 |
| Maître, B | 1 |
| Magnenat, S | 1 |
| Heim, V | 1 |
| El Mdawar, MB | 1 |
| Gachet, C | 2 |
| de la Salle, H | 1 |
| Giustino, G | 3 |
| Ariti, C | 2 |
| Chieffo, A | 3 |
| Lattuca, B | 1 |
| Fabbro-Peray, P | 1 |
| Schmutz, L | 1 |
| Ledermann, B | 1 |
| Cornillet, L | 1 |
| Benezet, JF | 1 |
| Macia, JC | 1 |
| de La Coussaye, JE | 1 |
| Messner-Pellenc, P | 1 |
| Milionis, H | 1 |
| Stroumbis, C | 1 |
| Vakalis, I | 1 |
| Vemmos, K | 1 |
| Basaraba, JE | 1 |
| Barry, AR | 1 |
| Yu, J | 2 |
| Kini, A | 2 |
| Skurk, C | 1 |
| Shlofmitz, RA | 1 |
| Zhou, CF | 1 |
| Ren, YH | 1 |
| Song, YQ | 1 |
| Yi, J | 1 |
| Han, BS | 1 |
| Xue, Q | 1 |
| Fu, ZH | 1 |
| Li, DY | 1 |
| Ahn, Y | 1 |
| Pya, Y | 1 |
| Bekbossynova, M | 1 |
| Metzger, C | 1 |
| Dangas, GD | 1 |
| Francese, DP | 1 |
| Ozan, O | 1 |
| Cong, H | 1 |
| Zhang, F | 1 |
| Li, X | 1 |
| Du, M | 3 |
| Zhang, D | 2 |
| Shi, Y | 1 |
| Shah, RR | 1 |
| Pillai, A | 1 |
| Omar, A | 1 |
| Zhao, J | 1 |
| Arora, V | 1 |
| Kapoor, D | 1 |
| Poommipanit, P | 1 |
| Eikelboom, JW | 9 |
| Mancini, GB | 2 |
| Cohen, EA | 3 |
| Vijayaraghavan, R | 1 |
| Cheema, AN | 2 |
| Udell, JA | 1 |
| Niznick, J | 1 |
| Faza, NN | 1 |
| Mentias, A | 1 |
| Parashar, A | 1 |
| Chaudhury, P | 1 |
| Barakat, AF | 1 |
| Agarwal, S | 1 |
| Wayangankar, S | 1 |
| Murat Tuzcu, E | 1 |
| Kapadia, SR | 1 |
| Whalen, JD | 1 |
| Davies, G | 2 |
| Oguz, M | 2 |
| Bash, LD | 1 |
| Ozer-Stillman, I | 1 |
| Shimada, YJ | 1 |
| Bansilal, S | 2 |
| Vaduganathan, M | 2 |
| Zhang, YQ | 1 |
| Wei, CL | 1 |
| Hu, YH | 1 |
| Tokgözoğlu, L | 1 |
| Yamaç, AH | 1 |
| Göktekin, O | 1 |
| Holmes, LE | 1 |
| Gupta, R | 2 |
| Rajendran, S | 1 |
| Luu, J | 1 |
| French, JK | 1 |
| Juergens, CP | 2 |
| Liu, X | 2 |
| Zang, H | 1 |
| Guo, L | 1 |
| Zhao, W | 1 |
| Lin, J | 1 |
| Lin, Y | 1 |
| Xu, J | 1 |
| Brener, SJ | 2 |
| Montefusco, A | 1 |
| Scarano, S | 1 |
| Abu-Assi, E | 1 |
| Raposeiras-Roubín, S | 1 |
| Henriques, JP | 1 |
| Saucedo, J | 1 |
| González-Juanatey, JR | 1 |
| Wilton, SB | 1 |
| Nuñez-Gil, I | 1 |
| Ariza-Sole, A | 1 |
| Song, X | 1 |
| Liebetrau, C | 1 |
| Kawaji, T | 1 |
| Nie, SP | 1 |
| Fujii, T | 1 |
| Correia, L | 1 |
| Kawashiri, MA | 1 |
| García-Acuña, JM | 1 |
| Southern, D | 1 |
| Alfonso, E | 1 |
| Terol, B | 1 |
| Garay, A | 1 |
| Osman, N | 1 |
| Möllmann, H | 1 |
| Shiomi, H | 2 |
| Kowara, M | 1 |
| Filipiak, K | 1 |
| Yan, Y | 1 |
| Ikari, Y | 2 |
| Nakahayshi, T | 1 |
| Sakata, K | 1 |
| Yamagishi, M | 1 |
| Kalpak, O | 1 |
| Kedev, S | 1 |
| Hoshi, T | 1 |
| Sato, A | 1 |
| Nogami, A | 1 |
| Gosho, M | 1 |
| Aonuma, K | 1 |
| Jin, L | 1 |
| Yu, H | 1 |
| Dong, T | 1 |
| Zhang, B | 1 |
| Liao, H | 1 |
| Zou, X | 1 |
| Westerman, ME | 1 |
| Sharma, V | 1 |
| Scales, J | 1 |
| Gearman, DJ | 1 |
| Ingimarsson, JP | 1 |
| Krambeck, AE | 1 |
| Magnus Ohman, E | 1 |
| Meena, N | 1 |
| Abouzgheib, W | 1 |
| Patolia, S | 1 |
| Rosenheck, J | 1 |
| Boujaoude, Z | 1 |
| Bartter, T | 1 |
| Chang, CY | 1 |
| Lin, SY | 1 |
| Tsai, JR | 1 |
| Tsai, CH | 1 |
| Chen, YC | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 1 |
| Kedhi, E | 1 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 2 |
| Magnani, G | 3 |
| Esposito, G | 1 |
| Pang, M | 1 |
| Zhuang, K | 1 |
| Bhat, A | 1 |
| Park, TK | 2 |
| Shin, SJ | 1 |
| Ge, H | 1 |
| Lv, X | 1 |
| Ren, H | 1 |
| Jiang, Y | 1 |
| Wang, YQ | 1 |
| Wang, CH | 1 |
| Saporito, R | 1 |
| Michael Gibson, C | 2 |
| Cohen, D | 1 |
| Moliterno, D | 1 |
| Stuckey, T | 2 |
| Henry, T | 1 |
| Gabriel Steg, P | 1 |
| Gori, T | 1 |
| Thalmeier, A | 1 |
| Löw, A | 1 |
| Teupser, D | 1 |
| Malek, L | 1 |
| Horstkotte, J | 1 |
| Baylacher, M | 1 |
| Schwinger, R | 1 |
| Abnousi, F | 1 |
| Ozmete, O | 1 |
| Bali, C | 1 |
| Ergenoglu, P | 1 |
| Suner, HI | 1 |
| Aribogan, A | 1 |
| Gunarathne, A | 1 |
| Hussain, S | 1 |
| Gershlick, AH | 1 |
| Schaffer, A | 2 |
| Pourdjabbar, A | 1 |
| Le May, MR | 3 |
| Simard, T | 1 |
| Ramirez, FD | 1 |
| Lugomirski, P | 1 |
| Maze, R | 1 |
| Bernick, J | 1 |
| Wells, G | 1 |
| Jakubowski, JA | 2 |
| Ferri, LA | 1 |
| Morici, N | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Toso, A | 1 |
| Ferrario, M | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 2 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 1 |
| Cavallini, C | 1 |
| Moffa, N | 1 |
| Déry, JP | 2 |
| Fisher, HN | 1 |
| Zhang, X | 2 |
| Zhu, YE | 1 |
| Lavi, S | 1 |
| Cieza, T | 1 |
| Henderson, MA | 1 |
| Lutchmedial, S | 1 |
| Siega, AJ | 1 |
| Wong, BY | 1 |
| Kokis, A | 1 |
| Dehghani, P | 1 |
| Wimmer, NJ | 1 |
| Dufour, AB | 1 |
| Cho, K | 1 |
| Gagnon, DR | 1 |
| Quach, L | 1 |
| Ly, S | 1 |
| Do, JM | 1 |
| Ostrowski, S | 1 |
| Michael Gaziano, J | 1 |
| Kinlay, S | 2 |
| Carrero, JJ | 1 |
| Szummer, K | 2 |
| Evans, M | 1 |
| Spaak, J | 1 |
| Kinnear, N | 1 |
| Hennessey, DB | 1 |
| Douglass-Molloy, H | 1 |
| Jack, G | 1 |
| Pieper, M | 1 |
| Schmitz, J | 1 |
| McBane, R | 1 |
| Knudsen, J | 1 |
| McMenomy, B | 1 |
| Wennberg, P | 1 |
| Atwell, T | 1 |
| Hahn, JY | 2 |
| Song, YB | 2 |
| Lee, JB | 1 |
| Doh, JH | 1 |
| Yang, JH | 1 |
| Choi, JH | 2 |
| Choi, SH | 2 |
| Kukula, K | 2 |
| Kunicki, PK | 1 |
| Jamiolkowski, J | 2 |
| Debski, A | 2 |
| Bekta, P | 2 |
| Polanska-Skrzypczyk, M | 1 |
| Chmielak, Z | 2 |
| Witkowski, A | 2 |
| Fowkes, FG | 1 |
| Heizer, G | 1 |
| Berger, JS | 5 |
| Held, P | 1 |
| Katona, BG | 1 |
| Norgren, L | 2 |
| Blomster, J | 1 |
| Millegård, M | 1 |
| Reist, C | 1 |
| Kunicki, P | 1 |
| Sawlani, NN | 1 |
| Xu, H | 1 |
| Ping, Y | 1 |
| Lin, H | 1 |
| He, P | 1 |
| Li, W | 1 |
| Dai, H | 1 |
| Jalal, Z | 1 |
| Dinet, ML | 1 |
| Combes, N | 1 |
| Pillois, X | 1 |
| Renou, P | 1 |
| Sibon, I | 1 |
| Iriart, X | 1 |
| Thambo, JB | 1 |
| Zuo, FT | 1 |
| Wu, HJ | 1 |
| Su, N | 1 |
| Liu, JQ | 1 |
| Dong, AQ | 1 |
| Della Riva, D | 1 |
| Bacchi Reggiani, L | 1 |
| Sangiorgi, D | 1 |
| Angelini, GD | 1 |
| Pufulete, M | 1 |
| Giannopoulos, G | 1 |
| Oualim, S | 1 |
| Elharda, CA | 1 |
| Benzeroual, D | 1 |
| Hattaoui, ME | 1 |
| Rahman, MM | 1 |
| Scalese, MJ | 1 |
| Hansen, RA | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Hsu, CY | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Ooi, SY | 1 |
| Iliev, L | 1 |
| Bruno, V | 1 |
| Hübl, W | 1 |
| Willheim, M | 1 |
| Wojta, J | 1 |
| Cabrera-Fuentes, HA | 1 |
| Cho, YR | 1 |
| Park, K | 1 |
| Kim, YD | 1 |
| Yoon, SC | 1 |
| Zuliani Mauro, MF | 1 |
| Costa, R | 1 |
| Piva E Mattos, LA | 1 |
| Siqueira, D | 1 |
| Sousa, A | 1 |
| Lee, H | 1 |
| Lim, SW | 1 |
| Bae, JW | 1 |
| Kim, BS | 1 |
| Chase, M | 1 |
| Ozan, MO | 1 |
| Yokoyama, S | 1 |
| Motoyama, Y | 1 |
| van Klaveren, D | 1 |
| Pilgrim, T | 1 |
| Steyerberg, EW | 1 |
| Sullivan, J | 1 |
| Amarshi, N | 1 |
| Alberts, MJ | 2 |
| Hanley, DF | 1 |
| Payne, CD | 1 |
| Li, YG | 1 |
| Brandt, JT | 1 |
| Small, DS | 1 |
| Farid, NA | 1 |
| Salazar, DE | 1 |
| Mertens, L | 1 |
| Eyskens, B | 1 |
| Boshoff, D | 1 |
| Gewillig, M | 1 |
| Bauersachs, J | 1 |
| Eigenthaler, M | 1 |
| Manzano-Fernández, S | 1 |
| Pastor, FJ | 1 |
| Marín, F | 3 |
| Cambronero, F | 1 |
| Caro, C | 1 |
| Pascual-Figal, DA | 1 |
| Garrido, IP | 1 |
| Pinar, E | 1 |
| Valdés, M | 1 |
| Murphy, SA | 7 |
| Antman, EM | 9 |
| Weerakkody, G | 3 |
| Morocutti, G | 1 |
| McCabe, CH | 8 |
| Ghosh, S | 1 |
| Bandyopadhyay, D | 1 |
| Büttner, HJ | 1 |
| Khattab, AA | 1 |
| Minners, J | 1 |
| Graf, I | 1 |
| Skelding, KA | 1 |
| Dirschinger, J | 2 |
| Berger, PB | 14 |
| Kent, DM | 1 |
| Thaler, DE | 1 |
| Sacco, RL | 1 |
| Diener, HC | 3 |
| Cotton, D | 1 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 1 |
| Martin, RH | 1 |
| Albers, GW | 2 |
| Bath, P | 1 |
| Bornstein, N | 1 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Cunha, L | 1 |
| Dahlöf, B | 1 |
| De Keyser, J | 1 |
| Donnan, GA | 1 |
| Estol, C | 1 |
| Gorelick, P | 1 |
| Gu, V | 1 |
| Hermansson, K | 1 |
| Hilbrich, L | 1 |
| Kaste, M | 1 |
| Lu, C | 1 |
| Machnig, T | 1 |
| Pais, P | 1 |
| Roberts, R | 1 |
| Skvortsova, V | 1 |
| Teal, P | 1 |
| Toni, D | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Yoon, BW | 1 |
| Alexander, D | 1 |
| Ou, FS | 2 |
| Pollack, CV | 6 |
| Gibler, WB | 2 |
| Fintel, DJ | 1 |
| Brown, DL | 1 |
| Pogue, J | 6 |
| Haladyn, K | 1 |
| Peters, RJ | 2 |
| Avezum, A | 1 |
| Gersh, BJ | 3 |
| Rupprecht, HJ | 4 |
| Jackevicius, CA | 1 |
| Tu, JV | 1 |
| Demers, V | 1 |
| Melo, M | 1 |
| Cox, J | 1 |
| Rinfret, S | 3 |
| Kalavrouziotis, D | 1 |
| Johansen, H | 1 |
| Behlouli, H | 1 |
| Newman, A | 1 |
| Pilote, L | 2 |
| Halperin, JL | 3 |
| Roldán, V | 1 |
| Graw, J | 1 |
| Schwenk, W | 1 |
| Volk, T | 1 |
| Satler, LF | 3 |
| Lansky, AJ | 1 |
| Tsuchiya, Y | 1 |
| Brener, M | 1 |
| Cristea, E | 1 |
| Pietras, C | 1 |
| Grines, CL | 1 |
| Garcia, E | 1 |
| Tcheng, JE | 5 |
| Turco, M | 1 |
| Carroll, JD | 1 |
| Rutherford, BD | 1 |
| Moses, J | 1 |
| Chrolavicius, S | 6 |
| Diaz, R | 3 |
| Jolly, S | 2 |
| Roy, P | 1 |
| Torguson, R | 2 |
| de Labriolle, A | 1 |
| Slottow, TL | 1 |
| Steinberg, DH | 1 |
| Kaneshige, K | 2 |
| Xue, Z | 2 |
| Kent, KM | 2 |
| Suddath, WO | 2 |
| Pichard, AD | 2 |
| Lindsay, J | 1 |
| Waksman, R | 2 |
| Molfese, M | 1 |
| Mihalcsik, L | 1 |
| Mantovani, P | 1 |
| Bass, TA | 1 |
| Della Rovere, F | 1 |
| Heer, T | 2 |
| Juenger, C | 1 |
| Gitt, AK | 1 |
| Bauer, T | 2 |
| Towae, F | 1 |
| Zahn, R | 3 |
| Senges, J | 2 |
| Levin, A | 1 |
| Ben-Artzi, M | 1 |
| Beckerman, P | 1 |
| Haber, G | 1 |
| Varon, D | 1 |
| Ben-Yehuda, A | 1 |
| Muszkat, M | 1 |
| Mariani, G | 1 |
| Lortie, E | 1 |
| Girard, F | 1 |
| Boudreault, D | 1 |
| Ruel, M | 2 |
| Mansour, S | 1 |
| Blais, N | 1 |
| Hardy, JF | 1 |
| Serebruany, V | 3 |
| Shalito, I | 1 |
| Kopyleva, O | 1 |
| Calatzis, A | 1 |
| Hobson, A | 1 |
| Curzen, N | 1 |
| Wong, PC | 2 |
| Crain, EJ | 2 |
| Watson, CA | 2 |
| Hua, J | 1 |
| Schumacher, WA | 1 |
| Rehfuss, R | 1 |
| Tay, KH | 1 |
| Lane, DA | 3 |
| Schalekamp, T | 1 |
| Klungel, OH | 1 |
| Souverein, PC | 1 |
| de Boer, A | 1 |
| Guasch, E | 1 |
| Sionis, A | 1 |
| Reverter, JC | 1 |
| Andrea, R | 1 |
| Loma-Osorio, P | 1 |
| Freixa, X | 1 |
| Lauritzen, B | 1 |
| Tranholm, M | 1 |
| Ezban, M | 1 |
| Aronow, HD | 1 |
| Steinhubl, SR | 17 |
| Brennan, DM | 7 |
| Topol, EJ | 20 |
| Singh, J | 1 |
| Zeller, W | 1 |
| Zhou, N | 1 |
| Hategen, G | 1 |
| Mishra, R | 1 |
| Polozov, A | 1 |
| Yu, P | 1 |
| Onua, E | 1 |
| Zembower, D | 1 |
| Kiselyov, A | 1 |
| Ramírez, JL | 1 |
| Sigthorsson, G | 1 |
| Bjornsson, JM | 1 |
| Thorsteinsdottir, M | 1 |
| Andrésson, T | 1 |
| Bjarnadottir, M | 1 |
| Magnusson, O | 1 |
| Fabre, JE | 1 |
| Stefansson, K | 1 |
| Gurney, ME | 1 |
| Mohler, ER | 1 |
| Mak, KH | 6 |
| Shao, M | 5 |
| Haffner, SM | 2 |
| Hankey, GJ | 5 |
| Mahla, E | 1 |
| Antonino, MJ | 1 |
| Motovska, Z | 1 |
| Kala, P | 1 |
| Merlini, P | 1 |
| Furlan, AJ | 1 |
| Zibaeenezhad, MJ | 1 |
| Mazloum, Y | 1 |
| Slattery, D | 1 |
| Mitchell, P | 1 |
| Pfeffer, M | 1 |
| Usman, MH | 1 |
| Notaro, LA | 1 |
| Nagarakanti, R | 1 |
| Brahin, E | 1 |
| Dessain, S | 1 |
| Gracely, E | 1 |
| Chua, D | 1 |
| Ignaszewski, A | 1 |
| Argüello Viudez, L | 1 |
| Biller, J | 1 |
| Lordkipanidzé, M | 1 |
| Diodati, JG | 1 |
| Pharand, C | 1 |
| Jähne, J | 2 |
| Schirren, J | 2 |
| Marzot, F | 1 |
| Pengo, V | 1 |
| Bölükbas, S | 1 |
| Sambola, A | 1 |
| Ferreira-González, I | 2 |
| Angel, J | 1 |
| Alfonso, F | 2 |
| Maristany, J | 1 |
| Rodríguez, O | 1 |
| López-Minguez, JR | 1 |
| Zueco, J | 1 |
| Fernández-Avilés, F | 1 |
| San Román, A | 1 |
| Prendergast, B | 1 |
| Mainar, V | 1 |
| García-Dorado, D | 2 |
| Tornos, P | 1 |
| Martens, A | 1 |
| Haverich, A | 1 |
| Ball, J | 1 |
| Aleil, B | 1 |
| Jacquemin, L | 1 |
| Zaehringer, M | 1 |
| Cazenave, JP | 1 |
| Dickele, MC | 1 |
| Monassier, JP | 2 |
| Lincoff, AM | 10 |
| Manoukian, SV | 2 |
| Chew, D | 1 |
| Feit, F | 1 |
| Ware, JH | 1 |
| Bertrand, ME | 3 |
| Saw, J | 4 |
| Densem, C | 1 |
| Walsh, S | 1 |
| Jokhi, P | 1 |
| Starovoytov, A | 1 |
| Fox, R | 1 |
| Buller, C | 1 |
| Ricci, D | 1 |
| Fung, A | 1 |
| Frere, C | 2 |
| Bali, L | 2 |
| Moro, PJ | 2 |
| Choe, KS | 1 |
| Jani, AB | 1 |
| Liauw, SL | 1 |
| Alexander, JH | 1 |
| Cools, F | 2 |
| Crea, F | 1 |
| Dellborg, M | 2 |
| Lewis, BS | 4 |
| Mohan, P | 1 |
| Ruda, M | 1 |
| Ruzyllo, W | 2 |
| Verheugt, F | 1 |
| Makarov, LM | 1 |
| Spinler, SA | 3 |
| Moussa, ID | 1 |
| Kittisupamongkol, W | 1 |
| Van Werkum, JW | 1 |
| Hamm, C | 2 |
| Dill, T | 2 |
| Gosselink, AT | 2 |
| Van Houwelingen, G | 2 |
| Hoorntje, JC | 1 |
| Koopmans, PC | 1 |
| Carrel, T | 1 |
| Englberger, L | 1 |
| Katus, H | 4 |
| Scirica, BM | 2 |
| Skene, A | 1 |
| Freij, A | 1 |
| Thorsén, M | 1 |
| Poyet, R | 1 |
| Gaborit, B | 3 |
| Castillo-Sang, M | 1 |
| Tsang, AW | 1 |
| Almaroof, B | 1 |
| Cireddu, J | 1 |
| Sferra, J | 1 |
| Zelenock, GB | 1 |
| Engoren, M | 1 |
| Kasper, G | 1 |
| Bagur, R | 2 |
| Bertrand, OF | 3 |
| Larose, E | 2 |
| Nguyen, CM | 2 |
| Noel, B | 1 |
| Larochellière, RD | 1 |
| Poirier, P | 2 |
| Costerousse, O | 2 |
| Roy, L | 2 |
| Borderías Clau, L | 1 |
| Garrapiz López, J | 1 |
| Caballero, G | 1 |
| Aranki, SF | 1 |
| Body, SC | 1 |
| Goldstein, LB | 1 |
| Richard, T | 1 |
| Butaffuoco, F | 1 |
| Vanhaeverbeek, M | 1 |
| Watson, PD | 1 |
| Joy, PS | 1 |
| Nkonde, C | 1 |
| Hessen, SE | 1 |
| Karalis, DG | 1 |
| Proulx, G | 1 |
| Gleeton, O | 1 |
| De Larochellière, R | 1 |
| Badreldin, A | 1 |
| Kroener, A | 1 |
| Kamiya, H | 1 |
| Lichtenberg, A | 1 |
| Hekmat, K | 1 |
| Kannan, AO | 1 |
| Makarov, L | 1 |
| Healey, JS | 1 |
| Apostolakis, S | 1 |
| Shantsila, E | 1 |
| Norgard, NB | 1 |
| Abu-Fadel, M | 1 |
| McNulty, S | 1 |
| Amine, M | 1 |
| Chew, DP | 2 |
| French, WJ | 2 |
| Leisch, F | 1 |
| Parikh, KH | 1 |
| Hacke, W | 7 |
| Stegherr, J | 2 |
| von Beckerath, N | 2 |
| Kowalczyk, M | 1 |
| Banach, M | 2 |
| Mikhailidis, DP | 1 |
| Hannam, S | 1 |
| Rysz, J | 1 |
| Lazar, LD | 1 |
| Fitchett, D | 1 |
| Eikelboom, J | 2 |
| Fremes, S | 1 |
| Mazer, D | 1 |
| Singh, S | 1 |
| Bittira, B | 1 |
| Brister, S | 1 |
| Graham, J | 2 |
| Gupta, M | 1 |
| Karkouti, K | 2 |
| Lee, A | 1 |
| Love, M | 1 |
| McArthur, R | 1 |
| Peterson, M | 1 |
| Yau, T | 1 |
| Abildstrom, SZ | 1 |
| Hvelplund, A | 2 |
| Andersson, C | 2 |
| Jørgensen, C | 1 |
| Madsen, JK | 3 |
| Gunay, R | 1 |
| Sensoz, Y | 1 |
| Kayacioglu, I | 1 |
| Demirtas, MM | 1 |
| Guerra, DR | 1 |
| Mahoney, EM | 1 |
| Arnold, SV | 1 |
| Proskorovsky, I | 1 |
| Antman, E | 1 |
| Chhatriwalla, AK | 1 |
| Gerber, RT | 1 |
| Wells, GA | 3 |
| Glover, CA | 1 |
| O'Brien, ER | 1 |
| Turek, M | 1 |
| Thomas, A | 1 |
| Kass, M | 1 |
| Jadhav, S | 1 |
| Carlhed, R | 1 |
| Bojestig, M | 1 |
| Peterson, A | 1 |
| Aberg, C | 1 |
| Garmo, H | 1 |
| Lindahl, B | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Vural, A | 1 |
| Islek, M | 1 |
| Avsar, O | 1 |
| Cattaneo, M | 3 |
| Wartak, SA | 1 |
| Lotfi, A | 1 |
| Rothberg, M | 1 |
| Zafar, MU | 1 |
| Ibáñez, B | 1 |
| Choi, BG | 1 |
| Vorchheimer, DA | 1 |
| Piñero, A | 1 |
| Jin, X | 1 |
| Sharma, RK | 1 |
| Badimon, JJ | 1 |
| Koch, W | 1 |
| Gebhard, D | 1 |
| Schuster, T | 1 |
| Izuhara, Y | 1 |
| Yamaoka, N | 1 |
| Kodama, H | 1 |
| Dan, T | 1 |
| Takizawa, S | 1 |
| Hirayama, N | 1 |
| Meguro, K | 1 |
| van Ypersele de Strihou, C | 1 |
| Miyata, T | 1 |
| Tavassoli, N | 1 |
| Voisin, S | 1 |
| Lapeyre-Mestre, M | 1 |
| Galinier, M | 1 |
| Montastruc, JL | 1 |
| Pathak, A | 1 |
| Wait, SD | 1 |
| Abla, AA | 1 |
| Killory, BD | 1 |
| Starke, RM | 1 |
| Spetzler, RF | 1 |
| Nakaji, P | 1 |
| Hayashi, F | 1 |
| Mokhtar, OA | 1 |
| Armero, S | 1 |
| Mancini, J | 1 |
| Bonello, C | 1 |
| Tahirou, I | 1 |
| Dignat-George, F | 1 |
| Camoin-Jau, L | 2 |
| Szlam, F | 1 |
| Tanaka, KA | 1 |
| Rumph, B | 1 |
| Bolliger, D | 1 |
| Levy, JH | 3 |
| Schwalm, JD | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Tsukahara, K | 1 |
| Kimura, K | 1 |
| Morita, S | 1 |
| Ebina, T | 1 |
| Kosuge, M | 1 |
| Hibi, K | 1 |
| Okuda, J | 1 |
| Iwahashi, N | 1 |
| Maejima, N | 1 |
| Nakachi, T | 1 |
| Ohtsuka, F | 1 |
| Hashiba, K | 1 |
| Tahara, Y | 1 |
| Sugano, T | 1 |
| Umemura, S | 1 |
| Kim, BH | 1 |
| Kim, KP | 1 |
| Lim, KS | 1 |
| Kim, JR | 1 |
| Yoon, SH | 1 |
| Lee, YO | 1 |
| Lee, KH | 1 |
| Jang, IJ | 1 |
| Shin, SG | 1 |
| Yu, KS | 1 |
| Nie, B | 1 |
| Yan, ZX | 1 |
| Jia, de A | 1 |
| Yu, M | 1 |
| Petersen, JL | 1 |
| Barron, JJ | 1 |
| Hammill, BG | 1 |
| Cziraky, MJ | 1 |
| Wahl, PM | 1 |
| Eisenstein, EL | 1 |
| Califf, RM | 4 |
| Schulman, KA | 1 |
| Curtis, LH | 1 |
| Bhindi, R | 1 |
| Latini, RA | 1 |
| Pizzocri, S | 1 |
| Lanotte, S | 1 |
| Biondi Zoccai, GG | 1 |
| Laudisa, ML | 1 |
| Brambilla, N | 1 |
| Banning, AP | 1 |
| Bedogni, F | 1 |
| Doraiswamy, VA | 1 |
| Islam, AM | 1 |
| Patel, PM | 1 |
| Maegdefessel, L | 1 |
| Azuma, J | 1 |
| Tsao, PS | 1 |
| Dumont, LA | 1 |
| Rongières, M | 1 |
| Tchénio, P | 1 |
| Gangloff, D | 1 |
| Garrido-Stowhas, I | 1 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 2 |
| Geraghty, OC | 1 |
| Kennedy, J | 1 |
| Chandratheva, A | 1 |
| Marquardt, L | 1 |
| Buchan, AM | 1 |
| Rothwell, PM | 1 |
| Pickett, AM | 1 |
| Taylor, DA | 1 |
| Stiefelhagen, P | 1 |
| Ben-Dor, I | 1 |
| Scheinowitz, M | 1 |
| Delhaye, C | 2 |
| Wakabayashi, K | 1 |
| Syed, AI | 1 |
| Collins, SD | 1 |
| Gonzalez, MA | 1 |
| Gaglia, MA | 1 |
| Sudre, A | 1 |
| Lablanche, JM | 1 |
| Fukushima, K | 1 |
| Kobayashi, Y | 1 |
| Kitahara, H | 1 |
| Iwata, Y | 1 |
| Kuroda, N | 1 |
| Ooyama, M | 1 |
| Nomura, F | 1 |
| Komuro, I | 1 |
| Fuster, V | 3 |
| Ambrosio, G | 1 |
| Steinhubl, S | 2 |
| Gresele, P | 2 |
| Tritto, I | 1 |
| Zuchi, C | 1 |
| Moses, JW | 2 |
| Yusuf, SW | 1 |
| Iliescu, C | 1 |
| Bathina, JD | 1 |
| Daher, IN | 1 |
| Durand, JB | 1 |
| Burdess, A | 1 |
| Nimmo, AF | 1 |
| Garden, OJ | 1 |
| Murie, JA | 1 |
| Dawson, AR | 1 |
| Newby, DE | 1 |
| Flather, MD | 4 |
| Givol, N | 1 |
| Halkin, A | 1 |
| Schöchl, H | 1 |
| Posch, A | 1 |
| Hanke, A | 1 |
| Voelckel, W | 1 |
| Solomon, C | 1 |
| Aboyans, V | 1 |
| Le Guyader, A | 1 |
| Lacroix, P | 1 |
| Pevzner, DV | 1 |
| Staroverov, II | 1 |
| Frolova, NS | 1 |
| Mazurov, AV | 1 |
| Ruda, MY | 1 |
| Pakhomov, IaM | 1 |
| Hindy-François, C | 1 |
| Le Bonniec, B | 1 |
| Grelac, F | 1 |
| Dizier, B | 1 |
| Emmerich, J | 1 |
| Belch, JJ | 1 |
| Dormandy, J | 1 |
| Biasi, GM | 1 |
| Biasi, BM | 1 |
| Cairols, M | 1 |
| Diehm, C | 1 |
| Eikelboom, B | 1 |
| Golledge, J | 1 |
| Jawien, A | 1 |
| Lepäntalo, M | 1 |
| Becquemin, JP | 1 |
| Bergqvist, D | 1 |
| Clement, D | 1 |
| Stonebridge, P | 1 |
| Vermassen, F | 1 |
| Matyas, L | 1 |
| Leizorovicz, A | 1 |
| Renda, G | 1 |
| Merino, A | 1 |
| Roldán, I | 1 |
| Worner, F | 1 |
| Aïssaoui, N | 2 |
| Marsal, JR | 1 |
| Ribera, A | 1 |
| Permanyer-Miralda, G | 1 |
| García-Del Blanco, B | 1 |
| Martí, G | 1 |
| Cascant, P | 1 |
| Martín-Yuste, V | 1 |
| Brugaletta, S | 1 |
| Sabaté, M | 1 |
| Capote, ML | 1 |
| De La Torre, JM | 1 |
| Ruíz-Lera, M | 1 |
| Sanmiguel, D | 1 |
| Cárdenas, M | 1 |
| Pujol, B | 1 |
| Baz, JA | 1 |
| Iñiguez, A | 1 |
| Trillo, R | 1 |
| González-Béjar, O | 1 |
| Casanova, J | 1 |
| Sánchez-Gila, J | 1 |
| Christ, G | 2 |
| Kubica, J | 3 |
| Herkner, H | 1 |
| Jilma, B | 2 |
| Kontny, F | 1 |
| Spinar, J | 1 |
| Buck, KK | 1 |
| Parikh, K | 1 |
| Löwenberg, EC | 1 |
| Crosby, JR | 1 |
| MacLeod, AR | 1 |
| Zhao, C | 1 |
| Gao, D | 1 |
| Black, C | 1 |
| Revenko, AS | 1 |
| Meijers, JC | 1 |
| Stroes, ES | 1 |
| Levi, M | 1 |
| Monia, BP | 1 |
| Joyner, CD | 2 |
| Afzal, R | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Clausen, MT | 1 |
| Fog-Petersen, ML | 1 |
| Raunsø, J | 1 |
| Gadsbøll, N | 1 |
| Folke, F | 1 |
| Andersen, SS | 1 |
| Schramm, TK | 1 |
| Abildstrøm, SZ | 2 |
| Poulsen, HE | 1 |
| Kim, IS | 1 |
| Yun, SE | 1 |
| Kang, MK | 1 |
| Bakaeen, F | 1 |
| Chu, D | 2 |
| Feldman, DN | 1 |
| Minutello, RM | 1 |
| Bergman, G | 2 |
| Moussa, I | 2 |
| Wong, SC | 2 |
| Schlitt, A | 2 |
| Paré, G | 2 |
| Anand, SS | 1 |
| Hirsh, J | 2 |
| Simonsen, K | 1 |
| Finkelstein, A | 1 |
| Kilhamn, J | 1 |
| Olofsson, S | 1 |
| Weaver, WD | 1 |
| Mangalpally, KK | 1 |
| Sibbald, M | 1 |
| Yan, AT | 1 |
| Huang, W | 1 |
| Gore, JM | 2 |
| Eagle, KA | 2 |
| Brieger, D | 2 |
| Shehab, N | 1 |
| Sperling, LS | 1 |
| Kegler, SR | 1 |
| Budnitz, DS | 1 |
| Gendlin, GE | 1 |
| Tronina, OA | 1 |
| Storozhakov, GI | 1 |
| Marchini, J | 1 |
| Morrow, D | 1 |
| Resnic, F | 1 |
| Manica, A | 1 |
| Kirshenbaum, J | 1 |
| Cannon, C | 1 |
| Croce, K | 1 |
| Armani, AM | 1 |
| Kulik, A | 1 |
| Voisine, P | 1 |
| Tardif, JC | 1 |
| Delarochelliere, R | 1 |
| Naidoo, S | 1 |
| Mesana, TG | 1 |
| Fernandez, A | 1 |
| Aboodi, MS | 1 |
| Milewski, K | 1 |
| Delgado, JA | 1 |
| Rodríguez, A | 1 |
| Granada, JF | 1 |
| Minarelli, M | 1 |
| Rechner, AR | 1 |
| Ivandic, B | 1 |
| Park, JH | 1 |
| Singh, PP | 1 |
| Singh, M | 1 |
| Bedi, U | 1 |
| Molnar, J | 1 |
| Arora, R | 1 |
| Khosla, S | 1 |
| Bansal, V | 1 |
| Fortlage, D | 1 |
| Doucet, J | 2 |
| Potenza, B | 1 |
| Coimbra, R | 1 |
| Václavík, J | 1 |
| Táborský, M | 1 |
| Cadiou, G | 1 |
| Adam, M | 1 |
| Caussin, M | 1 |
| Landrin, I | 1 |
| Mariette, N | 1 |
| Capet, C | 1 |
| Mouton-Schleifer, D | 1 |
| Remy, E | 1 |
| Kadri, N | 1 |
| Pasceri, V | 3 |
| Vizzi, V | 1 |
| Di Sciascio, G | 3 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| Bischofs, C | 1 |
| Banya, W | 1 |
| Müller, K | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| May, AE | 2 |
| Flather, M | 2 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| White, JA | 1 |
| Giugliano, RP | 2 |
| Newby, LK | 1 |
| Goodwin, MM | 1 |
| Desilets, AR | 1 |
| Willett, KC | 1 |
| Cruden, NL | 1 |
| Morch, K | 1 |
| Wong, DR | 1 |
| Klinke, WP | 1 |
| Ofiesh, J | 1 |
| Hilton, JD | 1 |
| Ahmed, S | 1 |
| Sabatine, MS | 6 |
| Suissa, S | 2 |
| Charlot, M | 2 |
| Fosbøl, EL | 1 |
| Teirstein, PS | 1 |
| Puri, S | 1 |
| Robbins, M | 2 |
| Stillabower, ME | 1 |
| Stillablower, ME | 1 |
| Aragon, JR | 1 |
| Stinis, CT | 1 |
| Lee, MS | 2 |
| Schork, NJ | 1 |
| Connor, S' | 1 |
| Payot, L | 2 |
| Bellemain-Appaix, A | 3 |
| Aout, M | 1 |
| Steiger, H | 1 |
| Uddin, FS | 1 |
| Davila, RE | 1 |
| Harford, WV | 1 |
| Spechler, SJ | 1 |
| Fujishiro, M | 1 |
| Scharf, RE | 1 |
| Bellemain, A | 1 |
| Lindbäck, J | 1 |
| Hofman-Bang, C | 1 |
| Stenestrand, U | 1 |
| Samnegard, A | 1 |
| Ziegelstein, RC | 2 |
| Green, A | 1 |
| Sauder, M | 1 |
| Guthrie, R | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Mantovani, F | 1 |
| Demola, MA | 1 |
| Suriano, P | 1 |
| Kozinski, M | 2 |
| Castriota, F | 1 |
| Hochholzer, W | 1 |
| Contant, CF | 1 |
| Nijjer, SS | 2 |
| Watson, G | 1 |
| Athanasiou, T | 1 |
| Malik, IS | 1 |
| Cohen, MG | 1 |
| Rossi, JS | 1 |
| Garbarino, J | 1 |
| Bowling, R | 1 |
| Motsinger-Reif, AA | 1 |
| Schuler, C | 1 |
| Dupont, AG | 1 |
| Gabriel, D | 2 |
| Quinlan, DJ | 1 |
| Fitchett, DH | 1 |
| Théroux, P | 3 |
| Martin, MT | 1 |
| Nutescu, EA | 1 |
| Amin, AP | 1 |
| Kennedy, KF | 1 |
| Pencina, M | 1 |
| Berger, P | 1 |
| Piana, RN | 1 |
| Lopez, J | 2 |
| Kleiman, N | 1 |
| Zabalza, M | 1 |
| Subirana, I | 1 |
| Sala, J | 1 |
| Lluis-Ganella, C | 1 |
| Lucas, G | 1 |
| Tomás, M | 1 |
| Masiá, R | 1 |
| Brugada, R | 1 |
| Elosua, R | 1 |
| Biancari, F | 1 |
| Airaksinen, KE | 1 |
| Puymirat, E | 1 |
| Coste, P | 1 |
| Dentan, G | 1 |
| Bataille, V | 1 |
| Drouet, E | 1 |
| Mulak, G | 1 |
| Simon, T | 2 |
| Bhala, N | 1 |
| Taggar, JS | 1 |
| Rajasekhar, P | 1 |
| Banerjee, A | 1 |
| Bakaeen, FG | 1 |
| Alber, HF | 1 |
| Pachinger, O | 1 |
| Frick, M | 1 |
| Yan, BP | 1 |
| Brennan, AL | 1 |
| Loane, P | 1 |
| Lee, JS | 1 |
| Ahn, SW | 1 |
| Song, JW | 1 |
| Shim, JK | 1 |
| Yoo, KJ | 1 |
| Kwak, YL | 1 |
| Molines, L | 1 |
| Abu-Yousef, MM | 1 |
| Larson, JH | 1 |
| Kuehn, DM | 1 |
| Wu, AS | 1 |
| Laroia, AT | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 1 |
| Al Suwaidi, J | 1 |
| Anderson, FA | 1 |
| Goldberg, RJ | 1 |
| Qureshi, Z | 1 |
| Hobson, AR | 1 |
| Skolnick, BE | 1 |
| Shenouda, M | 1 |
| Khutoryansky, NM | 1 |
| Pusateri, AE | 1 |
| Carr, ME | 1 |
| Kalinczuk, L | 1 |
| Lubiszewska, B | 1 |
| Demkow, M | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Dalén, M | 1 |
| van der Linden, J | 2 |
| Lindvall, G | 2 |
| Ivert, T | 1 |
| Nielsen, VG | 1 |
| Chawla, N | 1 |
| Mangla, D | 1 |
| Gomes, SB | 1 |
| Arkebauer, MR | 1 |
| Wasko, KA | 1 |
| Sadacharam, K | 1 |
| Vosseller, K | 1 |
| Mariscalco, G | 1 |
| Bruno, VD | 1 |
| Cottini, M | 1 |
| Borsani, P | 1 |
| Piffaretti, G | 1 |
| Dominici, C | 1 |
| Beghi, C | 1 |
| Sala, A | 1 |
| Ng, J | 1 |
| Hohnloser, S | 1 |
| Burcham, P | 1 |
| Blais, D | 1 |
| Firstenberg, MS | 1 |
| French, J | 1 |
| Basra, SS | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| Brilakis, ES | 1 |
| Rosiello, R | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Tang, HL | 1 |
| Hu, YF | 1 |
| Xie, HG | 1 |
| Comin, J | 1 |
| Kallmes, D | 1 |
| Mercadier, A | 1 |
| Lancar, R | 1 |
| Costagliola, D | 1 |
| Maitra, S | 1 |
| Chakraborty, A | 1 |
| Han, KR | 1 |
| Hong, TJ | 1 |
| Chung, WY | 1 |
| Choi, YJ | 1 |
| Kim, BO | 1 |
| Wouter Jukema, J | 1 |
| Mark, B | 2 |
| Fichtlscherer, S | 1 |
| Werner, G | 1 |
| Schöller, R | 1 |
| Diller, F | 1 |
| Holmes, MV | 1 |
| Perel, P | 1 |
| Shah, T | 1 |
| Hingorani, AD | 1 |
| Casas, JP | 1 |
| Nissen, SE | 2 |
| Davies, JE | 1 |
| Francis, DP | 1 |
| Delle-Karth, G | 1 |
| Lang, IM | 1 |
| Neunteufl, T | 1 |
| Linkowska, K | 1 |
| Grzybowski, T | 1 |
| Powers, D | 1 |
| Stather, DR | 1 |
| MacEachern, P | 1 |
| Chee, A | 1 |
| Tremblay, A | 1 |
| You, JJ | 1 |
| Howard, PA | 1 |
| Eckman, MH | 1 |
| Fang, MC | 1 |
| Hylek, EM | 1 |
| Schulman, S | 1 |
| Hughes, M | 1 |
| Spencer, FA | 2 |
| Manning, WJ | 1 |
| Mackay, SM | 1 |
| Zhou, YH | 1 |
| Wei, X | 1 |
| Ye, XF | 1 |
| Wu, MJ | 1 |
| Xu, JF | 1 |
| Qin, YY | 1 |
| He, J | 1 |
| Herout, PM | 1 |
| Harshaw, Q | 1 |
| Frye, CB | 1 |
| Perera, M | 1 |
| Suarez, A | 1 |
| Luzardo, H | 1 |
| Molero, T | 1 |
| Hermanides, RS | 1 |
| Ottervanger, JP | 1 |
| Dambrink, JH | 1 |
| Stella, PR | 1 |
| Johnston, SS | 1 |
| Bell, K | 1 |
| Gdovin, J | 1 |
| Jing, Y | 1 |
| Boulé, S | 1 |
| Marquié, C | 1 |
| Vanesson-Bricout, C | 1 |
| Kouakam, C | 1 |
| Brigadeau, F | 1 |
| Guédon-Moreau, L | 1 |
| Acheré, C | 1 |
| Goéminne-Boulé, C | 1 |
| Lacroix, D | 1 |
| Klug, D | 1 |
| Kacet, S | 1 |
| Stephens, JC | 1 |
| Askari, AT | 1 |
| Simonsen, KL | 1 |
| Emison, ES | 1 |
| Bhakta, N | 1 |
| Cacoub, P | 2 |
| Creager, MA | 2 |
| Murugesan, G | 1 |
| Kottke-Marchant, K | 1 |
| Rossi, M | 1 |
| Serraino, GF | 1 |
| Spadafora, A | 1 |
| Renzulli, A | 1 |
| Reese, ES | 1 |
| Daniel Mullins, C | 1 |
| Beitelshees, AL | 1 |
| Onukwugha, E | 1 |
| Shuldiner, AR | 1 |
| Vesely, MR | 1 |
| Fisch, A | 1 |
| Mega, JL | 1 |
| Siasos, G | 1 |
| Tousoulis, D | 1 |
| Fosbol, EL | 1 |
| Li, S | 1 |
| Shah, B | 1 |
| Mills, RM | 1 |
| Klaskala, W | 1 |
| Alexander, KP | 2 |
| Di Pierro, F | 1 |
| Rinaldi, F | 1 |
| Lucarelli, M | 1 |
| Rossoni, G | 1 |
| Sorich, MJ | 1 |
| Polasek, TM | 1 |
| Wiese, MD | 1 |
| Nusca, A | 1 |
| Sheikh-Taha, M | 1 |
| Ghosn, S | 1 |
| Lyseng-Williamson, KA | 1 |
| Mustonen, P | 1 |
| Puurunen, M | 1 |
| Varughese, CJ | 1 |
| Konosic, S | 1 |
| Burcar, I | 1 |
| Tada, T | 1 |
| Natsuaki, M | 1 |
| Morimoto, T | 1 |
| Furukawa, Y | 1 |
| Nakagawa, Y | 1 |
| Kadota, K | 1 |
| Iwabuchi, M | 1 |
| Shizuta, S | 1 |
| Tazaki, J | 1 |
| Abe, M | 1 |
| Ehara, N | 1 |
| Mizoguchi, T | 1 |
| Mitsuoka, H | 1 |
| Inada, T | 1 |
| Araki, M | 1 |
| Kaburagi, S | 1 |
| Taniguchi, R | 1 |
| Eizawa, H | 1 |
| Nakano, A | 1 |
| Suwa, S | 1 |
| Takizawa, A | 1 |
| Nohara, R | 1 |
| Fujiwara, H | 1 |
| Mitsudo, K | 1 |
| Nobuyoshi, M | 1 |
| Kita, T | 1 |
| Steiner, S | 2 |
| Moertl, D | 1 |
| Coyle, D | 1 |
| Smith, PK | 1 |
| Goodnough, LT | 1 |
| Poston, RS | 1 |
| Short, MA | 1 |
| Weerakkody, GJ | 1 |
| Lenarz, LA | 1 |
| Thompson, VP | 1 |
| McClure, MW | 1 |
| Gretler, DD | 1 |
| Berdan, LG | 1 |
| Paynter, G | 1 |
| Madan, M | 2 |
| Lawler, E | 1 |
| Young, M | 1 |
| Gaziano, M | 1 |
| Warlé-Van Herwaarden, MF | 1 |
| Roukens, M | 1 |
| Pop, GA | 1 |
| Lamfers, EJ | 1 |
| De Smet, PA | 1 |
| Kramers, C | 1 |
| Ueno, T | 1 |
| Igarashi, K | 1 |
| Kobayashi, M | 1 |
| Dai, ZL | 1 |
| Chen, H | 1 |
| Wu, XY | 1 |
| Ahmad, S | 1 |
| Laine, M | 1 |
| Bessereau, J | 1 |
| Sébastien, A | 1 |
| Kar, S | 1 |
| Foody, JM | 1 |
| Funk, M | 1 |
| Nielsen, LH | 1 |
| Lindhardsen, J | 1 |
| Ahlehoff, O | 1 |
| Olsen, AM | 1 |
| Rollini, F | 1 |
| Tello-Montoliu, A | 1 |
| Darnborough, S | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
| Shevelev, VI | 2 |
| Kanorskiĭ, SG | 1 |
| Limper, U | 1 |
| Lynch, J | 1 |
| Tamura, T | 1 |
| Sakaeda, T | 1 |
| Kadoyama, K | 1 |
| Okuno, Y | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Karasoy, D | 1 |
| Vavalle, JP | 1 |
| Kopjar, T | 1 |
| Djuric, Z | 1 |
| Svetina, L | 1 |
| Burgess, S | 1 |
| Mallard, TA | 1 |
| McClure, LA | 1 |
| Szychowski, JM | 1 |
| El Mallah, W | 1 |
| May, CH | 1 |
| Einecke, D | 2 |
| Uchiyama, S | 3 |
| Tanahashi, N | 1 |
| Minematsu, K | 1 |
| Moore, TJ | 1 |
| Bennett, CL | 1 |
| Wieloch, M | 1 |
| Lumsden, J | 1 |
| Rydell, E | 1 |
| Ohman, J | 1 |
| Jones, GM | 1 |
| Twilla, JD | 1 |
| Hoit, DA | 1 |
| Arthur, AS | 1 |
| Meyer, S | 1 |
| Lala, A | 1 |
| Sharma, G | 1 |
| Scott Braithwaite, R | 1 |
| Ladapo, JA | 1 |
| Abdel Samie A, A | 1 |
| Sun, R | 1 |
| Vöhringer, U | 1 |
| Theilmann, L | 1 |
| Zalt, MB | 1 |
| Bechara, RI | 1 |
| Parks, C | 1 |
| Berkowitz, DM | 1 |
| Salisbury, AC | 1 |
| Jones, PG | 1 |
| Spertus, JA | 1 |
| Ghose, A | 1 |
| Sharma, A | 1 |
| Guha, G | 1 |
| Mukherjee, D | 2 |
| Frankel, R | 1 |
| Hanna, EB | 1 |
| Fusari, M | 1 |
| Song, HG | 1 |
| Lee, JY | 1 |
| Kim, WJ | 1 |
| Yun, SC | 1 |
| Kanorsky, SG | 1 |
| Cucherat, M | 1 |
| Jacq, L | 1 |
| Bernasconi, F | 1 |
| Jeske, W | 1 |
| Thethi, I | 1 |
| Azoulay, L | 1 |
| Dell'Aniello, S | 1 |
| Renoux, C | 1 |
| Weber, R | 1 |
| Saut, N | 1 |
| Cohen, W | 1 |
| Chen, YD | 1 |
| Lü, SZ | 1 |
| Jin, ZN | 1 |
| Song, XT | 1 |
| Ducas, J | 1 |
| Chan, MC | 1 |
| Miller, A | 1 |
| Kashour, T | 1 |
| Sare, GM | 1 |
| Lloyd, FR | 1 |
| Stower, MJ | 1 |
| Maier, C | 1 |
| Gleim, M | 1 |
| Weiss, T | 1 |
| Stachetzki, U | 1 |
| Nicolas, V | 1 |
| Zenz, M | 1 |
| Turpie, AG | 1 |
| Tognoni, G | 2 |
| Zhao, F | 5 |
| Hunt, D | 1 |
| Franzosi, MG | 1 |
| Beasley, JW | 1 |
| Cheitlin, MD | 1 |
| Jones, RH | 1 |
| Kereiakes, D | 1 |
| Kupersmith, J | 1 |
| Levin, TN | 1 |
| Pepine, CJ | 1 |
| Schaeffer, JW | 1 |
| Smith, EE | 1 |
| Steward, DE | 1 |
| Gibbons, RJ | 1 |
| Alpert, JS | 1 |
| Gregoratos, G | 1 |
| Hiratzka, LF | 1 |
| Jacobs, AK | 1 |
| Commerford, PJ | 2 |
| Blumenthal, M | 1 |
| Wittlinger, T | 1 |
| Meyer, BJ | 1 |
| Tsakiris, DA | 1 |
| Mychaskiw, G | 1 |
| Vaughn, C | 1 |
| Watters, K | 1 |
| McConn Walsh, R | 1 |
| Gerschutz, GP | 1 |
| von Bardeleben, RS | 1 |
| Ehrlich, A | 1 |
| Eimermacher, A | 1 |
| Peetz, D | 1 |
| Dahm, M | 1 |
| Schroeder, WS | 1 |
| Gandhi, PJ | 1 |
| Friess, D | 1 |
| Lämmle, B | 1 |
| Alberio, L | 1 |
| Brennan, D | 1 |
| Kopp, CW | 1 |
| Priglinger, U | 1 |
| Probst, P | 1 |
| Kopecky, SL | 1 |
| Valentin, V | 1 |
| Wodlinger, AM | 1 |
| Pieper, JA | 1 |
| Remes, V | 1 |
| Helenius, I | 1 |
| Robb-Nicholson, C | 1 |
| Exaire, JE | 1 |
| Wolski, K | 2 |
| Raymond, RE | 2 |
| Orford, JL | 1 |
| Fasseas, P | 1 |
| Melby, S | 1 |
| Burger, K | 1 |
| Golmard, JL | 1 |
| Tanguy, ML | 2 |
| Ankri, A | 2 |
| Choussat, R | 2 |
| Drobinski, G | 1 |
| Vignolles, N | 1 |
| Thomas, D | 2 |
| Dumaine, R | 1 |
| Gallois, V | 1 |
| Wolski, KE | 1 |
| Peters, R | 1 |
| Lakkis, N | 1 |
| Moore, M | 1 |
| Power, M | 1 |
| Kerr, JL | 1 |
| Oppelt, TF | 1 |
| Rowen, RC | 1 |
| Betriu, A | 1 |
| Rutsch, W | 1 |
| Wilcox, RG | 1 |
| Erdmann, E | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Bogousslavsky, J | 2 |
| Mattle, HP | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| Schleinitz, MD | 1 |
| Heidenreich, PA | 1 |
| Momi, S | 1 |
| Pitchford, SC | 1 |
| Alberti, PF | 1 |
| Minuz, P | 1 |
| Del Soldato, P | 1 |
| Leopold, JA | 1 |
| Hill, KA | 1 |
| Skene, AM | 1 |
| Wahidi, MM | 1 |
| Garland, R | 1 |
| Feller-Kopman, D | 1 |
| Herth, F | 1 |
| Becker, HD | 1 |
| Ernst, A | 1 |
| von Heymann, C | 1 |
| Schoenfeld, H | 1 |
| Sander, M | 1 |
| Ziemer, S | 1 |
| Grubitzsch, H | 1 |
| Spies, C | 1 |
| Buresly, K | 1 |
| Eisenberg, MJ | 1 |
| Madi-Jebara, S | 1 |
| Rkeiby-Kassabian, N | 1 |
| Yazigi, A | 1 |
| Behounek, BD | 1 |
| Carney, RJ | 1 |
| Lazzam, C | 1 |
| McKay, RG | 1 |
| Sciagrà, R | 1 |
| Memisha, G | 1 |
| Moschi, G | 1 |
| Pupi, A | 1 |
| Tiaden, JD | 1 |
| Wenzel, E | 1 |
| Berthold, HK | 1 |
| Müller-Oerlinghausen, B | 1 |
| Kannan, S | 1 |
| Arab, D | 1 |
| Lewis, B | 1 |
| Cho, L | 1 |
| Steen, L | 1 |
| Joyal, D | 1 |
| Leya, F | 1 |
| Nitschmann, S | 1 |
| Hartung, HP | 1 |
| Siebler, M | 1 |
| Gill, SS | 1 |
| Morrow, DA | 1 |
| Hagiwara, A | 1 |
| Matsuda, T | 1 |
| Shimazaki, S | 1 |
| Bezerra, DC | 1 |
| Nakamura, T | 1 |
| Yamazaki, M | 1 |
| Kimura, Y | 1 |
| Iwata, M | 1 |
| Sauer, H | 1 |
| Leschke, M | 1 |
| Black, HR | 1 |
| Mas, JL | 2 |
| Pearson, TA | 2 |
| Weber, MA | 1 |
| Fabry-Ribaudo, L | 1 |
| Booth, J | 1 |
| Kapetanakis, EI | 1 |
| Medlam, DA | 1 |
| Petro, KR | 1 |
| Haile, E | 1 |
| Hill, PC | 1 |
| Dullum, MK | 1 |
| Bafi, AS | 1 |
| Boyce, SW | 1 |
| Corso, PJ | 1 |
| Calvet, D | 1 |
| Touzé, E | 1 |
| Khurram, Z | 1 |
| Chou, E | 1 |
| Minutello, R | 1 |
| Parikh, M | 1 |
| Naidu, S | 1 |
| Walsh, SJ | 1 |
| McClelland, AJ | 1 |
| Adgey, JA | 1 |
| Lutsep, HL | 1 |
| Kongsaengdao, S | 1 |
| Arayawichanont, A | 1 |
| Kamalesh, M | 1 |
| Smith, SD | 1 |
| Galor, A | 1 |
| Hoffman, GS | 1 |
| Kjaer, J | 1 |
| Larsen, CH | 1 |
| Poulsen, TS | 1 |
| Møller, JE | 1 |
| Mickley, H | 1 |
| Bromberg-Marin, G | 1 |
| Parsons, LS | 1 |
| Canto, JG | 1 |
| Rogers, WJ | 1 |
| Sartipy, U | 1 |
| Poston, R | 1 |
| Soulat, L | 1 |
| Lambert, Y | 1 |
| Adgey, J | 1 |
| Sánchez-Torrijos, J | 1 |
| Gudín-Uriel, M | 1 |
| Ridocci-Soriano, F | 1 |
| Campbell, ME | 1 |
| Mathias, J | 1 |
| Pieper, KS | 1 |
| Tolleson, TR | 1 |
| O'Shea, JC | 1 |
| Guo, W | 1 |
| Wexler, RR | 1 |
| Lam, PY | 1 |
| Quan, ML | 1 |
| Knabb, RM | 1 |
| Liao, JK | 1 |
| Tonelli, M | 1 |
| Mann, JF | 2 |
| Sitkei, E | 1 |
| Hawken, S | 1 |
| Fitzgerald, DJ | 2 |
| DeEugenio, D | 1 |
| Kolman, L | 1 |
| DeCaro, M | 2 |
| Andrel, J | 1 |
| Chervoneva, I | 1 |
| Duong, P | 1 |
| Lam, L | 1 |
| McGowan, C | 1 |
| Lee, G | 1 |
| Ruggiero, N | 1 |
| Singhal, S | 1 |
| Greenspon, A | 1 |
| Cherfan, A | 1 |
| Arabi, Y | 1 |
| Al Askar, A | 1 |
| Al Shimemeri, A | 1 |
| de Borst, GJ | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Jackson, AJ | 1 |
| Teenan, RP | 1 |
| Orr, DJ | 1 |
| Macdonald, S | 1 |
| Chow, G | 1 |
| Collins, JS | 1 |
| Meinertz, T | 1 |
| Anand, S | 1 |
| Xie, C | 1 |
| Sussex, B | 1 |
| Guzman, R | 1 |
| Cina, C | 1 |
| Crowell, R | 1 |
| Gosselin, G | 1 |
| Chassot, PG | 1 |
| Delabays, A | 1 |
| Spahn, DR | 1 |
| Fox, K | 1 |
| Wang, TH | 1 |
| Helton, TJ | 1 |
| Bavry, AA | 1 |
| Kumbhani, DJ | 1 |
| Duggal, S | 1 |
| Roukoz, H | 1 |
| Rivkin, A | 1 |
| Vilahur, G | 1 |
| Casaní, L | 1 |
| Badimon, L | 1 |
| Brulotte, S | 1 |
| Sénéchal, M | 1 |
| Lemieux, A | 1 |
| Bergeron, S | 1 |
| Motivala, AA | 1 |
| Tamhane, U | 1 |
| Saab, F | 1 |
| Rogers, EK | 1 |
| Froehlich, J | 1 |
| Moscucci, M | 1 |
| Peters, G | 1 |
| Riesmeyer, J | 1 |
| Bruskina, O | 1 |
| Dotzer, F | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Yow, E | 1 |
| Berezny, KY | 1 |
| Bokesch, PM | 1 |
| Takahashi, M | 1 |
| Graham, TP | 1 |
| Sanders, SP | 1 |
| Sidi, D | 1 |
| Bonnet, D | 1 |
| Ewert, P | 1 |
| Michelson, AD | 1 |
| Johnson, SG | 1 |
| Rogers, K | 1 |
| Delate, T | 1 |
| Witt, DM | 1 |
| Gitt, A | 1 |
| Jünger, C | 1 |
| Koeth, O | 1 |
| Gottwik, M | 1 |
| Popławski, C | 1 |
| Jakubczyk, P | 1 |
| Jakubczyk, M | 1 |
| Kwa, AT | 1 |
| Rogers, JH | 1 |
| Foley, P | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Dorsch, MP | 1 |
| Schaerlig, E | 1 |
| Lefebvre, CW | 1 |
| Hoekstra, JW | 1 |
| Bonaca, M | 1 |
| Giugliano, R | 1 |
| Schwartz, NE | 1 |
| Best, PJ | 1 |
| Dasgupta, A | 1 |
| Szczech, LA | 1 |
| Langton, PE | 1 |
| Billett, HH | 1 |
| Pinkau, T | 1 |
| Purushothaman, B | 1 |
| Hermosillo, AJ | 1 |
| Voitk, J | 1 |
| Hasin, Y | 1 |
| Chandna, H | 1 |
| Macias, W | 1 |
| Alvarez, W | 1 |
| Riley, AB | 1 |
| Tafreshi, MJ | 1 |
| Haber, SL | 1 |
| Brommer, EJ | 1 |
| Cortelazzo, S | 1 |
| Finazzi, G | 1 |
| Ruggeri, M | 1 |
| Vestri, O | 1 |
| Galli, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 1 |
| Caliendo, G | 1 |
| Bradbury, K | 1 |
| Mehl, B | 1 |
| Karrillon, GJ | 1 |
| Benveniste, E | 1 |
| Bunouf, P | 1 |
| Aubry, P | 1 |
| Chevalier, B | 1 |
| Commeau, P | 1 |
| Cribier, A | 1 |
| Eiferman, C | 1 |
| Grollier, G | 1 |
| Guerin, Y | 1 |
| Henry, M | 1 |
| Lefevre, T | 1 |
| Livarek, B | 1 |
| Louvard, Y | 1 |
| Marco, J | 1 |
| Makowski, S | 1 |
| Pernes, JM | 1 |
| Rioux, P | 1 |
| Spaulding, C | 1 |
| Zemour, G | 1 |
| Pan, M | 1 |
| Suárez de Lezo, J | 1 |
| Velasco, F | 1 |
| Romero, M | 1 |
| Medina, A | 1 |
| Segura, J | 1 |
| Hernández, E | 1 |
| Pavlovic, D | 1 |
| Melian, F | 1 |
| Gallardo, A | 1 |
| Zayas, R | 1 |
| Ruiz, M | 1 |
| Torres, A | 1 |
| Schafer, AI | 1 |
| Iturbe, T | 1 |
| Sánchez, C | 1 |
| Moreno, JA | 1 |
| Olave, T | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Civeira, E | 1 |
| Peleato, J | 1 |
| Cornudella, R | 1 |
| Anzuini, A | 1 |
| Rosanio, S | 1 |
| Tocchi, M | 1 |
| Coppi, R | 1 |
| Bonnier, H | 1 |
| Sheiban, I | 1 |
| Kulbertus, HE | 1 |
| Chierchia, SL | 1 |
| Fleck, E | 1 |
| Bonnier, J | 1 |
| Emmanuelson, H | 1 |
| Missault, L | 1 |
| Chierchia, S | 1 |
| Casaccia, M | 1 |
| Niccoli, L | 1 |
| Oto, A | 1 |
| White, C | 1 |
| Webb-Peploe, M | 1 |
| Van Belle, E | 1 |
| McFadden, EP | 1 |
| Baim, DS | 1 |
| Popma, JJ | 1 |
| Gordon, PC | 1 |
| Ho, KK | 1 |
| Giambartolomei, A | 1 |
| Diver, DJ | 1 |
| Lasorda, DM | 1 |
| Williams, DO | 1 |
| Kuntz, RE | 1 |
| Ruf, A | 1 |
| Pogátsa-Murray, G | 1 |
| Dickfeld, T | 1 |
| Zohlnhöfer, D | 1 |
| Oetgen, M | 1 |
| Roubin, G | 1 |
| Iyer, S | 1 |
| Maida, R | 1 |
| Collins, M | 1 |
| Kreps, E | 1 |
| McCullough, PA | 1 |
| Marks, KR | 1 |
| Boysen, G | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Gent, M | 1 |
| Quinn, MJ | 1 |
| Dunlop, H | 1 |
| Siu, K | 1 |
| Hirsch, AT | 1 |
| Ringleb, PA | 1 |
| Yip, HK | 1 |
| Chang, HW | 1 |
| Wu, CJ | 1 |
| Chen, MC | 1 |
| Hang, CL | 1 |
| Fang, CY | 1 |
| Hsieh, KY | 1 |
| Hutten, BA | 1 |
| Plokker, HW | 1 |
| Yadav, JS | 1 |
| Kilaru, PK | 1 |
| Schweiger, MJ | 1 |
| Kozman, HA | 1 |
| Weil, TR | 1 |
| Taniuchi, M | 1 |
| Kurz, HI | 1 |
| Lasala, JM | 1 |
| Fox, KK | 1 |
| Chapman, TW | 1 |
| Bowley, DM | 1 |
| Lambert, AW | 1 |
| Walker, AJ | 1 |
| Ashley, SA | 1 |
| Wilkins, DC | 1 |
| Owen, A | 1 |
| Yende, S | 1 |
| Doggrell, SA | 1 |
| Ward, DJ | 1 |
| Taylor, R | 1 |
| Khot, UN | 1 |
| Sone, R | 1 |
| Nagayama, T | 1 |
| Shibagaki, Y | 1 |
| Kobayashi, I | 1 |
| Maruyama, S | 1 |
| Kusakabe, K | 1 |
| Tsujinaka, T | 1 |
| Itoh, T | 1 |
| Uemura, Y | 1 |
| Sakon, M | 1 |
| Kambayashi, J | 1 |
| Mori, T | 1 |
| Hatsuoka, M | 1 |
| Seiki, M | 1 |
| Sasaki, K | 1 |
| Kashii, A | 1 |
| Criado, A | 1 |
| Juffé, A | 1 |
| Carmona, J | 1 |
| Otero, C | 1 |
| Avello, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02513810] | 3,020 participants (Anticipated) | Interventional | 2015-12-02 | Active, not recruiting | |||
| [NCT02494895] | Phase 4 | 3,056 participants (Anticipated) | Interventional | 2015-08-01 | Recruiting | ||
| Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Guided by Either Intravascular Ultrasound or Angiography in Patients With Acute Coronary Syndrome: The Prospective, Multicenter, Randomized, Placebo-[NCT03971500] | 3,710 participants (Actual) | Interventional | 2019-08-20 | Active, not recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395] | Phase 2 | 3,037 participants (Actual) | Interventional | 2015-04-20 | Completed | ||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C[NCT02164864] | Phase 3 | 2,725 participants (Actual) | Interventional | 2014-07-22 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI[NCT01959451] | Phase 4 | 2,600 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606] | Phase 4 | 272 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298] | 2,062 participants (Actual) | Observational [Patient Registry] | 2012-12-21 | Completed | |||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699] | Phase 4 | 2,690 participants (Anticipated) | Interventional | 2023-03-28 | Recruiting | ||
| What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing[NCT00769938] | Phase 4 | 573 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction[NCT03182855] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Practice Patterns of Antithrombotic Therapy in REAL-world Patients Undergoing PCI in Spain: Parenteral Antiplatelet Agents[NCT05193019] | 1,000 participants (Anticipated) | Observational | 2022-03-14 | Recruiting | |||
| International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt[NCT00396877] | Phase 3 | 906 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail[NCT03079674] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2017-06-01 | Not yet recruiting | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study[NCT05644314] | 144 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial[NCT01830491] | Phase 4 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention[NCT01774955] | 2,047 participants (Actual) | Observational [Patient Registry] | 2012-02-29 | Completed | |||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events[NCT01186146] | Phase 4 | 5,000 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753] | 1,001 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.[NCT01347580] | Phase 4 | 1,875 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771] | Phase 4 | 64 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
| "Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent (Biofreedom): the CHANCE a Multicenter Study"[NCT03622203] | 1,000 participants (Actual) | Observational [Patient Registry] | 2016-01-01 | Completed | |||
| Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020] | 1,240 participants (Anticipated) | Observational | 2011-11-30 | Not yet recruiting | |||
| Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial[NCT02206815] | Phase 4 | 296 participants (Actual) | Interventional | 2014-09-19 | Completed | ||
| THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve[NCT00530894] | 1,057 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206] | Phase 4 | 4,005 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003] | Phase 4 | 2,272 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Platelet Function in Resuscitated Patients-2[NCT03445546] | 25 participants (Actual) | Observational | 2016-05-01 | Completed | |||
| Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319] | Phase 3 | 1,606 participants (Actual) | Interventional | 2011-06-30 | Active, not recruiting | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Comparison of Biolimus Eluted From an Erodable Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction and In Vivo 3-Vessel Assessment of Time-Related Changes of Culprit and Non-Culprit Lesions by IVUS/OCT in AMI[NCT00962416] | Phase 4 | 1,161 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Inflammation and Acute Coronary Syndromes (ACS) - Novel Strategies for Prevention and Clinical Management[NCT01000701] | 4,000 participants (Anticipated) | Observational | 2009-10-31 | Recruiting | |||
| A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775] | Phase 2 | 203 participants (Actual) | Interventional | 2013-02-06 | Completed | ||
| A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643] | Phase 3 | 220 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254] | Phase 4 | 420 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes[NCT02944123] | Phase 3 | 120 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Prospective, Randomized, Open-Label, Multicenter Study Assessing Efficacy and Safety of Ticagrelor De-escalation Strategy in East Asian Acute Myocardial Infarction With Coronary Intervention: EASTYLE Trial[NCT04755387] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2021-02-15 | Recruiting | ||
| Zotarolimus Eluting Stent Versus Sirolimus Eluting Stent in High Bleeding Risk Angioplasty[NCT05240781] | 280 participants (Anticipated) | Interventional | 2021-09-29 | Recruiting | |||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127] | 5,031 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281] | 1,079 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not? The CAPITAL OPTI-CROSS Study.[NCT02054663] | Phase 4 | 60 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503] | 12,227 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822] | Phase 3 | 13,885 participants (Actual) | Interventional | 2012-12-04 | Completed | ||
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890] | Phase 4 | 510 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| "Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study"[NCT03567733] | 1,000 participants (Actual) | Observational [Patient Registry] | 2018-06-18 | Completed | |||
| Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial[NCT05262803] | Phase 4 | 2,808 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| The Predictive Value of PRECISE DAPT Score in Patients With ST Segment Elevation Myocardial Infarction (STEMI) After Primary Percutaneous Coronary Intervention (PPCI)[NCT04549766] | 150 participants (Anticipated) | Observational | 2020-09-30 | Not yet recruiting | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054] | Phase 4 | 4,570 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[NCT01158846] | Phase 4 | 800 participants (Anticipated) | Interventional | 2010-08-31 | Not yet recruiting | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial[NCT04259853] | 1,016 participants (Anticipated) | Interventional | 2020-01-30 | Enrolling by invitation | |||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [NCT01032668] | Phase 3 | 192 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.[NCT00313300] | Phase 2 | 1,741 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease[NCT02110303] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting[NCT05566301] | 1,140 participants (Anticipated) | Observational | 2021-09-02 | Recruiting | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study[NCT04057300] | Phase 4 | 1,038 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow[NCT03654157] | 1,576 participants (Actual) | Observational | 2018-03-25 | Completed | |||
| Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889] | Phase 3 | 516 participants (Anticipated) | Interventional | 2023-11-09 | Recruiting | ||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293] | 1,505 participants (Actual) | Observational | 2021-07-20 | Completed | |||
| A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients[NCT02430493] | 1,066 participants (Actual) | Observational [Patient Registry] | 2015-05-28 | Completed | |||
| Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients- A Database Retrospective Study[NCT04861363] | 20,000 participants (Anticipated) | Observational | 2019-06-19 | Enrolling by invitation | |||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events[NCT02291419] | Phase 4 | 6 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Enrollment expectations were not met) | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373] | Phase 3 | 100 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction[NCT01381185] | Phase 4 | 154 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00305162] | Phase 3 | 8,882 participants (Actual) | Interventional | 2006-04-30 | Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor) | ||
| Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture[NCT02475187] | 33 participants (Anticipated) | Observational | 2015-09-30 | Terminated | |||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171] | Phase 2/Phase 3 | 150 participants (Anticipated) | Interventional | 2018-08-01 | Active, not recruiting | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study[NCT06015477] | 180 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery[NCT00701142] | Phase 2 | 80 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759] | Phase 3 | 1,460 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574] | 84 participants (Actual) | Observational | 2019-02-26 | Completed | |||
| Chinese People's Liberation Army General Hospital[NCT02798874] | 240 participants (Anticipated) | Interventional | 2016-05-31 | Enrolling by invitation | |||
| Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevati[NCT00089895] | Phase 3 | 9,406 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety[NCT00645918] | 2,800 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| Effect of the Omega n3 Fatty on Human Platelet Function[NCT00515541] | Phase 2 | 43 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607] | Phase 4 | 1,466 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651] | 69 participants (Anticipated) | Observational | 2016-05-31 | Enrolling by invitation | |||
| Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.[NCT01611545] | 130 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838] | 1,200 participants (Anticipated) | Observational | 2023-08-09 | Recruiting | |||
| A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI[NCT00751231] | Phase 2 | 652 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting[NCT01159639] | Phase 4 | 200 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation[NCT02224066] | Phase 4 | 65 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Femoral Versus Radial Access for Coronary Intervention in the Acute Phase of ST-Elevation Myocardial Infarction[NCT00356044] | Phase 4 | 439 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013] | 42 participants (Actual) | Observational | 2013-08-31 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy[NCT00714961] | Phase 3 | 3,491 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease[NCT00125671] | Phase 3 | 2,400 participants | Interventional | 2000-01-31 | Active, not recruiting | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Dose-Ranging Pharmacodynamic Assessment of Platelet Aggregation Inhibition With Clopidogrel in Children of Blalock-Taussig Shunt Age Categories (Neonates and Infants/Toddlers)[NCT00115375] | Phase 2 | 92 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667] | Phase 4 | 220 participants (Anticipated) | Interventional | 2017-04-10 | Recruiting | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401] | Phase 3 | 2,399 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086] | 165 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism[NCT02447809] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis[NCT00837954] | Phase 4 | 32 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban 2.5 mg Twice Daily (BID) | 80 |
| Acetylsalicylic Acid 100 mg Once Daily (OD) | 74 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 55 |
| Dabigatran Etexilate 150mg | 30 |
| Warfarin | 48 |
| Warfarin (Excluding Elder Patients Outside USA) | 35 |
"Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.~CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 37 |
| Dabigatran Etexilate 150mg | 21 |
| Warfarin | 31 |
| Warfarin (Excluding Elder Patients Outside USA) | 24 |
"Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.~Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 14 |
| Dabigatran Etexilate 150mg | 4 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
"Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.~This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was patient died) or when there was insufficient supporting information or detail to assign the cause of death." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 4 |
| Dabigatran Etexilate 150mg | 5 |
| Warfarin | 4 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 107 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 80 |
| Warfarin (Excluding Elder Patients Outside USA) | 57 |
Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE). (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 108 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 83 |
| Warfarin (Excluding Elder Patients Outside USA | 60 |
| All Dabigatran Etexilate | 168 |
Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 149 |
| Dabigatran Etexilate 150mg | 90 |
| Warfarin | 131 |
| Warfarin (Excluding Elder Patients Outside USA) | 98 |
| All Dabigatran Etexilate | 239 |
"Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.~Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.~Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.~Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 151 |
| Dabigatran Etexilate 150mg | 154 |
| Warfarin | 264 |
| Warfarin (Excluding Elder Patients Outside USA) | 196 |
Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 44 |
| Dabigatran Etexilate 150mg | 26 |
| Warfarin | 29 |
| Warfarin (Excluding Elder Patients Outside USA) | 22 |
"Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.~SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 3 |
| Dabigatran Etexilate 150mg | 1 |
| Warfarin | 3 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 15 |
| Dabigatran Etexilate 150mg | 7 |
| Warfarin | 8 |
| Warfarin (Excluding Elder Patients Outside USA) | 7 |
"Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 17 |
| Dabigatran Etexilate 150mg | 9 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 76 |
| Dabigatran Etexilate 150mg | 51 |
| Warfarin | 69 |
| Warfarin (Excluding Elder Patients Outside USA) | 52 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Treatment Arm | 257 |
| Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
| Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
| Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
| Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
| Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times. (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Spontaneous | Post-traumatic | Puncture (vascular access site) | Surgical | |
| Clopidogrel 0.2 mg/kg/Day | 56 | 11 | 9 | 17 |
| Placebo | 60 | 6 | 19 | 10 |
"The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.~Only the first event was counted." (NCT00396877)
Timeframe: Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Death / Shunt Thrombosis / Cardiac Procedure | - Death | - Shunt thrombosis | - Cardiac procedure <120 days of thrombotic nature | |
| Clopidogrel 0.2 mg/kg/Day | 89 | 51 | 26 | 12 |
| Placebo | 90 | 60 | 21 | 9 |
"Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted." (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 87 | 30 | 1 | 9 |
| Placebo | 88 | 32 | 1 | 9 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death (NCT01347580)
Timeframe: during the 30 days of treatment
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 41 |
| In-hospital Ticagrelor | 42 |
Death/MI/urgent revascularization. Adjudicated events except death (NCT01347580)
Timeframe: within 30 days of study
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 39 |
| In-hospital Ticagrelor | 34 |
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint (NCT01347580)
Timeframe: during 30 days of treatment
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 2 |
| In-hospital Ticagrelor | 11 |
non CABG related bleeds (PLATO definition) include life threatening and other major bleedings (NCT01347580)
Timeframe: after 48hours post-first dose
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 11 |
| In-hospital Ticagrelor | 11 |
non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds (NCT01347580)
Timeframe: within 48 hours of first dose
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 16 |
| In-hospital Ticagrelor | 15 |
non CABG related bleeds (PLATO definition) (NCT01347580)
Timeframe: within 48 hours of first dose
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 24 |
| In-hospital Ticagrelor | 24 |
non CABG related bleeds (PLATO definition) (NCT01347580)
Timeframe: after 48 hours post first dose
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 18 |
| In-hospital Ticagrelor | 16 |
ST segment elevation resolution post PCI >=70% is defined as complete resolution (NCT01347580)
Timeframe: Between baseline and ECG 60 mn post-PCI
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 410 |
| In-hospital Ticagrelor | 390 |
ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (<70%) resolution. (NCT01347580)
Timeframe: Between baseline and PCI
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 102 |
| In-hospital Ticagrelor | 102 |
(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion. (NCT01347580)
Timeframe: At initial angiography, pre PCI
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 143 |
| In-hospital Ticagrelor | 145 |
Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention. (NCT01347580)
Timeframe: during PCI
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 78 |
| In-hospital Ticagrelor | 100 |
TIMI) flow grade 3 is complete perfusion post-PCI. (NCT01347580)
Timeframe: at coroangiography post-PCI
| Intervention | patients (Number) |
|---|---|
| Pre-hospital Ticagrelor | 625 |
| In-hospital Ticagrelor | 630 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Death from any cause or repeat hospitalization after intervention. (NCT00530894)
Timeframe: duration of study
| Intervention | participants (Number) |
|---|---|
| Inoperable: TAVR | 76 |
| Inoperable: Medical Therapy | 126 |
Death from any cause. (NCT00530894)
Timeframe: 1 Year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 84 |
| High Risk: SAVR | 89 |
| Inoperable: TAVR | 55 |
| Inoperable: Medical Therapy | 89 |
NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort. (NCT00530894)
Timeframe: Baseline to 1 year
| Intervention | Units on scale (Least Squares Mean) |
|---|---|
| High Risk: TAVR | 2.50 |
| High Risk: SAVR | 2.60 |
| Inoperable: TAVR | 2.88 |
| Inoperable: Medical Therapy | 3.92 |
Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure (NCT00530894)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 93 |
| High Risk: SAVR | 97 |
| Inoperable: TAVR | 61 |
| Inoperable: Medical Therapy | 93 |
Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization. (NCT00530894)
Timeframe: 1 year
| Intervention | Days (Mean) |
|---|---|
| High Risk: TAVR | 17.42 |
| High Risk: SAVR | 20.14 |
| Inoperable: TAVR | 25.24 |
| Inoperable: Medical Therapy | 17.04 |
"The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.~KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.~SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status." (NCT00530894)
Timeframe: Baseline and 1 Year
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| KCCQ Overall | SF-12 Physical | SF-12 Mental | |
| High Risk: SAVR | 71.1 | 36.9 | 52.9 |
| High Risk: TAVR | 70.0 | 36.3 | 52.0 |
| Inoperable: Medical Therapy | 46.98 | 29.68 | 46.59 |
| Inoperable: TAVR | 69.41 | 34.85 | 53.31 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo Arm | 1.8 |
| Thienopyridine Therapy | 2.0 |
| Surveillance Arm | 4.8 |
"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo Arm | 1.0 |
| Thienopyridine Therapy | 0.5 |
| Surveillance Arm | 2.4 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo Arm | 4.3 |
| Thienopyridine Therapy | 4.8 |
| Surveillance Arm | 16.9 |
Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 1 |
| Edoxaban | 3 |
Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 3 |
| Edoxaban | 1 |
Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Clopidogrel | 34.7 |
| Edoxaban | 30.9 |
"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 30 |
| Edoxaban | 31 |
Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Including Access Site Bleeding (IASB) | Excluding Access Site Bleed (EASB) | |
| Clopidogrel | 8 | 6 |
| Edoxaban | 11 | 6 |
The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| IASB : Major Bleeding | IASB: CRNM Bleeding | IASB: Minor Bleeding | EASB : Major Bleeding | EASB : CRNM Bleeding | EASB : Minor Bleeding | |
| Clopidogrel | 5 | 4 | 20.8 | 4 | 3 | 17.8 |
| Edoxaban | 1 | 10 | 20 | 1 | 5 | 19 |
The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | units on a scale (Mean) |
|---|---|
| Prasugrel | 40.36 |
| Other | 41.87 |
(NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | grams/deciliter (g/dL) (Mean) |
|---|---|
| Prasugrel | 14.59 |
| Other | 14 |
Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 1.35 |
| Clopidogrel | 1.79 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 12.67 |
| Clopidogrel | 15.89 |
MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 13.14 |
| Clopidogrel | 17.12 |
Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Received DES | Received only BMS | STEMI | Other Race (Non-Caucasian) | Cardiogenic Shock on Presentation | Male Participants | EQ-5D US index = 1 vs. <1 | Married Participants | Participant has Diabetes | No BMS or DES | |
| Other | 6282 | 2491 | 4508 | 1049 | 176 | 6342 | 3873 | 5601 | 2472 | 331 |
| Prasugrel | 2365 | 672 | 1831 | 365 | 79 | 2451 | 1516 | 2044 | 767 | 86 |
Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month | 6 months | 12 months | 15 months | |
| Clopidogrel | 0.45 | 1.62 | 2.77 | 3.86 | 4.21 |
| Prasugrel | 0.54 | 1.22 | 1.93 | 2.72 | 3.10 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 month | 6 months | 15 months | |
| Clopidogrel | 5.40 | 12.04 | 19.13 |
| Prasugrel | 4.63 | 9.64 | 14.26 |
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 117 |
| Clopidogrel 75 mg od | 115 |
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 628 |
| Clopidogrel 75 mg od | 635 |
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 179 |
| Clopidogrel 75 mg od | 208 |
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1211 |
| Clopidogrel 75 mg od | 1250 |
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg bd | 751 |
| Clopidogrel 75 mg od | 740 |
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 766 |
| Clopidogrel 75 mg od | 759 |
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 839 |
| Clopidogrel 75 mg od | 833 |
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 363 |
| Clopidogrel 75 mg od | 343 |
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1312 |
| Clopidogrel 75 mg od | 1314 |
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 846 |
| Clopidogrel 75 mg od | 892 |
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 100 |
| Clopidogrel 75 mg od | 116 |
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 349 |
| Clopidogrel 75 mg od | 334 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1119 |
| Clopidogrel 75 mg od | 1140 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1183 |
| Clopidogrel 75 mg od | 1199 |
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 983 |
| Clopidogrel 75 mg od | 992 |
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 789 |
| Clopidogrel 75 mg od | 786 |
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 250 |
| Clopidogrel 75 mg od | 272 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 206 |
| Clopidogrel 75 mg od | 188 |
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 168 |
| Clopidogrel 75 mg od | 112 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 113 |
| Clopidogrel 75 mg od | 109 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 193 |
| Clopidogrel 75 mg od | 175 |
"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Change in ABI/TBI (Mean) | |||
|---|---|---|---|---|
| ABI - 6 months N = 6184(Tica), 6319(Clopi) | ABI - End of treatment N = 4951(Tica), 5073(Clopi) | TBI - 6 months N = 55(Tica), 48(Clopi) | TBI - End of treatment N = 36(Tica), 21(Clopi) | |
| Clopidogrel 75 mg od | 0.011 | 0.016 | 0.036 | -0.065 |
| Ticagrelor 90 mg bd | 0.016 | 0.022 | 0.050 | 0.059 |
"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | |||||
|---|---|---|---|---|---|---|
| Stage I - End of treatment | Stage IIa - End of treatment | Stage IIb - End of treatment | Stage III - End of treatment | Stage IV - End of treatment | Missing - End of treatment | |
| Clopidogrel - Stage I | 743 | 230 | 56 | 9 | 4 | 250 |
| Clopidogrel - Stage IIa | 723 | 1956 | 311 | 15 | 7 | 724 |
| Clopidogrel - Stage IIb | 198 | 557 | 450 | 23 | 10 | 370 |
| Clopidogrel - Stage III | 33 | 33 | 38 | 23 | 5 | 60 |
| Clopidogrel - Stage IV | 19 | 21 | 15 | 12 | 13 | 45 |
| Ticagrelor - Stage I | 775 | 227 | 45 | 7 | 7 | 248 |
| Ticagrelor - Stage IIa | 683 | 1948 | 269 | 24 | 7 | 743 |
| Ticagrelor - Stage IIb | 171 | 560 | 469 | 12 | 5 | 403 |
| Ticagrelor - Stage III | 15 | 41 | 39 | 31 | 1 | 59 |
| Ticagrelor - Stage IV | 26 | 28 | 19 | 7 | 13 | 47 |
"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Category 0 - End of treatment | Category 1/2 - End of treatment | Category 3 - End of treatment | Category 4 - End of treatment | Category 5 - End of treatment | Category 6 - End of treatment | Missing - End of treatment | |
| Clopidogrel - Cat 0 | 743 | 230 | 56 | 9 | 2 | 2 | 250 |
| Clopidogrel - Cat 1/2 | 723 | 1956 | 311 | 15 | 6 | 1 | 724 |
| Clopidogrel - Cat 3 | 198 | 557 | 450 | 23 | 6 | 4 | 370 |
| Clopidogrel - Cat 4 | 33 | 33 | 38 | 23 | 4 | 1 | 60 |
| Clopidogrel - Cat 5 | 13 | 18 | 12 | 11 | 12 | 0 | 34 |
| Clopidogrel - Cat 6 | 6 | 3 | 3 | 1 | 1 | 0 | 11 |
| Ticagrelor - Cat 0 | 775 | 227 | 45 | 7 | 5 | 2 | 248 |
| Ticagrelor - Cat 3 | 171 | 560 | 469 | 12 | 3 | 2 | 403 |
| Ticagrelor - Cat 4 | 15 | 41 | 39 | 31 | 1 | 0 | 59 |
| Ticagrelor - Cat 5 | 23 | 23 | 13 | 4 | 11 | 0 | 33 |
| Ticagrelor - Cat 6 | 3 | 5 | 6 | 3 | 0 | 2 | 14 |
| Ticagrelor - Stage II | 683 | 1948 | 269 | 24 | 4 | 3 | 743 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 6.1 |
| Apixaban 2.5mg BID | 15.1 |
| Apixaban 10mg QD | 17.6 |
| Apixaban 10mg BID | 24.2 |
| Apixaban 20 mg QD | 23.9 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 10.5 |
| Apixaban 2.5mg BID | 20.6 |
| Apixaban 10mg QD | 22.5 |
Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 5.0 |
| Apixaban 10mg QD | 5.6 |
| Apixaban 10mg BID | 7.8 |
| Apixaban 20 mg QD | 7.3 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups. (NCT00313300)
Timeframe: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.0 |
| Apixaban 2.5mg BID | 5.7 |
| Apixaban 10mg QD | 7.9 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.0 |
| Apixaban 2.5mg BID | 0.8 |
| Apixaban 10mg QD | 0.0 |
| Apixaban 10mg BID | 2.9 |
| Apixaban 20 mg QD | 4.1 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). (NCT00313300)
Timeframe: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 1.6 |
| Apixaban 10mg QD | 1.9 |
Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B (NCT00313300)
Timeframe: Day of randomization to 182 days after day of randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 54 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 20 |
Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: Randomization to 182 days after randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 53 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 19 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization and ends on high dose termination date, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization up to high dose termination, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
Time to first occurence of All-cause death. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Cardiovascular death. The number of patients with events was reported. (NCT02291419)
Timeframe: Up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Non-fatal stroke. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
(NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
(a patient could have multiple procedural events) (NCT00305162)
Timeframe: during index PCI
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 127 |
| Clopidogrel Arm | 141 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 151 |
| Clopidogrel Arm | 120 |
excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 78 |
| Clopidogrel Arm | 65 |
(excluding STEMI) (NCT00305162)
Timeframe: randomization through 1 year after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 116 |
| Clopidogrel Arm | 120 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 34 |
| Clopidogrel Arm | 29 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 285 |
| Clopidogrel Arm | 261 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 321 |
| Clopidogrel Arm | 298 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 343 |
| Clopidogrel Arm | 327 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 290 |
| Clopidogrel Arm | 276 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 10 |
| Clopidogrel Arm | 11 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 44 |
| Clopidogrel Arm | 52 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 297 |
| Clopidogrel Arm | 276 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 5 |
| Clopidogrel Arm | 7 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 19 |
| Clopidogrel Arm | 14 |
(NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 8 |
| Clopidogrel Arm | 5 |
(NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 13 |
| Clopidogrel Arm | 23 |
"Stroke is defined as a sudden, focal neurological defect resulting from a cerebrovascular cause that is not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or trauma. All suspected strokes were reviewed and adjudicated by the Clinical Events Committee (CEC) who considered all clinically relevant information and imaging studies to classify all strokes as:~primary hemorrhagic - stroke with focal collections of intracranial blood~ischemic cerebral infarction - stroke without focal collections of intracranial blood~infarction with hemorrhagic conversion - cerebral infarction with blood thought to represent hemorrhagic conversion and not primary bleeding~uncertain - no imaging or autopsy data are available." (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| primary hemorrhagic | infarction with hemorrhagic conversion | cerebral infarction | uncertain type | |
| Cangrelor Arm | 1 | 0 | 5 | 0 |
| Clopidogrel Arm | 0 | 0 | 7 | 0 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
(NCT00089895)
Timeframe: 96 hours after randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Eptifibatide | 9.3 |
| Placebo | 10.0 |
(NCT00089895)
Timeframe: 30 days after randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Eptifibatide | 11.2 |
| Placebo | 12.3 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
was there any bleeding occurance during the accessed interval (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | Number of occurance (Number) |
|---|---|
| Group A: Subject on Lovaza Only | 0 |
| Group B: Subject on Lovaza + Aspirin | 1 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | 0 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | 0 |
Bleeding time is a measure of how well platelets interact with blood vessel walls to form a clot. A manual blood pressure cuff is placed 2 inches above the antecubital fossa and inflated to 40mmHg. Using a standard Surgicutt device, a small incision is made and a stopwatch is started. The incision edge is blotted at 30 second intervals with standard filter paper until the bleeding has stopped. The time to hemostasis is noted. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | seconds (Median) | ||||
|---|---|---|---|---|---|
| Baseline (Week 0) | 1 gram Lovaza Daily (Week 6) | 2 grams Lovaza Daily (Week 12) | 4 grams Lovaza Daily (Week 18) | 8 grams Lovaza Daily (Week 24) | |
| Group A: Subject on Lovaza Only | 150 | 240 | 240 | 255 | 255 |
| Group B: Subject on Lovaza + Aspirin | 240 | 345 | 390 | 330 | 360 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | 570 | 720 | 690 | 600 | 600 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | 240 | 285 | 285 | 240 | 270 |
Measurements were made using a modified device (EQELS) to specifications of constant current, high electric field and a scattering angle of 30 degrees. EQELS provides a sensitive assessment of subtle changes in the cell surface that occurs with activation, ligand binding or apoptosis. These changes are the result of different distributions of charged groups that define a surface charge finger print for the current state of activation of the cell. Resting state platelets have a negative surface charge, whereas fully activated platelets have a positive surface charge. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | mobility units (Median) | ||||
|---|---|---|---|---|---|
| Baseline (Week 0) | 1 gram Lovaza Daily (Week 6) | 2 grams Lovaza Daily (Week 12) | 4 grams Lovaza Daily (Week 18) | 8 grams Lovaza Daily (Week 24) | |
| Group A: Subject on Lovaza Only | 0.28 | -0.45 | -0.95 | -1.08 | -0.88 |
| Group B: Subject on Lovaza + Aspirin | -0.04 | -0.72 | -1.30 | -0.94 | -0.97 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | -1.04 | -0.73 | -1.29 | -1.14 | -0.89 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | -1.10 | -0.50 | -0.58 | -0.44 | -0.19 |
The PAP-8E measures platelet aggregation in platelet rich plasma (PRP). Platelet responses to a series of common agonists cause changes in optical density that are measured. The instrument is blanked (100% baseline (optimal transmission)) by inserting a platelet poor plasma (PPP) specimen into the appropriate channel. The PRP is then inserted into the same well. The difference in optical density between the PPP and the PRP 0% baseline (optical transmission) is recorded for several minutes when the agonist reagent is added to the PRP. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | percent (Median) | ||||
|---|---|---|---|---|---|
| Baseline (Week 0) | 1 gram Lovaza Daily (Week 6) | 2 grams Lovaza Daily (Week 12) | 4 grams Lovaza Daily (Week 18) | 8 grams Lovaza Daily (Week 24) | |
| Group A: Subject on Lovaza Only | 79.5 | 79.5 | 87.5 | 82 | 83 |
| Group B: Subject on Lovaza + Aspirin | 0 | 3 | 2.5 | 0 | 3 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | 5.5 | 6.5 | 6 | 4 | 5 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | 8 | 9 | 12 | 10 | 22 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
206 reviews available for ticlopidine and Bleeding
| Article | Year |
|---|---|
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; H | 2017 |
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
[Management of the bleeding risk associated with antiplatelet agents].
Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans | 2017 |
Antiplatelet Therapy, Platelet Function Testing, and Bleeding Complications in Cardiac Surgery Patients.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Hemorrhage; Humans; Platelet Aggregation Inhi | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamo | 2017 |
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; | 2017 |
[Antiplatelet agents and transfusion].
Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pla | 2017 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2017 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2017 |
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona | 2018 |
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2017 |
Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders.
Topics: Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; P-Selectin; Platelet Aggreg | 2018 |
Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Administration Schedule | 2018 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; | 2018 |
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
Topics: Adult; Aspirin; Cause of Death; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Ische | 2018 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor | 2018 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochl | 2014 |
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperaz | 2013 |
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2013 |
Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Hemorrhage; Humans; Met | 2013 |
[The most important aspects of risk assessment].
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Clopidogrel; Digestive System Surgical Procedures; Dru | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans | 2014 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent | 2013 |
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; | 2014 |
Efficacy and safety of prasugrel in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibito | 2014 |
Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug | 2014 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Hum | 2014 |
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Safety; Strok | 2014 |
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Hemorrhage; Humans; My | 2014 |
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
Topics: Algorithms; Animals; Blood Platelets; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; | 2015 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2014 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc | 2015 |
Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis.
Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; | 2014 |
Resistance to antiplatelet drugs: what progress has been made?
Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent | 2014 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
Use of antiplatelet drugs after cardiac operations.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combinatio | 2014 |
Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part I.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; He | 2015 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; H | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre | 2015 |
High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis.
Topics: Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Drug Resistance; Heart Diseases; He | 2015 |
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Hum | 2015 |
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Percutaneous Coronar | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Pla | 2015 |
Practical experience with ticagrelor: an Australian and New Zealand perspective.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Pl | 2015 |
Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Stroke; Ticlopidine | 2015 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.
Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Hospitalization; Humans; Purinergic P2Y Receptor A | 2016 |
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2 | 2016 |
Clopidogrel Response Variability: Review of the Literature and Practical Considerations.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosi | 2016 |
Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies.
Topics: Clopidogrel; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Agg | 2016 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Percuta | 2016 |
[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
Topics: Administration, Oral; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans; | 2016 |
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Hem | 2016 |
[Switching from clopidogrel to prasugrel: Efficacy and safety data].
Topics: Clopidogrel; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Agg | 2015 |
Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis.
Topics: Clopidogrel; Cytochrome P-450 CYP3A; Drug Resistance; Genetic Association Studies; Hemorrhage; Human | 2016 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Hu | 2016 |
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy; Fibrinolytic Agents; He | 2016 |
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Dual antiplatelet therapy with clopidogrel and aspirin.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Contraindications; Coronary Artery Bypass; Hemorrhage | 2008 |
[Clopidogrel--clinical use and potential therapeutic problems].
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Dose-Response Relationship, Dr | 2008 |
Prasugrel development - claims and achievements.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu | 2009 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose- | 2008 |
Does timing matter? Upstream or downstream administration of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Algorithms; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration | 2009 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Com | 2009 |
Clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction | 2009 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2009 |
Prasugrel for the treatment of patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Tri | 2009 |
[Drug-eluting stents: implications for modern coronary revascularization].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug | 2008 |
Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Hemorrhage; H | 2009 |
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, C | 2009 |
Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Co | 2009 |
Coronary bypass surgery in patients treated with clopidogrel. Is it safe?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Hemorrhage; Huma | 2009 |
Platelet function testing and implications for clinical practice.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl | 2009 |
[Long-term use of oral antiplatelet therapy: from studies to practice].
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Fibrinolytic | 2010 |
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazine | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
Prasugrel: Clinical development and therapeutic application.
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggrega | 2009 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. III. therapeutic application of clopidogrel as monotherapy (without acetylsalicylic acid)].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2009 |
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Topics: Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inh | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hem | 2010 |
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
Topics: Age Factors; Atrial Fibrillation; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature.
Topics: Angioplasty; Anticoagulants; Aspirin; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Arte | 2010 |
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedu | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2010 |
[Reduction of haemorrhagic risk in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Huma | 2011 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido | 2010 |
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2011 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; | 2010 |
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; F | 2011 |
The safety of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; H | 2011 |
[Antithrombotic therapy in patients with prosthetic heart valves].
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Heart Valve Diseases | 2010 |
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials | 2010 |
Platelet function testing in clinical diagnostics.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Intracranial Embolism; Intracranial T | 2011 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombos | 2011 |
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fib | 2011 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2011 |
Thienopyridines in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platel | 2011 |
Antiplatelet agents in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2011 |
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electroca | 2011 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as To | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Com | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; | 2011 |
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Fema | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorr | 2011 |
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemo | 2011 |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genot | 2012 |
Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
Topics: Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Di | 2012 |
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment.
Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazi | 2011 |
Clopidogrel "resistance": where are we now?
Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Substitution; Hemorrhage; Human | 2013 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hum | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Predisposition to Dise | 2012 |
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Pip | 2012 |
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; | 2011 |
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel | 2012 |
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cl | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2012 |
Acute coronary syndromes: identifying the appropriate patient for prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet A | 2012 |
What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Benchmarking | 2012 |
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Association S | 2012 |
Platelet function and inhibition in ischemic heart disease.
Topics: Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Myocardial Ischemia; Platelet Agg | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr | 2012 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; H | 2012 |
Clinical use of clopidogrel.
Topics: Blood Platelets; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug I | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hem | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statist | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr | 2012 |
Review of ticagrelor in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation I | 2012 |
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation I | 2012 |
New anti-platelet agents: the end of resistance?
Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resista | 2012 |
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR).
Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Thalidomide; Thrombosis; T | 2012 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; | 2013 |
Clopidogrel, aspirin and proton pump inhibition after percutaneous valve implants: an update.
Topics: Aspirin; Clopidogrel; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Platelet Aggregation | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; H | 2012 |
Metabolic differences of current thienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2013 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Emergency Medical Services; Fibrinolytic Agents; Hemor | 2003 |
The role of clopidogrel in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; C | 2003 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 2004 |
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; | 2004 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Antiplatelet therapy in anticoagulated patients requiring coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hem | 2005 |
Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
Topics: Aspirin; Clopidogrel; Depressive Disorder; Drug Interactions; Hemorrhage; Humans; Platelet Aggregati | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
Clopidogrel in the treatment of ischaemic heart disease.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Hemorrhage; H | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers | 2007 |
The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass | 2007 |
Perioperative use of anti-platelet drugs.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Hemorrhage; Humans; Periope | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2007 |
Clopidogrel: who, when, and how?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug A | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
Topics: Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; | 2008 |
Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2008 |
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combi | 2008 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Art | 2008 |
Antiplatelet agents and arterial thrombosis.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggreg | 2008 |
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com | 2008 |
Prasugrel: a novel antiplatelet agent.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation | 2008 |
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Topics: Aspirin; Dipyridamole; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Pla | 1997 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 1998 |
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 1999 |
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance.
Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Platelet | 2002 |
231 trials available for ticlopidine and Bleeding
| Article | Year |
|---|---|
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; D | 2022 |
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; | 2023 |
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Drug-Eluting S | 2020 |
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice
Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Drug-Eluting Stents; Dual Anti-Platel | 2021 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M | 2017 |
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Dose-Response | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Dru | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combina | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con | 2017 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He | 2017 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Topics: Aged; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Hemorr | 2018 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2013 |
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocar | 2013 |
Clopidogrel in infants with systemic-to-pulmonary-artery shunts.
Topics: Anastomosis, Surgical; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Heart Defects, C | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Managem | 2013 |
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Thera | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Arte | 2014 |
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Rela | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.
Topics: Adult; Aged; Anticoagulants; Brazil; Clopidogrel; Cross-Sectional Studies; Databases, Factual; Dose- | 2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Esti | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th | 2014 |
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; M | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2015 |
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule | 2015 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therap | 2014 |
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Topics: Acute Coronary Syndrome; Aged; Antithrombins; Clopidogrel; Drug Therapy, Combination; Europe; Female | 2015 |
Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Female; Hemorrhage; Humans; Male; | 2014 |
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; | 2015 |
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El | 2014 |
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardi | 2014 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu | 2015 |
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combina | 2015 |
Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Echocardiography; Female; Foll | 2014 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug- | 2015 |
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middl | 2015 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Fe | 2015 |
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co | 2015 |
Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial.
Topics: Aged; Clopidogrel; Coronary Disease; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug | 2015 |
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Est | 2016 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femora | 2016 |
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Growth Differentiation Factor 15; Hemorrhage; Humans; N | 2016 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind | 2016 |
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; L | 2016 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Com | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Fem | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Hu | 2016 |
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Do | 2016 |
[TRILOGY-ACS and ACCOAST trial from an expert's perspective].
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochlo | 2015 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopid | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin | 2017 |
The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorr | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Respons | 2016 |
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Follow-Up Studies; Hemorrhage; Huma | 2016 |
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes
Topics: Acute Coronary Syndrome; Adult; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Adminis | 2017 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo | 2016 |
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Ove | 2017 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolim | 2016 |
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2017 |
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Drug Therapy, Combination; Female | 2017 |
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
Topics: Arterial Occlusive Diseases; Aspirin; China; Clopidogrel; Dose-Response Relationship, Drug; Drug The | 2017 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati | 2017 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Doubl | 2008 |
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; | 2008 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Huma | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su
Topics: Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Electrocardiography; Female; Hemorrhage; Hos | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, C | 2009 |
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrha | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Heparin infusion after successful percutaneous coronary intervention: a prospective, randomized trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Female; | 2009 |
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Double-Blind Method; Ethnicity; Female; Follow-U | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel | 2008 |
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; C | 2008 |
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Resp | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hemorrha | 2009 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp | 2009 |
A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.
Topics: Administration, Oral; Adult; Bleeding Time; Clopidogrel; Cross-Over Studies; Dose-Response Relations | 2010 |
High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dose-Resp | 2010 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers.
Topics: Adult; Asian People; Bleeding Time; Blood Platelets; Chromatography, High Pressure Liquid; Cross-Ove | 2010 |
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A | 2011 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt | 2010 |
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche | 2010 |
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Dia | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F | 2010 |
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cyto | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2011 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardio | 2011 |
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Angiography; Female; Fibrinolysis; Glomerular Filtrat | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationsh | 2011 |
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombi | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged | 2011 |
Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel.
Topics: Adult; Aspirin; Bleeding Time; Blood Platelets; Chi-Square Distribution; Clopidogrel; Dose-Response | 2011 |
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind M | 2011 |
Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Blood Coagulation; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2011 |
Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study.
Topics: Adult; Biopsy; Clopidogrel; Double-Blind Method; Factor VIIa; Hemorrhage; Hemostasis; Hemostatics; H | 2011 |
Optimal timing of discontinuation of clopidogrel and risk of blood transfusion after coronary surgery. Propensity score analysis.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Fe | 2011 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind | 2011 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Emergency Medical Services; Femal | 2012 |
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Hu | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2012 |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause | 2012 |
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Do | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality | 2012 |
Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Croatia; Drug Resistance; Dru | 2012 |
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double- | 2012 |
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Mid | 2013 |
Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combinati | 2013 |
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Comb | 2002 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA).
Topics: Administration, Oral; Adult; Aged; Aortic Valve; Aspirin; Clopidogrel; Drug Therapy, Combination; Fe | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2003 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2004 |
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Disease; | 2004 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose- | 2005 |
A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies | 2005 |
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera | 2005 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal | 2005 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Me | 2007 |
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combi | 2007 |
Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Mi | 2007 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Biomarkers; Cardiovascular Surgica | 2008 |
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Infant; Infant, Newborn; | 2008 |
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fema | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
The effect of Ticlopidine upon platelet function, haemorrhage and post-operative thrombosis in patients undergoing suprapubic prostatectomy.
Topics: Bleeding Time; Hemorrhage; Humans; Male; Platelet Function Tests; Postoperative Complications; Prost | 1981 |
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; | 1995 |
Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.
Topics: Aged; Anticoagulants; Aspirin; Coronary Vessels; Female; France; Hemorrhage; Heparin, Low-Molecular- | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
Topics: Administration, Oral; Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Coronary Disease; | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel | 2000 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
500 other studies available for ticlopidine and Bleeding
| Article | Year |
|---|---|
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
Topics: Aged; Algorithms; Asian People; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Comorbidity; C | 2022 |
Platelet function assessed by ROTEM
Topics: Aspirin; Clopidogrel; Deamino Arginine Vasopressin; Hemorrhage; Humans; Platelet Aggregation Inhibit | 2022 |
Cost Utility of Prasugrel in Postangioplasty Diabetic Patients.
Topics: Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 2022 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2022 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percut | 2023 |
miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; MicroR | 2023 |
Reduced bleeding with genotype-guided antiplatelet therapy.
Topics: Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; T | 2019 |
One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2019 |
1 vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention-Reply.
Topics: Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2019 |
Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Hemorrha | 2019 |
Adenosine Diphosphate Receptor Inhibitors: Balancing Perioperative Bleeding and Protection From Adverse Coronary Events.
Topics: Adenosine Diphosphate; Clopidogrel; Hemorrhage; Humans; Purinergic P2Y Receptor Antagonists; Ticlopi | 2021 |
Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel.
Topics: Administration, Oral; Aged; Anticoagulants; Clopidogrel; Colonic Polyps; Colonoscopy; Female; Gastro | 2021 |
Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Clopidogrel; Coronary Artery Disease; Female; Hem | 2017 |
Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Hemorrhage; | 2017 |
Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Topics: Adenosine; Aged; Blue Cross Blue Shield Insurance Plans; Clopidogrel; Drug Utilization Review; Ethni | 2017 |
Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect.
Topics: Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2017 |
Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combinatio | 2017 |
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female; | 2017 |
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Fem | 2017 |
Association of measured platelet reactivity with changes in P2Y
Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; M | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Huma | 2017 |
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2017 |
Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Greece; | 2017 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy.
Topics: Adenosine; Aged; Clopidogrel; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Drug Thera | 2017 |
Quantification of bleeding during dental extraction in patients on dual antiplatelet therapy.
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Dental Ca | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospita | 2017 |
Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
Topics: Aged; Asian People; Calcium Channel Blockers; Clopidogrel; Female; Hemorrhage; Hospitalization; Huma | 2018 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
A retrospective comparison between delayed and early hip fracture surgery in patients taking clopidogrel: same total bleeding but different timing of blood transfusion.
Topics: Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Female; Fracture Fixation, Internal; Hemiar | 2017 |
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; G | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr | 2017 |
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi | 2017 |
Platelet transfusion to reverse antiplatelet therapy before decompressive surgery in patients with intracranial haemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Decompression, Surgical; Female; Hemorrhage; Humans; In | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbi | 2018 |
Proton Pump Inhibitors may Reduce Bleeding Risk in Older Patients on Antiplatelet Therapy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Risk Fac | 2017 |
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; M | 2017 |
Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Pla | 2017 |
Letter: bleeding in cirrhotics receiving coronary stenting and antiplatelet therapy.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Liver Cirrhosis; Platelet Aggregation Inhibi | 2017 |
Letter: bleeding in cirrhotics receiving coronary stenting and antiplatelet therapy - author's reply.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Liver Cirrhosis; Platelet Aggregation Inhibi | 2017 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human | 2017 |
Outcome of Transurethral Resection of Bladder Tumor: Does Antiplatelet Therapy Really Matter? Analysis of a Retrospective Series.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carcinoma, Transitional Cell; Clopidogrel; C | 2017 |
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; D | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Dec | 2018 |
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition | 2018 |
Perioperative Management of Dual Antiplatelet Therapy.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation | 2018 |
A clinical risk score to identify patients at high risk of very late stent thrombosis.
Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A | 2018 |
Perioperative Use of Anticoagulant and Platelet-inhibiting Medications for Elective Spine Surgery: Results of a Nationwide Survey.
Topics: Anticoagulants; Clopidogrel; Elective Surgical Procedures; Fibrinolytic Agents; Health Care Surveys; | 2018 |
Moving towards personalised antiplatelet therapy after PCI using risk scores.
Topics: Acute Coronary Syndrome; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2018 |
Bleeding after stenting: statistics in daily practice.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary I | 2018 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2018 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Perc | 2018 |
Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Prasugrel Hydrochloride; P | 2019 |
Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation.
Topics: Anticoagulants; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Interven | 2019 |
A Randomized Trial of Interrupted Clopidogrel in Patients Undergoing Polypectomy: More Questions Than Answers?
Topics: Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ticlopidine | 2019 |
RE: Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized, Trial.
Topics: Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ticlopidine | 2019 |
Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study.
Topics: Aged; Cohort Studies; Drug Combinations; Female; Ginkgo biloba; Hemorrhage; Humans; Incidence; Male; | 2019 |
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Dist | 2013 |
A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Iloprost; Integr | 2013 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ | 2013 |
Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties.
Topics: Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Comorbidity; Databases, Factual; Female; He | 2013 |
Bleeding complications during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2004 |
Operative treatment of hip fractures in patients on clopidogrel: a case-control study.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; Clopidogrel; | 2012 |
Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel.
Topics: Clopidogrel; Diagnosis, Differential; Eyelid Neoplasms; Female; Hemorrhage; Hidrocystoma; Humans; Mi | 2013 |
Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery?
Topics: Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregatio | 2013 |
Anti-thrombotic treatment in patients with a long-term indication for anticoagulant therapy undergoing coronary stenting.
Topics: Anticoagulants; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Hemor | 2013 |
Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Humans; Incidence; Mal | 2014 |
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost S | 2013 |
Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel.
Topics: Adult; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibito | 2013 |
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Ho | 2013 |
Is clopidogrel adequate in 2013?
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet | 2013 |
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; | 2013 |
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clopidogrel; Dru | 2013 |
Hidden implications: potential antiplatelet effects of adjuvant anaesthetic agents.
Topics: Adenosine Diphosphate; Adjuvants, Anesthesia; Aged; Aspirin; Cholecystectomy, Laparoscopic; Clopidog | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf | 2013 |
Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Vessels; Drug I | 2013 |
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benef | 2013 |
Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Human | 2013 |
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration S | 2013 |
'Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel' by Tehrani et al.
Topics: Eyelid Neoplasms; Female; Hemorrhage; Hidrocystoma; Humans; Platelet Aggregation Inhibitors; Sweat G | 2013 |
Comment on 'Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel'.
Topics: Eyelid Neoplasms; Female; Hemorrhage; Hidrocystoma; Humans; Platelet Aggregation Inhibitors; Sweat G | 2013 |
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecu | 2013 |
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Interv | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Is it possible? Predicting complications and morbidity in surgical patients on clopidogrel therapy with Thrombelastography Platelet Mapping.
Topics: Female; Hemorrhage; Hip Fractures; Humans; Male; Postoperative Complications; Ticlopidine | 2014 |
Withholding clopidogrel for 3 to 6 versus 7 days or more before surgery in hip fracture patients.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Clopidogrel; Female; Hemorrhage; Hip Fractures; Human | 2013 |
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Me | 2013 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; | 2014 |
Novel uses for platelet function testing in the clinical laboratory: where are we now?
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Hemorrhage; Humans; Platelet Aggrega | 2014 |
Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aspirin; Child; Child, Preschool; | 2014 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D | 2013 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopi | 2013 |
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera | 2014 |
Thromboelastography platelet mapping for surgical patients: lessons from cardiac surgery.
Topics: Female; Hemorrhage; Hip Fractures; Humans; Male; Postoperative Complications; Ticlopidine | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piper | 2014 |
Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piper | 2014 |
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function.
Topics: Adenosine Diphosphate; Animals; Antidepressive Agents; Blotting, Western; Calcium; Carotid Artery Th | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Warfarin: Impact on hemostasis after radial catheterization.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiac Catheterization; Catheterization, Peripher | 2015 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined | 2014 |
Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Topics: Aged; Alabama; Angioplasty; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Drug Ther | 2014 |
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.
Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage | 2014 |
Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Substitution; Female; Fibrinolytic Agents | 2014 |
Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment.
Topics: Clopidogrel; Confounding Factors, Epidemiologic; Drug-Eluting Stents; Electronic Health Records; Hem | 2014 |
Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.
Topics: Aspirin; Biodegradable Plastics; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; | 2014 |
Are we there yet? deciding when it is safe (and wise) to stop clopidogrel after stent implantation.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; T | 2014 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Corona | 2014 |
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Dr | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Th | 2014 |
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherenc | 2014 |
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha | 2014 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrh | 2014 |
Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats.
Topics: Animals; Aspirin; Cilostazol; Clopidogrel; Hemoglobins; Hemorrhage; Male; Peroxidase; Platelet Aggre | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middl | 2014 |
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemo | 2014 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; | 2014 |
Perioperative aspirin: to give or not to give?
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Female; Fibrinolytic Agents; H | 2014 |
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrh | 2014 |
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Carboxylic Ester Hydrolases; Clop | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; H | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr | 2015 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Foll | 2015 |
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Ele | 2014 |
From innovation to implementation: optimizing long-term outcomes after TAVR.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Ticlopidine; Transcat | 2014 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Fem | 2015 |
Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study.
Topics: Aged; Area Under Curve; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Resistance; Femal | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D | 2015 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem | 2015 |
Stent selection and antiplatelet therapy duration: one size does not fit all.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; | 2015 |
[Triple anticoagulant therapy - now what can I give for pain?].
Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Con | 2015 |
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido | 2015 |
Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Lactone | 2015 |
Glanzmann's thrombasthenia: meeting the anticoagulation challenge.
Topics: Aminocaproic Acid; Aspirin; Clopidogrel; Factor VIIa; Hemorrhage; Humans; Isoantibodies; Male; Middl | 2015 |
Uninterrupted perioperative clopidogrel and bleeding-related events after total joint arthroplasty: a case series.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clopidogre | 2015 |
Platelet Function Testing and Prediction of Bleeding in Patients Exposed to Clopidogrel Undergoing Coronary Artery Surgery.
Topics: Blood Platelets; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhi | 2015 |
Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He | 2015 |
Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve implantation (TAVI).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio | 2015 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic | 2015 |
Redesigning TRACER trial after TRITON.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Thera | 2015 |
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogre | 2015 |
Iatrogenic Endobronchial Bleeding: Speed Things Up or Cool It Down?
Topics: Biopsy; Bronchoscopy; Clopidogrel; Epinephrine; Hemorrhage; Humans; Iatrogenic Disease; Platelet Agg | 2015 |
Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; P | 2015 |
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc | 2015 |
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc | 2015 |
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc | 2015 |
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc | 2015 |
Authors' Reply.
Topics: Blood Platelets; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhi | 2015 |
Platelet reactivity in MitraClip patients.
Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit | 2016 |
Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardia | 2015 |
Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2016 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mor | 2015 |
[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty].
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate | 2015 |
Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
Topics: Apoptosis Regulatory Proteins; Arachidonic Acid; Aspirin; Blood Platelets; Blood Transfusion; Clopid | 2015 |
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2016 |
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration while Receiving Aspirin and Clopidogrel: Is It Always Safe?
Topics: Aspirin; Clopidogrel; Contraindications; Echocardiography, Doppler, Color; Endoscopic Ultrasound-Gui | 2015 |
Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiac Surgical Procedures; Clopidogrel; Comorbidity; Female | 2016 |
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Topics: Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substituti | 2016 |
Cochlear Implantation in the Setting of Perioperative Anticoagulation and Antiplatelet Therapy.
Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Cochlear Implantation; Female; Hem | 2016 |
[Impact of preoperative dual antiplatelet therapy on perioperative bleeding in patients undergoing off-pump coronary artery bypass grafting].
Topics: Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Humans; Plate | 2015 |
Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; H | 2015 |
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Biotransformation; Chi-Square Distribution; China; | 2016 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination | 2016 |
Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study.
Topics: Aged; Asia, Eastern; Asian People; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 C | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy.
Topics: Abciximab; Adenosine; Aged; Antibodies, Monoclonal; Catheterization, Peripheral; Clopidogrel; Female | 2016 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Fe | 2016 |
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human | 2016 |
Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.
Topics: Aged; Aspirin; Asymptomatic Diseases; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; | 2016 |
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Databases, Factual; Disease Management; Female; Health R | 2016 |
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female | 2016 |
Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Blood Platelets; Blood Transfusion; Clopidogrel; Diphtheri | 2016 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St | 2016 |
One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Ag | 2016 |
Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition stu
Topics: Aged; Algorithms; Clinical Decision-Making; Clopidogrel; Hemorrhage; Humans; Middle Aged; Percutaneo | 2016 |
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Cl | 2016 |
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Pe | 2016 |
[Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hematoma; Hemo | 2016 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu | 2017 |
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2016 |
Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe.
Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Clopidogrel; Europe; Female; Follow-Up Studies; Hemorr | 2016 |
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; H | 2016 |
EBUS-TBNA and EUS-FNA: Risk Assessment for Patients Receiving Clopidogrel.
Topics: Age Factors; Aged; Biopsy, Fine-Needle; Clopidogrel; Endoscopic Ultrasound-Guided Fine Needle Aspira | 2016 |
Successful multivessel percutaneous coronary intervention for acute coronary syndrome in a HIV-positive severe haemophiliac.
Topics: Acute Coronary Syndrome; Clopidogrel; Hematuria; Hemophilia A; Hemorrhage; HIV Infections; Humans; M | 2016 |
Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection.
Topics: Aged; alpha-Cyclodextrins; Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Contr | 2017 |
Influence of CYP2C19 genetic polymorphisms on clinical outcomes of intracranial aneurysms treated with stent-assisted coiling.
Topics: Adolescent; Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Hemorrhag | 2017 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug | 2017 |
Resuscitation experience in a patient with left ventricular assist device.
Topics: Anesthesia, General; Anticoagulants; Capnography; Cardiopulmonary Resuscitation; Clopidogrel; Defibr | 2016 |
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiv | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2016 |
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical | 2016 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Life-threatening Wunderlich's syndrome with concurrent clopidogrel use.
Topics: Acute Kidney Injury; Blood Transfusion; Clopidogrel; Embolization, Therapeutic; Hemorrhage; Humans; | 2016 |
Bleeding Complications following Image-Guided Percutaneous Biopsies in Patients Taking Clopidogrel-A Retrospective Review.
Topics: Aged; Aged, 80 and over; Biopsy, Large-Core Needle; Clopidogrel; Drug Administration Schedule; Femal | 2017 |
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occl | 2016 |
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Fem | 2017 |
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Fema | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2017 |
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Foll | 2017 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl | 2017 |
Dyspnea in patients treated with P2Y
Topics: Acute Coronary Syndrome; Adenosine; Dyspnea; Female; Greece; Hematocrit; Hemorrhage; Humans; Male; M | 2017 |
Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Lung Diseases; Middle A | 2016 |
Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Dipeptidyl-Peptidase IV Inhibitors; H | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Platelet turnover predicts outcome after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square D | 2017 |
Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA).
Topics: Aged; Aspirin; Cause of Death; Chi-Square Distribution; Clopidogrel; Disease-Free Survival; Drug Adm | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Safety and efficacy of clopidogrel in children with heart disease.
Topics: Adolescent; Aspirin; Child; Child, Preschool; Clopidogrel; Female; Heart Diseases; Hemorrhage; Human | 2008 |
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As | 2008 |
Haemorrhagic herpes zoster associated with clopidogrel treatment.
Topics: Clopidogrel; Female; Hemorrhage; Herpes Zoster; Humans; Middle Aged; Platelet Aggregation Inhibitors | 2009 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridam | 2008 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree | 2009 |
A paradigm shift in anti-platelet therapy?
Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Platelet Aggrega | 2008 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2008 |
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Contusions; Coronary Angiography; Coronary Artery | 2008 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru | 2009 |
Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Clopidogrel; Creatinine; Dose-Response Relatio | 2009 |
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials | 2009 |
Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits.
Topics: Abdomen; Animals; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Flow Cytom | 2009 |
Another view on prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu | 2009 |
Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug-Eluting Stents; | 2009 |
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogr | 2009 |
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coumarins; Dipyridamo | 2008 |
Effect of oral antiplatelet agents on major bleeding in users of coumarins.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagula | 2008 |
Safety issues of adjunctive clopidogrel in patients discharged after percutaneous coronary intervention with stent placement and requiring oral anticoagulation.
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidog | 2011 |
rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats.
Topics: Animals; Clopidogrel; Factor VII; Factor VIIa; Hemorrhage; Hemostasis; Platelet Count; Rats; Recombi | 2009 |
Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.
Topics: Acrylamides; Animals; Clopidogrel; Dinoprostone; Female; Hemorrhage; Humans; Male; Platelet Aggregat | 2009 |
Ischaemia versus bleeding: the art of clinical decision-making.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; H | 2009 |
Point-of-care platelet function analysis ready for prime time?
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; | 2009 |
The ischaemia/bleeding balance in PCI.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Lactones; | 2009 |
Summaries for patients. What aspirin dose is safest and most effective for preventing heart disease?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Summaries for patients. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combi | 2009 |
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Byp | 2009 |
[Do antiplatelet agents (aspirin and other antiplatelets such as clopidogrel) increase the risk of hemorrhagic complications after endoscopic polypectomy or endoscopic sphincterotomy and should these drugs therefore be withdrawn 7-10 days before these pro
Topics: Aspirin; Clopidogrel; Colonic Polyps; Colonoscopy; Hemorrhage; Humans; Platelet Aggregation Inhibito | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido | 2009 |
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo | 2009 |
[Patients with coronary artery stents: when and how should operations be carried out?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru | 2009 |
[Drug-eluting stents: implications for surgery patients].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res | 2009 |
Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Chronic Disease; Clopidogrel; Coronary Disease | 2009 |
Clopidogrel. Bleeding and resistance.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Platelet Aggregation Inhi | 2009 |
External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anticoagulants; Clopidogrel; F | 2010 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorr | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Ad | 2009 |
Femoral artery complications after cardiac catheterization: a study of patient profile.
Topics: Aged; Anticoagulants; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Female; Femoral | 2010 |
[Pulmonary haemorrhage and haemothorax after massive ingestion of clopidogrel as a suicide attempt].
Topics: Clopidogrel; Female; Hemorrhage; Hemothorax; Humans; Lung Diseases; Middle Aged; Platelet Aggregatio | 2009 |
Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2009 |
[Prasugrel or clopidogrel in patients with coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint | 2009 |
Effect of clopidogrel on perioperative blood loss and transfusion in coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug | 2010 |
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.
Topics: Aged; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Mal | 2010 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; | 2009 |
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinica | 2009 |
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as To | 2009 |
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; C | 2010 |
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Se | 2009 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar | 2009 |
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combina | 2009 |
The right oral antithrombotics in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
eComment: Controversies on the antiplatelet therapy before coronary artery bypass grafting surgery.
Topics: Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug Therap | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cos | 2010 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative.
Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Guideline Adherence; Hemorrhage; | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocard | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 2009 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.
Topics: 4-Aminobenzoic Acid; Animals; Disease Models, Animal; Drug Design; Female; Fibrinolytic Agents; Hemo | 2010 |
Safety of carotid endarterectomy while on clopidogrel (Plavix). Clinical article.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Edema; E | 2010 |
Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Pla | 2010 |
Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention.
Topics: Aged; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Vessels; Female; Hemorrhage; Humans; | 2010 |
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coagula | 2010 |
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Ther | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2010 |
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Drug Administration Schedule; Drug-Eluting St | 2010 |
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug | 2010 |
Delays of event adjudication in the TRITON trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary | 2010 |
[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers].
Topics: Aspirin; Clopidogrel; Drug Monitoring; Evidence-Based Practice; Fibrinolytic Agents; France; Hemorrh | 2010 |
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fol | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar | 2010 |
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2010 |
Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art | 2010 |
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2010 |
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 2010 |
[Dental management of patients using anti agregant drugs: background, risks and clinical guidelines].
Topics: Atherosclerosis; Clopidogrel; Dentistry; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practi | 2009 |
High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake.
Topics: Aspirin; Clopidogrel; Drug Interactions; Fibrinogen; Glasgow Coma Scale; Hemorrhage; Hemostatics; Hu | 2010 |
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; Pur | 2010 |
Letter by Aboyans et al regarding article, "Smoking, clopidogrel, and mortality in patients with established cardiovascular disease".
Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Fact | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhag | 2010 |
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2010 |
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mi | 2010 |
Fine-tuning therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorr | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Clopidogrel and cardiac operations.
Topics: Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlo | 2010 |
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Chi | 2010 |
It is standard practice, but is it really best practice or clinical biocreep?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Coronary Angiog | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug The | 2010 |
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Electrocardiogr | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topi | 2010 |
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Age | 2010 |
A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Injury Severity Score; Male; Platelet Aggregation Inh | 2011 |
Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; | 2012 |
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding St
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dos | 2011 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Emergency Treatment; Female; Hemorrhage; Humans; Male; Mi | 2011 |
Immortal person-time bias in observational studies in cardiac surgery.
Topics: Aspirin; Bias; Clopidogrel; Coronary Artery Bypass; Data Interpretation, Statistical; Drug Therapy, | 2011 |
Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction.
Topics: Aged; Clopidogrel; Combined Modality Therapy; Comorbidity; Coronary Artery Bypass; Denmark; Female; | 2011 |
The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low.
Topics: Case-Control Studies; Clopidogrel; Colonic Polyps; Colonoscopy; Female; Hemorrhage; Humans; Male; Mi | 2011 |
Can endoscopists become more aggressive or have more options for patients with antithrombotic agents?
Topics: Clopidogrel; Colonic Polyps; Colonoscopy; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inh | 2011 |
[Do genetic factors reduce the effects of clopidogrel?].
Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Hum | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; | 2011 |
Dual antiplatelet therapy and the risk of bleeding.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag | 2011 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; H | 2011 |
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; M | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor | 2011 |
Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Blood Transfusion; Clopidogrel; Female; France; Hemor | 2011 |
Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.
Topics: Clopidogrel; Factor VIIa; Hemorrhage; Hemostasis; Hemostatics; Humans; Male; Platelet Aggregation In | 2011 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting.
Topics: Aspirin; Cerebrovascular Circulation; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Drug Th | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B | 2011 |
Safety of ultrasound-guided fine needle aspiration biopsy of neck lesions in patients taking antithrombotic/anticoagulant medications.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biopsy, Fine-Needle; Chi-Square | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
Normal chest radiograph and ground glass opacities on a thoracic computed tomographic scan in a patient with diffuse alveolar haemorrhage due to dual antiplatelet therapy prescribed after patent foramen ovale percutaneous device closure.
Topics: Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Foramen Ovale, Patent; Hemoptysis; H | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery.
Topics: Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Female; Hem | 2012 |
Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits.
Topics: Administration, Oral; Animals; Aspirin; Bleeding Time; Blood Coagulation; Carbon Monoxide; Clopidogr | 2011 |
Platelet inhibition and surgical bleeding. A plea for more science and evidence-based guidelines.
Topics: Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Female; Hemorrhage; Humans; Male; Plate | 2011 |
No free lunches: balancing bleeding and efficacy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregat | 2011 |
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
Clopidogrel (plavix).
Topics: Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2011 |
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidog | 2012 |
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Atherosclerosis; Female; Hemorrhage; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibit | 2012 |
Pharmacogenomics and clopidogrel: irrational exuberance?
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Hemor | 2011 |
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Cardi | 2012 |
Extension of Kaplan-Meier methods in observational studies with time-varying treatment.
Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Coronary Artery Dis | 2012 |
Safety of endobronchial ultrasound-guided transbronchial needle aspiration for patients taking clopidogrel: a report of 12 consecutive cases.
Topics: Aged; Aged, 80 and over; Biopsy, Fine-Needle; Bronchoscopy; Clopidogrel; Endosonography; Female; Fol | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor | 2012 |
Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Hospital Cos | 2012 |
Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures.
Topics: Cardiac Resynchronization Therapy; Case-Control Studies; Clopidogrel; Comorbidity; Drug-Related Side | 2012 |
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Comput | 2012 |
Erratum for Fernandez et al. “Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE Study)” Am J Cardiol
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2012 |
CYP2C19 genotype and cardiovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation; Pl | 2012 |
CYP2C19 genotype and cardiovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation; Pl | 2012 |
CYP2C19 genotype and cardiovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation; Pl | 2012 |
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet A | 2012 |
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat | 2012 |
Interaction between ticlopidine or warfarin or cardioaspirin with a highly standardized deterpened Ginkgo biloba extract (VR456) in rat and human.
Topics: Animals; Aspirin; Blood Pressure; Drug Interactions; Ginkgo biloba; Ginkgolides; Heart Rate; Hemorrh | 2010 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi | 2012 |
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel | 2012 |
How to prevent bleeding events in on- and off-pump coronary artery bypass patients exposed to clopidogrel preoperatively.
Topics: Acute Coronary Syndrome; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Male; Platele | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Thera | 2012 |
Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Clopidogrel; Community Pharma | 2014 |
Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2012 |
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf | 2012 |
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infar | 2010 |
Practice observed.
Topics: Aged; Buttocks; Clopidogrel; Contusions; Drug Interactions; Female; Ginkgo biloba; Hematuria; Hemorr | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo | 2012 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive Syste | 2012 |
Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Data Mining; Hemorrhage; Humans; Plat | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hem | 2012 |
[General antithrombotic therapy practice facing fundamental change].
Topics: Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic A | 2012 |
Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction?
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Clopidogrel; Drug Interactions; Dyspnea; Glomeru | 2012 |
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Comorb | 2012 |
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Topics: Blood Platelets; Clopidogrel; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial An | 2012 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Comp | 2013 |
Safety of endoscopic sphincterotomy in patients under dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cholangiopancreatography, Endoscopic Retrograde; Clopidogre | 2013 |
Effect of routine clopidogrel use on bleeding complications after ultrasound-guided thoracentesis.
Topics: Clopidogrel; Contraindications; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation | 2012 |
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Plat | 2012 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemo | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2012 |
The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combinat | 2013 |
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Mole | 2013 |
[Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization].
Topics: Acute Coronary Syndrome; Age of Onset; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Human | 2012 |
Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients.
Topics: Aged; Feasibility Studies; Female; Fibrinolytic Agents; Hemorrhage; Hemostasis, Surgical; Heparin An | 2002 |
Life-threatening haemorrhage after extracorporeal shockwave lithotripsy in a patient taking clopidogrel.
Topics: Clopidogrel; Hematoma; Hemorrhage; Humans; Lithotripsy; Male; Middle Aged; Platelet Aggregation Inhi | 2002 |
Severe bleeding following lumbar sympathetic blockade in two patients under medication with irreversible platelet aggregation inhibitors.
Topics: Aged; Anesthesia, Spinal; Autonomic Nerve Block; Fatal Outcome; Female; Hemorrhage; Humans; Magnetic | 2002 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2002 |
Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Hemorrhage | 2002 |
Clopidogrel plus aspirin for stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow- | 2002 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiov | 2003 |
Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm.
Topics: Catheter Ablation; Clopidogrel; Hemorrhage; Humans; Intraoperative Complications; Lung Neoplasms; Pl | 2003 |
Spontaneous pharyngeal haemorrhage in the anticoagulated patient.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans; Male; Pharyngeal Disease | 2003 |
Statistical versus clinical significance of the CURE study in acute coronary syndromes.
Topics: Angina, Unstable; Clinical Trials as Topic; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggr | 2003 |
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
Topics: Aged; Aspirin; Blood Platelet Disorders; Clopidogrel; Hemorrhage; Humans; Male; Platelet Aggregation | 2003 |
[Sudden edema and pain in the knee].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactio | 2003 |
By the way, doctor. A new television ad says I should ask my doctor about Plavix, a drug that reduces the risk of heart attack and stroke. I'm 65 years old and healthy. Should I be taking Plavix preventively?
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Health Status; Hemorrhage; Humans; Platelet Aggr | 2003 |
When guidelines collide...
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath | 2004 |
Perioperative hemorrhage and combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Combinations; Endarterectomy, Carotid; Female; G | 2004 |
[Secondary prevention of TIA and stroke. How much must thrombocytes not be inhibited?].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemo | 2004 |
[Peridural injections during acetylsalicylic acid and clopidogrel therapy?].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Injections, Epidural; I | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
[Clopidogrel as basic therapy in high-risk stroke patients].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Hemo | 2004 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice.
Topics: Animals; Aspirin; Blood Coagulation Tests; Clopidogrel; Disease Models, Animal; Drug Therapy, Combin | 2005 |
Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug A | 2005 |
Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy.
Topics: Animals; Aspirin; Biopsy, Needle; Bronchoscopy; Clopidogrel; Hemorrhage; Lung; Platelet Aggregation | 2005 |
Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates?
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Administration Schedule; Factor VIIa; | 2005 |
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug | 2005 |
[Antiplatelet agents and regional anaesthesia: experience in 130 patients].
Topics: Aged; Aspirin; Autonomic Nerve Block; Blood Loss, Surgical; Blood Vessel Prosthesis Implantation; Cl | 2005 |
Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Aspirin; Association; | 2005 |
Molecular mechanism of Clopidogrel and Aspirin therapy-induced bleeding episodes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Eicosanoids; Hemorrhage; Humans; Ticlopidine | 2006 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma | 2005 |
Bleeding complications in elderly patients following acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardia | 2005 |
Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report.
Topics: Abdominal Injuries; Accidental Falls; Aged, 80 and over; Aspirin; Embolization, Therapeutic; Female; | 2005 |
New modalities and aspects of antiplatelet therapy for stroke prevention.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi | 2006 |
[Recommendations for peri-procedural thrombocyte aggregation inhibition].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; He | 2006 |
Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?
Topics: Aged; Blood Transfusion; Case-Control Studies; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female | 2006 |
Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He | 2006 |
Good old warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Pla | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Incide | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2006 |
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose- | 2006 |
[Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agent | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary | 2006 |
Letter by van der Linden et al regarding article, "Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?".
Topics: Aprotinin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Hemostatics; Humans; Platelet | 2006 |
Letter by Poston regarding article, "Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?".
Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2006 |
[Safety of aspirin, clopidogrel, and acenocumarol combination in patients requiring anticoagulation].
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorr | 2006 |
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2007 |
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2007 |
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
Topics: Aged; Angiography; Anticoagulants; Blood Component Transfusion; Clopidogrel; Drug Interactions; Embo | 2007 |
The use of clopidogrel in carotid endarterectomy: an audit of current practice.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Endarterectomy, Carotid; Hemorrhage; Humans; Medica | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Clopidogrel: the good, the bad, and the ugly.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; Platelet Ag | 2007 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny | 2007 |
Admissions to a medical intensive care unit related to adverse drug reactions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse | 2007 |
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Topics: Administration, Oral; Animals; Aorta; Aspirin; Bleeding Time; Blood Coagulation; Clopidogrel; Diseas | 2007 |
Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema | 2007 |
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheteriza | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem | 2007 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2008 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
Analysis of the upper gastrointestinal tract bleeding prevalence in patients treated due ischaemic heart disease.
Topics: Acenocoumarol; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Clopidogrel; Fe | 2007 |
A retrospective study of the management of retro-peritoneal bleeding after percutaneous coronary intervention in the era of combination anti-platelet therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Fe | 2008 |
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].
Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet A | 2008 |
Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Emergency Service, Hospital; Hemorrhage; Humans; | 2009 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platel | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri | 2008 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hem | 2008 |
Anti-platelet agents and surgical delay in elderly patients with hip fractures.
Topics: Aged; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hip Fractures; Hum | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial | 2008 |
Ticlopidine, bleeding, and surgery.
Topics: Hemorrhage; Humans; Platelet Aggregation; Surgical Procedures, Operative; Ticlopidine | 1994 |
Reduction of thrombotic and hemorrhagic complications after stent implantation.
Topics: Acute Disease; Aged; Anticoagulants; Coronary Angiography; Coronary Thrombosis; Female; Follow-Up St | 1996 |
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation | 1997 |
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Adverse haematological effects of ticlopidine.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; France; Hemorrhage; Humans; Leukopenia; Platelet Ag | 1998 |
Serious hematologic reactions associated with ticlopidine--update.
Topics: Adverse Drug Reaction Reporting Systems; Hemorrhage; Humans; Leukopenia; Patient Education as Topic; | 1999 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
Diffuse alveolar hemorrhage after clopidogrel use.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Hemorrhage; Humans; Lung Diseases; Ma | 2001 |
Haemorrhage associated with combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aspirin; Clopidogrel; Drug Therapy, Combination | 2001 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; | 2002 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; | 2002 |
Guidelines for acute coronary syndrome without ST elevation.
Topics: Clopidogrel; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycopr | 2002 |
Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood P | 1989 |
Clinical application of a new in vitro bleeding time device on surgical patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aspirin; Bleeding Time; Epoprostenol; Hemorrhage; Hemostasis; H | 1988 |
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techni | 1986 |
Ticlopidine as a hemorrhagic risk factor in coronary surgery.
Topics: Adult; Coronary Disease; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Count; Pos | 1985 |